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Tamoxifen, a non steroidal partial oestrogen agonist, is the most widely used adjuvant
treatment for breast cancer and has been used by millions ofwomen worldwide since its
introduction in 1971. Although tamoxifen reduces cancer recurrence and reduces the rate
of contralateral cancer, since the late 1980's there has been concern about the effect of
tamoxifen on the endometrium. There is evidence ofa clear association between tamoxifen
use and the development of endometrial abnormalities, with endometrial cancer being
increased 2-3 times in women on tamoxifen. In view of this and the recent evidence that
prophylactic tamoxifen may benefit high risk women, endometrial screening for women on
tamoxifen has been advocated. To date, little work has been done to assess the risk of
abnormalities in asymptomatic women to establish whether a screening programme is
required and, if it is, what screening tool should be employed.
An initial pilot study was performed to assess the incidence of abnormalities in 120
asymptomatic women with breast cancer on tamoxifen and to establish the most appropriate
screening tool from the three assessed, transvaginal ultrasound scanning (TV USS), out¬
patient hysteroscopy and pipelle biopsy. The pilot study demonstrated that all
abnormalities seen at hysteroscopy were identified on TV USS. Following this a further
237 women on tamoxifen and 130 controls had transvaginal ultrasound scanning performed
and only went on to out-patient hysteroscopy if the scan was abnormal. There was a
statistically significant positive correlation between length of time on tamoxifen and
endometrial thickness on ultrasound scan (p<0.0001) and women on tamoxifen had a
significantly thicker endometrium than controls (pO.OOOl). 145 women (41%) had an
endometrium >5mm on USS and 134 of them had successful out-patient hysteroscopy. 61
women had atrophic endometrium at hysteroscopy giving a 46% false positive scan rate.
The remaining women had benign features to explain the ultrasound findings, including
cysts in 23 women, oedematous endometrium (23), polyps (21) and submucous fibroids (6).
It is concluded that ultrasound is a poor screening tool which gives a high false positive rate.
The low frequency of serious endometrial pathology in tamoxifen users and the absence
of an ideal screening tool indicates that endometrial screening in asymptomatic women is
not worthwhile.
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All women in the endometrial study had plasma tamoxifen and its metabolites measured to
investigate the relationship between endometrial thickness and tamoxifen levels. There
was no correlation between endometrial thickness and blood levels of tamoxifen or any of
its metabolites.
Pathology specimens from hysterectomised women on tamoxifen were retrieved to
investigate the cystic/oedematous findings seen at hysteroscopy and to assess the effect of
tamoxifen on cell turnover. The significant histological findings in tamoxifen users were
cystically dilated endometrial glands, low stromal cellularity and the presence or
prominence of collagen within the stroma. Immunohistochemistry of hysterectomy
specimens for ER and MIB 1 failed to show a significant difference in the expression of
either between women on tamoxifen and controls.
Because of the concern regarding tamoxifen's potentially serious side effects, newer more
specific antioestrogens and oral aromatase inhibitors are under investigation. Letrozole,
an oral aromatase inhibitor, was investigated in 24 postmenopausal women with primary
breast cancer and achieved a 92% (22/24) partial clinical response, which is at least as good
as results obtained with tamoxifen. This suggests that newer more specific endocrine




Tamoxifen is the endocrine therapy of choice for women with breast cancer.
History
Ethamoxytriphetol was the first antioestrogen to be synthesised in 1958 for use in
gynaecology and for the treatment of oestrogen dependent breast cancer. The hypothesis
was that an antioestrogen could be effective as a 'morning after pill' because it was found
to prevent pregnancy in laboratory animals after they had mated. However, trials with
ethamoxytriphetol found it to have a low potency and to produce many toxic side effects
and so this agent was not further evaluated [Lerner 1990, Wolf 1992].
The main successor compound to ethamoxytriphetol was clomiphene which is an analogue
of the oestrogen triphenylethylene and is composed of a mixture of cis and trans isomers.
It was found to be more potent than ethamoxytriphetol and clinical trials were initiated.
Rather than acting as an antifertility agent, clomiphene induced ovulation and it is currently
in widespread use as an ovulation induction agent in the treatment of infertility.
Tamoxifen is structurally very similar to clomiphene and is the trans isomer of
triphenylethylene. It is a non steroidal antioestrogenic compound which was first
synthesised in Great Britain in 1966. Although the option as a fertility regulator was
considered, it was marketed during the 1970's for the induction of ovulation because of its
structural similarity to clomiphene [Klopper 1971, Jaiyesimi 1995],
As well as inducing ovulation it was discovered to have antioestrogenic activity in rats and
primates. In particular, it was found to suppress carcinogen induced rat mammary tumours
so it was postulated it may be effective as an antitumour agent in women with breast cancer.
ICI 46,474 (tamoxifen) was first used in trials for disseminated breast cancer in 1971 and
licenced for the treatment ofmetastatic breast cancer in postmenopausal women in 1973 in
Great Britain and in 1977 in USA. Similar licences have been obtained in 110 other
countries. Since then tamoxifen has been approved as adjuvant therapy for pre and
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postmenopausal women with oestrogen (ER) receptor-positive, node-negative breast cancer,
for postmenopausal women with node-positive breast cancer and as adjuvant therapy (in
combination with chemotherapy) for premenopausal women with ER positive advanced
breast cancer. Tamoxifen is also used to treat breast cancer in men.
Tamoxifen has been used by millions ofwomenworldwide and is currently the most widely




Tamoxifen blocks the growth promoting effect of oestrogen in breast tissue by acting as a
competitive inhibitor of oestrogen in its binding to cytoplasmic ER (oestrogen receptor).
The tamoxifen/ER complex prevents oestrogen/ER mediated gene transcription, DNA
synthesis and cancer cell growth. In vitro, tamoxifen inhibits the proliferation of human
breast cancer cells by preventing the transition ofcells from early G1 phase to mid G1 phase
of the cell cycle, resulting in cytostatic effects - cells accumulate in the early stages in the
cell cycle while the number of cells later in the cycle diminish. Whether tamoxifen is also
cytocidal to breast cancer cells is still debatable [Jaiyesimi 1995], The mechanism of
action in ER negative tumours may vary from that ofER positive breast cancers. Data have
shown a decreased proportion of GO to G1 cells (early stages in the cell cycle) and an
increased percentage of cells later in the cell cycle [Reddell 1985, Osborne 1998].
At low concentrations, in tissue culture, the cytostatic effect of tamoxifen can be completely
blocked by oestradiol but at higher concentrations of tamoxifen this effect is not reversible
by oestrogens. Tamoxifen may inhibit cell replication by methods other than competitive
blockade of ER since approximately 10% of ER negative breast cancers respond to
tamoxifen therapy [Jordan 1988]. It produces an increase in antibody formation and also
inhibits angiogenesis [Gagliardi 1993], Transforming growth factor-P (TGF-P) has been
suggested as a cellular target and is involved in the inhibition of epithelial cell proliferation
and maintenance of normal pattern of gene expression in a wide variety of tissues. Loss
of response to TGF-P by cells is associated with subsequent malignant transformation.
Tamoxifen up-regulates the production ofTGF-P by breast cancer cells in vitro and in vivo
and may exert part of its antitumour effect by elevation of this cytokine [Jeng 1993, Butta
1992, Colletta 1994], In addition, tamoxifen mediated reduction in positive growth
regulators such as insulin-like growth factors I and II may contribute to the therapeutic
effect of the drug. Tamoxifen treatment in vitro and vivo has been shown to reduce serum
IGF-I levels [Colletta 1994, Pollak 1992, 1990], All of these functions of tamoxifen may
play a role in the inhibition of tumour growth in ER negative tumours.
Tamoxifen undergoes extensive hepatic metabolism and conjugation. The principle
metabolite is desmethyltamoxifen (DMT) and its binding affinity for ER is comparable to
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that of tamoxifen. Although present in large quantities, DMT is a relatively weak
antioestrogen. Another important metabolite is 4-hydroxytamoxifen (4-OHT) which is
present at lower concentrations in plasma than tamoxifen but binds to ER with 25 to 50
times the affinity of tamoxifen such that most of the tamoxifen bound to ER is 4-OHT.
4-OHT is the most potent of tamoxifen's metabolites [Jaiyesimi 1995, Etienne 1989, Wolf
1992], More recently, Metabolite E has been found to be present in very small quantities
and is thought to be the most oestrogenic of tamoxifen's metabolites as it lacks the
necessary side chain for antioestrogenic properties [Osborne 1994], Another metabolite,
bisphenol, also lacks the dimethylaminoxy side chain necessary for antioestrogenic
properties.
Bliary excretion is the main route of tamoxifen elimination in humans and only a very small
amount is excreted unchanged. The half life of tamoxifen and its metabolites ranges from
7-14 days and metabolites can remain in the system for up to 6 weeks following cessation
of treatment [Jaiyesimi 1995],
Tamoxifen is a very effective treatment for breast cancer. It increases overall survival and
disease free survival in breast cancer patients by decreasing recurrence, reducing the
incidence of contralateral breast cancer by 40-50% and by decreasing the incidence of
metastases. Initial studies showed that treatment for 2 years was more beneficial than no
adjuvant treatment. A subsequent Scottish trial showed a significant reduction in relapses
and deaths in those women who received 5 years of tamoxifen when compared with
controls [Scottish 1987]. Although there is still debate as to the optimum length of time
women should be on tamoxifen, most studies favour prolonged use - greater than 2 years.
The Cancer Research Campaign Breast Cancer Trials Group and the Swedish Breast Cancer
Co-operative Group have recently both reported that 5 years tamoxifen use is better than
2 years [Swedish 1996, CRC 1996]. Bisset et al concluded there was no evidence to
support continuation of tamoxifen beyond 5 years and this is supported by the National
Cancer Institute of America [Bisset 1994, Bulbrook 1996]. The optimum duration of
tamoxifen treatment remains under ongoing trial investigation, but currently 5 years of
tamoxifen use is considered by most to be appropriate [Cameron 1998, Rea 1998, Jordan
1991],
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In Edinburgh, at least 5 years is favoured and, until recently, tamoxifen was continued in
most women until the time of first recurrence. In a number of cases this has led to very
prolonged use of tamoxifen - over 10 years.
7
Oestrogenic Properties
As well as acting as an antioestrogen on the breast it is evident that tamoxifen has
oestrogenic actions on other organs which are beneficial. Studies on laboratory animals
have demonstrated that tamoxifen has an oestrogen-like effect on bone and may maintain,
or even increase, bone mineral density [Love 1992, Jordan 1987, 1993]. This is potentially
beneficial to postmenopausal women as it reduces fracture rate, in particular hip fractures
which are a major cause of morbidity and mortality in elderly women [Osborne 1998,
Jordan 1993, Wolf 1992],
In addition, paradoxically, tamoxifen causes lipid changes similar to those seen in women
taking oestrogen. It reduces low-density lipoproteins and total cholesterol and increases
high-density lipoproteins. This could have a significant effect in reducing coronary artery
disease in postmenopausal women, a major cause ofmorbidity and mortality. The Scottish
adjuvant tamoxifen trial showed a reduction in the incidence of fatal myocardial infarction
in postmenopausal women when compared with control patients [Scottish 1987, Wolf 1992,
Jordan 1993, Osborne 1998]. However, this reduction was not seen in the overview
analyses of tamoxifen's efficacy in breast cancer [EBCTCG 1998].
Tamoxifen also exerts partial oestrogen-like effects on the hypothalamic-pituitary axis. In
postmenopausal women this usually results in a decrease in the levels of circulating
gonodotrophins (luteinizing hormone (LH) and follicle stimulating hormone (FSH)),
although they remain within the normal postmenopausal range. This is largely irrelevant
with regard to the postmenopausal ovary. Serum levels of oestrogen are also reduced in
postmenopausal women [Kenemans 1996, Lonning 1995].
Conversely, in premenopausal women who continue to menstruate regularly, oestrogen and
progesterone are usually elevated (1 to 4 fold) and LH and FSH levels are unchanged or
slightly increased from levels before tamoxifen treatment [Miodrag 1991, Wolf 1992,
Uziely 1993, Sherman 1979, Osborne 1998, Cohen 1999(a)], The theory for this is that
tamoxifen reduces the level of circulating oestrogen available to the hypothalamus thus
stimulating the secretion of gonadotrophin releasing hormone which in turn stimulates the
release of pituitary LH and FSH. However, the fact that LH and FSH levels remain
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relatively unchanged, suggests that tamoxifen also acts directly on the ovary to increase
steroidogenesis, equalising its agonistic and antagonistic effects to maintain LH and FSH
at steady levels. Thyroid-binding globulin (TBG) and sex hormone binding globulin




Not all the oestrogenic effects of tamoxifen are beneficial. Tamoxifen has oestrogenic
effects on the endometrium which may lead to a range of endometrial abnormalities
including cancer. This has led to some concern especially in view of the recent ongoing
trials of the use of tamoxifen for preventing breast cancer. Killackey [1985] was the first
to suggest an association between tamoxifen and endometrial cancer in 1985 reporting 3
cases of endometrial cancer in breast cancer patients on tamoxifen. 1 premenopausal and
2 postmenopausal women who had all received 20mg/day tamoxifen for between 7 and 14
months developed endometrial cancer. Since then numerous other cases have been
reported and a recent survey of the world literature found 349 cases of endometrial cancer
in breast cancer patients who had received tamoxifen [Assikis 1996], This however must
be considered against the background that over 3 million women worldwide take tamoxifen
as part of their treatment for breast cancer.
Tamoxifen has also been linked with carcinogenesis in the liver. However, the concern
about hepatocellular carcinoma is based entirely on laboratory studies where very high
doses of tamoxifen were used. There is no evidence of an increase in the rate of
hepatocellular carcinoma in humans at the standard 20mg/day used [Jordan 1995].
Numerous studies carried out in the late 1980's linked tamoxifen with carcinoma of the
mouse uterus. The effect of tamoxifen on the growth of the endometrial tumour, EnCal 01,
was investigated by Gottardis et al [1988], They developed a useful model to investigate
the growth of hormone dependent human tumours in athymic mice by oestrogen
supplementation to study the effects of tamoxifen. Implants of endometrial cancer
EnCal01 in athymic mice were stimulated by 17P-oestradiol administration but also by
tamoxifen. This demonstrates the agonist action of tamoxifen on the uterus in the mouse
[Jordan 1991, Gottardis 1988, Satyaswaroop 1984],
The effect of the tamoxifen metabolite 4-hydroxytamoxifen on the proliferation of
endometrial cancer has been investigated using the Ishikawa line. 4-hydroxytamoxifen was
found to stimulate cell proliferation in this human endometrial cancer cell line [Anzai 1989,
Holinka 1991],
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Interestingly, Anzai showed that this effect is significantly greater than that ofoestradiol on
the same cell lines. Other studies including those using athymic mice have shown that the
stimulatory effect of tamoxifen is weaker than that seen with oestradiol.
Paradoxically, tamoxifen has been used to treat endometrial cancer. The theory behind this
was that it was believed tamoxifen was a pure antioestrogen and that endometrial cancer
is a hormone dependent tumour [Swenerton 1979, Tisman 1976, Bonte 1980], Small studies
have reported a favourable effect from tamoxifen but it is now accepted that tamoxifen is
not an appropriate treatment for endometrial cancer.
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Endometrial Adenocarcinoma
Endometrial adenocarcinoma is the most common gynaecological malignancy and the 4th
most common cancer in women accounting for 4-5% of all malignancies. Gynaecological
malignancies in general account for 15% of female malignancies [Hoskins 1992, Dewhurst
1986]. It has an age adjusted incidence of 12 per 100,000 women in the UK [Mahboubi
1982] and the disease is more prevalent in Caucasian women with the incidence for whites
being twice that for non-whites [Hoskins 1992, Koss 1984], The peak period of incidence
is in the 55 to 65 age group but 25% of cases occur in premenopausal women [Tindall
1987], The incidence of endometrial cancer in the USA peaked in 1975, probably as a
consequence of the use of unopposed oestrogen HRT [Dewhurst 1986, Mahboubi 1982],
but there has been a continuous decline since 1979. However, it continues to cause 4000
deaths per year. Risk factors for endometrial cancer include late menopause and early
menarche (ic long menstrual history), nulliparity, obesity, diabetes mellitus and polycystic
ovaries (all of these imply elevated endogenous oestrogens). Nulliparous women who
make up between 24-31 % of patients with endometrial cancer have 2-3 times the risk of
developing the disease compared with women with children [Dewhurst 1986],
The true cause of endometrial cancer is unknown and it can arise in normal, atrophic or
hyperplastic endometrium. Studies suggest that at least two different mechanisms are
implicated in its aetiology:
(i) a history of exposure to unopposed oestrogen, endogenous or exogenous. These
tumours begin as endometrial hyperplasia and progress to cancer. They tend to be
better differentiated and have a better prognosis. 1% of cystic hyperplasia, 14% of
adenomatous hyperplasia and 25-40% of atypical hyperplasia develop into cancer
[Hoskins 1992, Dewhurst 1986],
(ii) spontaneous tumours arising from a background of atrophic or inert endometrium.
In 75% ofwomen the tumour is confined to the uterine corpus and it tends to spread
over the endometrium to form a diffuse malignancy rather than invading the
myometrium (which is a rather late event). It tends to present early with bleeding,
usually postmenopausal bleeding as the majority of women who develop
endometrial cancer are postmenopausal (75%) [Hoskins 1992, Dewhurst 1986],
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Tumours are staged by the FIGO (International Federation ofGynaecology and Obstetrics)
system which was first introduced in 1971 and recently updated (1988):
Stage I A - Confined to the endometrium
B - Invasion to <14 myometrium
C - Invasion to >14 myometrium
Stage II A - Involving uterus and endocervical glands only
B - Cervical stromal invasion
Stage III A - Spread outside the uterus invading serosa and/or adnexa
and/or positive peritoneal cytology
B - Metastases to pelvic and/or para-aortic lymph nodes
Stage IV A - Tumour invasion ofbladder and/or bowel mucosa
B - Distant metastases including intra-abdominal and/or
inguinal lymph nodes
[Hoskins 1992, Dewhurst 1986, Tindall 1987]
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Most tumours are early stage (Stage 1), because these early cancers cause bleeding and
therefore the majority have a good prognosis (80% overall 5 year survival) [Jordan 1996
Mahboubi 1982],





[Shaw, Souter & Stanton 1997],
Tumours are also graded Gl-3 with regard to degree of differentiation. Grade I is well
differentiated with 5% or less of a non-squamous or non morular solid growth pattern and
Grade 3 is poorly differentiated with more than 50% of a non-squamous or non-morular
solid growth pattern.
Although adenocarcinoma is the most common type of endometrial cancer, there are other
tumours which are typically more aggressive - namely, serous carcinoma, papillary
carcinoma, clear cell carcinoma and sarcomas which include mixed mullerian tumours.
Sarcomas are associated with a history of pelvic irradiation.
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Tamoxifen and Endometrial Carcinoma
An association between breast cancer and endometrial cancer, regardless of tamoxifen use,
has been suggested because of the common risk factors [Adami 1987, Gaglione 1989,
Fotiou 1998], However, in addition to this background risk, and following Killackey's first
report, there have been a number of retrospective and prospective studies and non-
controlled case reports suggesting an association between tamoxifen use and the
development of endometrial cancer.
The first report of a higher frequency of endometrial cancer came from the Stockholm trial
[Rutqvist 1987, 1995], In this trial, 1846 postmenopausal breast cancer patients were
randomised to receive 40mg/day tamoxifen or placebo for 2 years. Those who were
disease free at 2 years were further randomised to an additional 3 years tamoxifen or
placebo. In the tamoxifen group 17 endometrial cancers were found compared with 3 in
the control group. The 1995 update revises numbers to 23 in the study group and 4 in the
control group. This study suggested that long-term tamoxifen resulted in more endometrial
cancers.
The biggest of the tamoxifen trials is the National Surgical Adjuvant Breast and Bowel
Project Study (NSABP B-14)[Fisher 1994], They compared rates of endometrial cancer
and other cancers in 2843 patients with node-negative, oestrogen receptor (ER) positive,
invasive breast cancer who were randomly assigned to 20mg/day tamoxifen or placebo and
in 1220 tamoxifen treated patients registered subsequent to randomisation. In the
tamoxifen group 23 endometrial cancers were found compared with 2 in the control group.
Most were stage 1 and therefore of good prognosis but 4 women in the tamoxifen group
died from their endometrial cancer. This trial reported an absolute risk of tamoxifen
induced cancer of 1-2 cases annually per 1000 women treated and a relative risk of 2-3
times greater than that seen in women with breast cancer not on tamoxifen. They also
showed a fairly constant rate of endometrial cancer over time on the drug.
Four other big trials have failed to show an increased risk:-
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• The Scottish trial involved 661 tamoxifen treated women and 651 controls. In the
tamoxifen treated group 4 women developed endometrial cancer compared with 2 in the
control group over the same time period (5 years or until time of first relapse). Women
received 20mg per day of tamoxifen. This trial concluded that there was no association
between tamoxifen use and endometrial cancer as there was no difference in the
frequency of endometrial tumours in both groups [Scottish 1987].
• The Christie trial, in which 282 patients were randomised to receive 20mg of tamoxifen
daily for 1 year, detected 1 tumour in each group (tamoxifen and control) after a follow-
up period of 13 years [Ribeiro 1988],
• The NATO (Nolvadex Adjuvant Trial Organisation) trial also failed to show an
increased incidence of endometrial cancer in the tamoxifen group (564 patients)
compared to controls (567 patients) over an 8 year follow-up [NATO 1988].
• Katase et al [1998] investigated gynaecological follow-up in 825 breast cancer patients
(279 on tamoxifen and 546 controls). They found 4 women on tamoxifen and 9 control
women who subsequently developed endometrial carcinoma and concluded there was
no increase in incidence with tamoxifen use.
There have been 8 major adjuvant trials, none designed specifically to look at the
association between tamoxifen and endometrial cancer, but all have retrospective data from
double blind randomised trials allowing them to draw conclusions. The cumulative
incidence, from all these trials of endometrial cancers in women treated with tamoxifen, is
0.9% compared with 0.2% in the control groups, which means an extra 7 women per 1000
who took adjuvant tamoxifen developed endometrial cancer. Although not all trials have
reported an increased incidence, it is likely that the numbers in some of these trials were not
sufficient to detect the small but significant difference in incidence between tamoxifen
treated women and controls.
Table 1 summarises these 8 trials.
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Table 1
Summary of eight major adjuvant tamoxifen trials showing incidence of endometrial
cancer in patients and controls.






No. Patients No. Developed
Endometrial
Cancer
Copenhagen 164 2 153 0
Christie 282 1 306 1
NATO 564 0 567 0
Scottish 661 4 651 2
ECOG-1178 85 1 83 2
Stockholm 931 17 915 3






Total 5524 48 4301 10
(0.9%) (0.2%)
[Jaieyesimi 1995]
As well as the large randomised trials comparing tamoxifen with placebo there have been
numerous other case reports and case control studies of endometrial cancer development
in women on tamoxifen.
Table 2 summarises some of these reports.
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Table 2
Case reports and case control studies of endometrial cancer in association with
tamoxifen use.
Author No. of Cases Dosage(mg) Duration(mths)
Kil lackey 3 20 7-14
Pons 1 30 10
Hardell 11 40 12-120
Fornander 13 40 24-60
Dauplat 2 20-30 18-24
Mathew 5 20 50-96
Malfento 7 20 18-48
Atlante 4 40-60 24-60
Neven 1 20 36
Rodier 1 40 8
Segna 11 10-20 5-84
Uziely 2 n.r. >24
Osborne 4 n.r. 12
O'Neill 1 20 60
Mignotte 20 20 29-102
Deprest 1 40 96
Le Boudec 4 20-30 3-30
Spinelli 3 20 24-36
Palacois 1 20 104
Teshima 4 20-40 24-96
Samelis 1 20-40 24-156
Dew 1 20 48
Seoud 6 20 0 >48
Lahti 1 20-40 6-95
Ismail 2 20-40 36-85
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Author No. of Cases Dosage(mg) Duration(mths)
Peters-Engl 8 20-40 6-60
Jose 1 20 72
Fotiou 5 10-30 >24
[Sismondi 1994, Peters-Engl 1996, Jose 1995, Fotiou 1998, O'Neill 1992, Mathew 1990]
What is not clear from the data is whether any increase in the number of cases of
endometrial cancer represents a true increase in endometrial cancer in tamoxifen treated
patients or results from lead time bias, ie an increase in detection of lesions that would
otherwise have remained silent [Barakat 1995, Dew 1995]. In none of these trials did
women undergo initial endometrial screening to give a baseline before starting tamoxifen
nor were they randomised with respect to major risk factors for the development of
endometrial cancer. In support of this Horwitz et al [1981] reported occult endometrial
cancer at autopsy in a general population five times higher than the reported rate for the
same geographical area over the same time period [Wolf 1992], In addition, current studies
fail to give clear information about the time period over which tamoxifen causes problems.
Some studies have looked at relatively short periods of tamoxifen use, ie 0-2 years and
whether true cause and effect can be drawn from studies of such short duration is debatable.
Although the Stockholm trial followed women for 5 years and concluded that endometrial
cancer was more frequent in patients who continued tamoxifen beyond 2 years, in their
study the majority of cancers were actually detected in patients who had been treated with
tamoxifen for 2 years or less.
The Christie trial, looking at short term tamoxifen, failed to show an increase in endometrial
cancer with tamoxifen use. Very few studies to date have looked at long term tamoxifen,
5-10 years or even 10+ years use. The Scottish trial did follow women on long term
therapy and failed to show an increased incidence of endometrial cancer, although with
longer follow-up there is a suggestion that those randomised to 5 years or longer are at
greater risk of endometrial cancer. Studies also vary in the dose of tamoxifen given -
20mg/day is the current recommended dose in the UK and the US but different centres
within Europe have used varying doses from 20mg up to 60mg daily.
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What is also not clear is whether tamoxifen acts as a true carcinogen or as a promoter of
existing lesions. Concern is such that in the USA tamoxifen has been labelled as a
carcinogen by the FDA [Jordan 1993].
From the literature, it is accepted that tamoxifen is associated with some increased risk of
endometrial cancer (ofan order of2-3 times) [Fisher 1994, Friedman 1994] but the benefits
of tamoxifen in the adjuvant treatment of breast cancer and in reducing contralateral
cancers far outweigh the risks of reported endometrial abnormalities.
Although most studies have reported that tumours which develop following tamoxifen use
are well differentiated at early stage and have a good prognosis [Seoud 1993, Barakat 1995,
Cuenca 1996, Katase 1998], some reports suggest that tamoxifen is linked to more
aggressive endometrial cancer. In the reported literature from 1984-1995, there were 18
mixed mullerian tumours and 9 sarcomas [Assikis 1996, Altaras 1993, Seoud 1993, Hardell
1988 (b)] as well as high grade, poorly differentiated adenocarcinomas which have
developed in women who have taken tamoxifen.
This information is summarised in Table 3.
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Table 3
Total number of endometrial cancers and high grade tumours in the reported
literature, 1984-1995.
Endometrial carcinomas 349





Duration of tamoxifen therapy
<2 years 91
>2 years 108
NB Information was not available for all patients regarding menopausal status or duration
of tamoxifen therapy.
[Assikis 1996]
Since then there have been other sporadic reports of high grade tumours [Clement 1996,
Dallenbach-hellweg 1995].
Sarcomas which include carcinosarcoma (mixed mullerian and mixed mesodermal
tumours), and leiomyosarcoma are rare in the general population and account for <5% of
all uterine cancers. They have an annual worldwide incidence of 0.5 - 3.3 cases per
100,000 women and, unlike endometrial carcinoma, occur more commonly in black
women. The peak incidence age is 70 years and previous pelvic irradiation appears to be
a risk factor. It is uncertain whether they arise from endometrium or myometrium but they
are highly aggressive with early lymphatic and haematogenous spread. Consequently
survival is poor with a 5 year survival of <10% [Tindall 1987, Hoskins 1992],
Magriples et al [1993] reported a retrospective cancer registry search in which 67% of
patients (10 women) in the tamoxifen group had poorly differentiated endometrial
carcinomas (including adenosquamous carcinoma) or carcinoma associated with poor
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outcome (papillary serous carcinoma, clear-cell carcinoma, mixed mullerian carcinoma).
They also reported that patients in the tamoxifen group were much more likely to die from
their endometrial cancer. Of interest in this study, all women received 40mg/day
tamoxifen. The Scottish trial reported 4 endometrial tumours in the tamoxifen group
studied and all were sarcomas [Stewart 1989], Malfento [1990] described 7 new cases of
endometrial cancer in breast cancer patients on tamoxifen, all ofwhom received 20mg/day
tamoxifen for an average of 28 months prior to diagnosis of endometrial cancer. Of the 7
cases, 2 were grade 3 (poorly differentiated) and 1 patient died from her endometrial cancer.
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Associated Pathology
Tamoxifen has also been linked with other endometrial abnormalities including polyps,
endometrial hyperplasia and endometriosis. Endometrial hyperplasia has been reported in
postmenopausal breast cancer patients taking tamoxifen. Gal et al [ 1991 ] initially obtained
endometrial biopsies from 38 women on tamoxifen and found 7 (18%) with endometrial
hyperplasia ranging from simple to complex with atypia. They went on to prospectively
monitor women on tamoxifen by means of endometrial biopsy and found new hyperplastic
changes in 3/11 women. Other studies support the finding of hyperplastic changes in
women taking tamoxifen [Uziely 1993, De Muylder 1991, Lahti 1993, Cohen 1993 (a),
Cohen 1994 (c)]. Cross and Ismail [1990] describe a case report of endometrial
hyperplasia in an oophorectomised woman on tamoxifen.
Polyps have also been associated with tamoxifen therapy, both in isolation and in
association with hyperplastic elements [Seoud 1993, De Muylder 1991, Nuovo 1989, Ismail
1994 (a), Corley 1992 Ugwumadu 1993, Cohen 1992, McGonigle 1996]. Endometrial
polyps in the general population are rarely associated with neoplastic change, with only a
0.5% chance of cancer being present within a polyp but Ramondetta et al [1999] reported
5 cases of tamoxifen associated endometrial polyps with foci of carcinoma within them.
Endometriosis (another oestrogen dependent condition) and hyperplasia of endometriotic
foci have been reported in several women taking tamoxifen [Ford 1988, Cano 1989, Le
Boudec 1991, Morgan 1994]. Endometriosis is a disease characterized by the presence and
proliferation of endometrial tissue outside the uterus. This has raised the possibility of
induction ofmalignant change in the endometriotic foci and not just the endometrium of
women on tamoxifen [Buckley 1990],
In addition, the growth ofuterine fibroids has been documented with tamoxifen use. [Rullo
1993, Ugwumanda 1994, Dew 1995].
As well as acting on the uterus, tamoxifen also has an oestrogen-like effect on vaginal
epithelium. This is not surprising because embryologically the uterus and upper 2/3rds of
the vagina are derived from the mullerian duct system. It would therefore seem logical that
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if tamoxifen has an effect on the uterus, it should also affect the vagina. Boccardo [1981,
1984] and Ferrazi [1977] obtained vaginal smears and determined the karyo-picnotic index
(KPI); this is the relation ofmature superficial cells to mature intermediate cells and is one
of the most common indices for cytohormonal evaluation. Administration of oestrogens
to postmenopausal women generally induces cellular maturity which increases KPI values.
In postmenopausal women, tamoxifen increases KPI values indicating a mild to moderate
oestrogenic effect [Lahti 1994]. Vaginal pH was measured in postmenopausal women on
tamoxifen by Miodrag et al [1991] and found to be significantly reduced towards levels
typically found in premenopausal women. Ferrazi [1977] found a zero KPI value before
tamoxifen treatment and reported smears returned to atrophic within 2 months of tamoxifen
withdrawal.
Friedrich et al [1998] investigated the effect of tamoxifen on vaginal and cervical
epithelium in postmenopausal women on tamoxifen use and showed an increase in the
maturation index with increasing length of tamoxifen use compared to controls. They also
showed an apparent increase in endocervical cell hyperplasia and metaplasia with tamoxifen
use. Reassuringly, both this study and that by Rayter et al [1994(b)] and Gill et al [1998]
failed to show any evidence of cervical dysplasia in tamoxifen treated patients.
It has been suggested that tamoxifen may also affect the ovaries reflecting common risk
factors and may affect pre and post menopausal ovaries differently [Ewertz 1990, Cohen
1996(b)]. Functional cysts in premenopausal women, most of which resolved
spontaneously, have been reported and have been postulated to be secondary to
supraphysiological oestradiol serum levels which are seen in premenopausal women on
tamoxifen [Shushan 1996, Cohen 1999(a)]. Data on cyst development in postmenopausal
women is scanty and requires further investigation. One small study suggested an
increased risk of cysts in postmenopausal women also [Cohen 1996(b)]. Vaginal
ultrasonography is a useful tool for assessing the endometrium and ovaries simultaneously
and could be used in further studies to address this issue [Lindahl 1997, Carter 1991],
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There are therefore a number ofproblems associated with tamoxifen use but clearly not all
women who take the drug develop problems. Kedar et al [1994] showed in their breast
cancer prevention trial that most women (61%) who took tamoxifen had an atrophic
endometrium at follow-up. The difficulty is predicting those women who will experience
an oestrogen-like effect from tamoxifen use, although the cumulative dose may be
important [van Leeuwen 1994, De Muylder 1991]. To date no method has been devised
for predicting which women will be affected.
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Endometrial Screening
The effect of tamoxifen on the endometrium has led to the question of whether there should
be screening for women on tamoxifen to detect endometrial abnormalities. If screening is
to be implemented, the best method both of picking up abnormalities early and patient
tolerability is yet to be established. Also under debate is how often women should be
screened - once only, or on a regular basis (ie yearly) and should women be assessed prior
to commencing tamoxifen. These all have enormous cost implications when taking into
consideration the number ofwomen on tamoxifen.
Tamoxifen is being investigated as a preventative agent for women at high risk of
developing breast cancer and trials are currently under way. Recent preliminary results
from one trial have shown a reduction in breast cancer incidence with prophylactic use of
tamoxifen and it now has a product licence in the USA for prevention of breast cancer in
high risk women. The implications for screening this group of women also need to be
considered as annual transvaginal ultrasound examination and biopsy of any ultrasound
detected lesions has been recommended by some [Bissett 1994, Ross 1995, Barakat 1995],
According to the WHO, a screening programme should fill the following criteria:
• the disease should be reasonably common and serious and its natural history should
be known.
• it should have a latent period during which time it would be appropriate to screen.
• treatment should be available and treatment at the time of diagnosis should improve
prognosis.
• the test should be valid and acceptable to patients.
• the cost of screening should be economically balanced in relation to expenditure on
medical care as a whole.
[Wilson 1968],
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There are a number of potential endometrial screening methods available:
• Ultrasound scanning - abdominal and transvaginal
• Hysteroscopy - out and in-patient
• Pipelle endometrial biopsy
• Dilation and curettage (D & C)
Ultrasound scanning is probably the easiest and least invasive of the screening techniques
and the transvaginal route is the scanning method of choice because the image obtained is
far superior to that of the transabdominal technique [Fleischer 1990, Mendelson 1988].
This is principally because of the short probe to target distance, allowing the use of higher
frequency transducers. It is accepted that an endometrial thickness in a postmenopausal
woman measuring 5mm or less is normal [Fleischer 1990, 1997, Granberg 1991, Bourne
1995, Goldstein 1990] whilst in premenopausal women the thickness of endometrium
depends on when in the menstrual cycle the scan is performed, but anything up to 10mm
in the late secretory phase is normal [Dodson 1995, Dijkhuizen 1996]. An abnormally
thick endometrium may suggest a precancerous or cancerous lesion, endometrial
hyperplasia or a polyp, none of which have specific morphologic features to allow
distinction between them [Varner 1991, Lewit 1990] but a thick endometrium with
hyperdense echoes and no distinct demarcation of endometrium/myometrium, fluid within
the cavity, an enlarged cavity and uterus are all suspicious of endometrial carcinoma in a
normal postmenopausal population [Carter 1991, Blumenfield 1996]. Bourne's [1995]
review of 1700 symptomatic postmenopausal women reported no endometrial cancer within
a uterus whose endometrium measured <5mm. Other studies support a very high
correlation between normal endometrial measurement on ultrasound scan and atrophic
endometrium at histology [Nasri 1989, 1991, Schoenfeld 1990, Granberg 1991, Possati
1994, Karlsson 1994, Mencaglia 1995].
A number of studies have been carried out assessing the use of transvaginal scanning mainly
in symptomatic women on tamoxifen and comparing this to other screening methods.
However, several workers have shown that thick cystic endometrium and alterations in the
uterine vessel vascularity - a decrease in the resistance index (RI) of vessels similar to that
seen in endometrial cancer - are frequent findings in women taking tamoxifen [Kurjak 1990,
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Bourne 1991, Achiron 1995(a), (c)]. They suggest that, in patients on tamoxifen,
transvaginal ultrasound findings may be misleading because thickening of the endometrium
is not always associated with epithelial disease [Anteby 1992, Hulka 1993, Goldstein 1994,
Bese 1996], It has also been suggested that tamoxifen may exert an echogenic and
sonolucent effect on the endometrial stroma and myometrium without necessarily causing
epithelial disease [Cohen 1993, Seoud 1993], Achiron [1995(a)] found this cystic
appearance in 44% of women studied and 2 large studies of postmenopausal women on
tamoxifen therapy failed to show any correlation between an endometrium measuring
>5mm in thickness and abnormal pathologic findings [Uziely 1993, Cohen 1993]. It may
be that cut-off values for endometrial thickness used in the general population do not apply
to women on tamoxifen and apparent increases in endometrial thickness on ultrasound scan
may be misinterpreted as abnormal.
In terms of a screening tool, ultrasound scanning is simple and cheap to perform, with a low
incidence of side effects but, from the literature, may have problems in terms of
interpretation of results, sensitivity and specificity.
Hysteroscopy and pipelle biopsy have also been suggested but are more invasive than
sonography and so may not be ideal screening tools.
Pipelle biopsy is a blind procedure and is potentially less sensitive than hysteroscopy.
Pipelle fails to obtain an adequate sample of endometrium in 20-30% ofwomen (higher in
postmenopausal women) [Guisa-Chiferi 1996, Gupta 1996, Weber 1997, Batool 1994].
D & C is also a blind procedure though it permits more thorough sampling of the
endometrium. Even with D & C, false negative rates of 10-15% have been cited and one
group found that in 60% of cases less than half the uterine cavity was curetted [Stock 1975,
Word 1958, Grimes 1982, Brooks 1988]. Several workers have therefore suggested
hysteroscopy is the 'gold standard' investigation for women [Finikiotis 1990, Gimpelson
1995, Dijkhuizen 1996, Towbin 1996, Gupta 1996], Hysteroscopy ensures that the whole
uterine cavity is visualised and so sampling can be directed. Finikiotis [1989] suggested
that in a series of 523 symptomatic women, based on hysteroscopic observation, D & C was
unnecessary in 56% and that where abnormalities were present, more were observed
visually on hysteroscopy than were detected by D & C. Specificity and positive predictive
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value of hysteroscopy has been quoted at near 100% [Parasnis 1992, Mencaglia 1995],
Although this is the best method available, it is not an ideal screening tool because of its
invasive nature.
There have been several studies comparing transvaginal ultrasound scanning to out-patient
hysteroscopy, mainly in non breast cancer non tamoxifen women, to compare their ability
to pick up abnormalities [Towbin 1996, Maia 1996, Widrich 1996, Gupta 1996, Emanuel
1995, Karlsson 1994, Indman 1995] but few have assessed patient tolerability for each
procedure and also whether patient tolerability affects the choice of screening method
employed.
Finikiotis [1993] reported that 70% of patients undergoing hysteroscopy report side effects
but that preoperative explanation of the type, severity and frequency of side effects reduces
patient anxiety at the time when side effects occur. Towbin et al [1996] reported that
141/149 patients who underwent out-patient hysteroscopy were "comfortable" during the
procedure. Downes et al [1993] went further and did score patient acceptability in 100
premenopausal women attending for out-patient hysteroscopy. They used a score of 0-10,
0= no pain/completely acceptable and 10= worst pain imaginable/completely unacceptable
and found that the mean maximum pain experienced during the procedure was 3.25 (S.D.
2.08) and the degree of acceptability was 3.02 (S.D. 1.96). Very few patients (3%) said
they would prefer a general anaesthetic if the procedure was to be performed again. De
Jong et al [1990] also aimed to assess patient acceptability of the out-patient procedure but
did so under paracervical block which could be argued to be unnecessary and more painful
than the procedure itself. In most of the women they studied, the level of discomfort was
described as tolerable but in 2 out of 152 women the procedure was abandoned because of
severe discomfort.
With the advent of narrow flexible hysteroscopes the need for paracervical block should
diminish and perhaps the only indication would be where cervical dilatation is required in
a patient with cervical stenosis [Nagele 1996], This most commonly occurs where the
patient is nulligravid, nulliparous and postmenopausal. The main source of discomfort
arises from insufflation with the C02 gas and not from passing the instrument through the
cervix.
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There is still no concensus about whether asymptomatic women on tamoxifen should be
screened nor what the ideal screening tool would be.
Thus, although it is well accepted that there is an association between tamoxifen use and
endometrial abnormalities, including cancer, the majority ofwomen have few problems on
tamoxifen. Little work has been done to assess who is at risk and whether they can be
identified prior to problems arising. This would give a target group to be screened because
at present workers are divided as to the merits of screening all women on tamoxifen trying
to pick up the few it will affect. The arguments against this centre on the cost implications
of regular screening and the large numbers of invasive procedures screening generates.
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Plasma Levels
Little work has been done trying to identity which women taking tamoxifen are at risk of
endometrial abnormalities. None of the studies to date have looked at whether plasma
levels of tamoxifen are important and relate to endometrial effects. The same daily dose
of tamoxifen is given to all women regardless of height and weight and therefore body mass
index (BMI) and few have examined whether this significantly affects plasma tamoxifen
levels. Other oncological drugs are given in different doses related to BMI so it would
seem logical that this should also be done with tamoxifen. Indeed, whilst 20mg/day of
tamoxifen is now the recommended dose, as noted above, in some studies 40mg or even
60mg/day has been used. Some researchers believe that cumulative dose may be important
[Fornander 1989], In the UK the recommended dose has decreased from 30mg/day to
20mg in the last decade after the efficacy of 20mg was demonstrated in advanced disease.
However, this dose was derived empirically.
We know that with oral administration steady state plasma levels are reached in 3 to 5
weeks. Tamoxifen is extensively metabolised in the human by hydroxylation and N-
demethylation and in plasma the main metabolite is desmethyltamoxifen (DMT). The ratio
ofDMT to unchanged tamoxifen at steady state is normally greater than 1.0 [Fried 1994],
Tamoxifen is excreted in urine and bile and has a half life of approx 10 days [de Vos 1992].
There are several methods described in the literature for the determination of tamoxifen and
its metabolites but there have been problems with recovery and analysis of the target
compounds. The analysis of tamoxifen is difficult because of its low plasma concentration
and extreme light sensitivity.
The basic principle of plasma determination of tamoxifen and its metabolites is by
extraction and high performance liquid chromatography (HPLC). Organic and solid phase
extraction methods have been used with varying success. Until recently, most pre HPLC
methods were time consuming leading to problems with photo degradation of tamoxifen,
but new quicker methods have been devised to alleviate this. Organic extraction yields
efficiencies of 60-90% whereas traditional solid phase extraction only 30%. However, a
rapid and simple solid phase extraction method has been designed in Edinburgh which gives
a reliable efficiency of approx 60% [MacCallum 1996],
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To enhance sensitivity because of the low plasma concentrations of tamoxifen and its
metabolites, photochemical activation can be employed, by which tamoxifen, a
triphenylethylene, is converted by ultraviolet (UV) radiation to a phenanthrene. This is a
unique property of tamoxifen's molecular structure which allows it to react under UV
irradiation. Thus levels can be estimated by UV fluorescence after conversion to
phenanthrene derivatives, either before or after HPLC [MacCallum 1996, Kikuta 1988,
Fried 1994, De Vos 1992],
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Tamoxifen Side-Effects
In addition to endometrial problems, women report a number of other symptoms related to
tamoxifen use. These include hot flushes/sweats and weight gain (probably the two most
commonly reported symptoms), fluid retention, vaginal dryness and vaginal discharge,
decreased sexual interest and low energy. Although these symptoms may not be classed
as "major", for some women they are very distressing and intolerable. A few find the risk
of stopping their tamoxifen before the recommended time more acceptable than having to
carry on with daily living coping with these symptoms. However this accounts for less than
5% ofwomen on tamoxifen [Jordan 1996, Wolf 1991],
In most cases there are options to try and alleviate these distressing symptoms including
megestrol acetate, clonidine, venlafaxine or prozac. If vaginal symptoms are caused by
significant vaginal atrophy, it is acceptable to try a short course ofVagifem, an oestrogenic
pessary with minimal systemic absorption.
These symptoms can be particularly distressing in premenopausal women with the relatively
sudden cessation of oestrogen especially if combined with oophorectomy.
The NSABP-14 trial compared tamoxifen versus placebo and investigated how commonly
these symptoms occurred in both pre and postmenopausal women and whether they were
confined to tamoxifen use. They found that hot flushes, vaginal discharge and irregular
menses were experienced more commonly in the tamoxifen group (Table 4). However,
many reports are anecdotal and it may be that symptoms such as weight gain and decreased
sexual interest are a reflection of the diagnosis and surgical treatment of breast cancer and
the psychological problems associated with that rather than subsequent tamoxifen treatment.
Hepatocellular cancer and ocular toxicity are 2 more serious side effects which have been
reported with tamoxifen use. Hepatocellular cancer has only been reported in laboratory
studies using very high doses of tamoxifen and is of theoretical risk only in vivo. Occular
toxicity has been reported in vivo but is rare and usually reversible following cessation of
tamoxifen [Kaiser-Kupfer 1978, Jordan 1995, Nayfield 1996],
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Table 4
NSABP-14 5 Year Tamoxifen Trial (20mg/day) vs Placebo. Reported Symptoms.
Adverse Effect Tamoxifen (n=1424) Placebo (n=1420)
Hot Flushes 63.9% 47.6%
Weight Gain (>5%) 38.1% 40.1%
Fluid Retention 32.4% 29.7%
Vaginal Discharge 29.6% 15.2%
Nausea 25.7% 23.9%
Irregular Menses 24.6% 18.8%
Weight Loss (>5%) 22.6% 18.0%
Skin Changes 18.7% 15.3%
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New Antioestrogens
Breast carcinomas in women can be separated into two types - those which are hormone
dependent and which contain oestrogen receptors and those which are hormone independent
and do not express the oestrogen receptor. The majority of tumours, particularly in
postmenopausal women are hormone dependent and treatments which lower circulating
levels of oestradiol or block its action in the breast result in tumour regression.
Tamoxifen has been the primary agent of choice for women with postmenopausal breast
cancer with ER positive large operable or metastatic breast cancer for the last 20 years and
has been shown in patients with tumours which are rich in oestrogen receptor to produce
partial or complete responses ranging from 79-85% [Howell 1998], It also has other effects
on the breast decreasing recurrence, decreasing contralateral cancer development and
decreasing the rate of development of metastases but, as described, there are unwanted
effects particularly on the endometrium, and much work has been done to find effective
alternatives to tamoxifen.
This has come in three forms:
(i) newer SERM's (selective oestrogen receptor modulators), eg raloxifene, toremifene,
idoxyphene.




Raloxifene is the most promising of the new SERM's (Selective oEstrogen Receptor
Modulators) which were originally titled non steroidal antioestrogens. Raloxifene
was developed for preventing osteoporosis and potentially for reducing the risk of
cardiovascular disease on the basis of its oestrogen-like activity [Delmas 1997,
Walsh 1998]. In addition, unlike tamoxifen, raloxifene may reduce the risk of breast
cancer without increasing that of endometrial cancer. In a trial evaluating the effect
of raloxifene on fractures in postmenopausal women it was found to produce a 76%
reduction in the incidence of breast cancer [Cummings 1999], As initial results are
promising, further trials of raloxifene versus tamoxifen are currently underway
assessing breast cancer incidence in pre and postmenopausal women [Jordan
1999(b)]. The potential effect of raloxifene on the endometrium is yet to be
established [Jordan 1999(a)], although this is promising because raloxifene has been
found to produce complete or near complete blockade of oestrogenic effect in the
uterus of castrated rats [Bryant 1995] and in chemoprevention trials halved the
endometrial cancer risk compared to a placebo group [Cummings 1998],
Specific Antioestrogens
Faslodex, ICI 182780, is a pure antioestrogen which appears to be more specific and
more potent than tamoxifen in vitro and in vivo because of its different mechanism
of action. Rather than acting as a competitive inhibitor (like tamoxifen), faslodex
substantially reduces the cellular content of the ER by decreasing the half-life of the
protein [Anderson 1996], It appears to have minimal side-effects in particular on the
uterus and has been shown in rat models to bind to the ER with high affinity, acting
as a complete antagonist [Anderson 1996, Wakeling 1991], Howell et al [1996]
reported no apparent effect of treatment with faslodex on the endometrium or the
hypothalamic-pituitary axis of 19 patients with advanced breast cancer resistant to
tamoxifen. The pure antioestrogens are therefore promising future alternatives
which are under further investigation.
Aromatase Inhibitors
Aromatase is an enzyme which is required for the conversion of androgens to
oestrogen as part of the steroid pathway (Fig 1). In premenopausal women, the
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primary source of oestradiol is the ovary, where the enzyme aromatase catalyses
conversion of androstenedione to oestrone and testosterone to oestradiol. The
amount of oestradiol produced depends on luteinising hormone (LH) which controls
the amount of substrate present and follicle stimulating hormone (FSH) which
regulates the activity of aromatase. Following the menopause, oestrogens are
primarily derived from peripheral aromatisation of adrenal precursors ofwhich the
largest concentration is androstenedione. Although several factors can influence the
output of androstenedione in postmenopausal women, eg stress and obesity, the
amount ofoestrogen produced is not controlled primarily by substrate availability but
by the magnitude of aromatase activity present. Aromatase is found predominantly
in fat, liver and muscle, the amount of fat being the major regulator of extraglandular
aromatase [Miller 1982, 1989], Following aromatisation of androstenedione to
oestrone, 17P hydroxysteroid dehydrogenase converts oestrone to oestradiol in
peripheral tissue. Since most peripheral tissues are not amenable to either surgical
or radiological ablation as treatment for breast cancer, oestrogen deprivation needs
to be based on therapies which destroy androgen producing tissues or drugs which
inhibit the enzymes involved in oestrogen biosynthesis, eg aromatase. Drug induced
oestrogen blockade is much more attractive in that it is potentially reversible and
produces minimal side effects [Jonat 1990, Miller 1995].
The concentrations ofmajor oestrogens differ markedly between the circulation and the
breast. Evidence for this is that:
(i) tissue concentrations of oestradiol are similar in pre and postmenopausal women
despite the marked reduction in peripheral oestradiol levels following the
menopause.
(ii) in postmenopausal women endogenous levels of oestrogen are significantly higher
in the breast compared with the circulation, the tissue : plasma ratio for oestrone is
approximately 3 and that for oestradiol is 20, and
(iii) oestrone and its sulphate levels predominate over those of oestradiol in the
circulation but levels of oestradiol are similar to or higher than oestrone in breast
tissue. The differences in oestrogen within mammary tissue could be because of -
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(a) selective uptake of specific oestrogens from the circulation against a
concentration gradient, or
(b) active synthesis or metabolism within the breast [Miller 1989],
In vivo studies have demonstrated significant uptake of oestrone and oestradiol into breast
tumours. Although receptor binding is a major determinant of tissue oestrogen levels,
several studies have supported the hypothesis that breast tumours can synthesise oestradiol
locally [Miller 1982], Androstenedione may be converted to oestrone by the aromatase
enzyme and oestrone may be produced from oestrone sulphate via the sulphatase enzyme
(Fig 2). A final common pathway is then necessary to convert oestrone to oestradiol
through the 170 hydroxysteroid dehydrogenase enzyme [Jonat 1990]. The enzymes for
each of these reactions have been demonstrated to be present in human breast cancer tissues
and the biological importance of tumour aromatase is that aromatase inhibitors can block
oestrogen production irrespective of the site of synthesis, whether it be glandular or
peripheral and will directly block oestradiol synthesis within a tumour. Clinically, useful
inhibitors should have the potential to suppress oestrogen levels beyond those achievable
by destruction of any individual endocrine gland [Miller 1989]. Oestrone sulphate,
oestrone and oestradiol all arise from aromatised androstenedione, so inhibition of
aromatase is a key target for reducing the amount of oestradiol available to stimulate breast
tumour growth.
The first aromatase inhibitor used in clinical practise was aminoglutethamide but it was
used originally without the knowledge that it had antiaromatase properties. It was
introduced as a form ofmedical adrenalectomy for the treatment ofmetastatic breast cancer.
It was, however, also found to block peripheral conversion of androgens to oestrogens and
to suppress circulating oestrogens. It was found to be a non specific inhibitor and affected
other cytochrome P450 systems, blocking cholesterol side chain cleavage and thus
corticosteroid production (Cortisol and aldosterone). Aminoglutethamide markedly
lowered plasma and urinary oestrogen levels (by 50-80%) and clinical trials revealed rates
of breast tumour regression similar to conventional antioestrogens. In postmenopausal
women with advanced breast cancer it produces 90-95% inhibition of aromatase and
response rates similar to those reported for other endocrine therapies [Santen 1999],
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However, whilst clinically effective, aminoglutethamide is not an ideal aromatase inhibitor
because of its non-specificity, side-effects and the requirement for corticoid replacement
when prescribed at higher doses because it interferes with glucocorticoid synthesis. A wide
variety of newer and more specific aromatase inhibitors have been developed and third
generation aromatase inhibitors include drugs such as anastrozole, letrozole and exemestane
which are substantially more potent than aminoglutethamide at inhibiting in-vitro aromatase
activity, are more selective and have substantially fewer side effects [Hamilton 1999],
To date the trend has been to use aromatase inhibitors as second or third line hormone
therapy, ie in advanced disease because of their low specificity and side effects but the
interest in the newer generation of aromatase inhibitors stems from the fact that they appear
to be more potent and much more specific. They suppress whole body aromatization by
>95% and oestrogen levels by at least 80% and these effects can be achieved without
measurable influences on other steroid hormones [Geisler 1995],
Neo-adjuvant (primary medical) treatment has been used to treat large operable and locally
advanced breast cancers but this has been mainly in the form of chemotherapy. Few
centres have evaluated neo-adjuvant endocrine therapy in hormone sensitive large operable
and locally advanced breast cancer. In postmenopausal women the most common neo¬
adjuvant endocrine agent used has been tamoxifen and in those with oestrogen receptor
positive tumours high response rates have been reported and significant reductions in
tumour volumes seen over a 3 month period [Keen 1997].
However, with the concern regarding tamoxifen's side effects and the development of the
newer potent, specific aromatase inhibitors, studies are in progress to investigate the
effectiveness of aromatase inhibitors as neo-adjuvant therapy for patients with locally


































Tamoxifen has an undisputed role in the treatment of breast cancer but early studies
suggested a link between tamoxifen use and the development of endometrial abnormalities,
including cancer. Subsequent research has attempted to establish the extent and determine
the frequency of endometrial abnormalities. Little work has been done to assess the risk
of abnormalities in asymptomatic women on tamoxifen and therefore to establish whether
screening for these women is required. If a screening programme is to be considered, the
ideal screening tool has yet to be established. There exists an ideal opportunity in
Edinburgh to investigate whether screening is of value as women, until recently, remained
on tamoxifen until the time of first recurrence of breast cancer, consequently giving a large
potential study population ofwomen receiving tamoxifen for variable lengths of time, some
for over 15 years.
Of particular interest is the standard dose of tamoxifen taken by all women, 20mg/day,
regardless ofbody mass index. Little work has been undertaken relating plasma levels of
tamoxifen to the subsequent development of endometrial abnormalities.
The aims of the present series of studies can therefore be summarised as:
to determine the incidence of endometrial abnormalities in asymptomatic patients
with breast cancer, taking tamoxifen;
to investigate the relationship between length of time on tamoxifen and endometrial
abnormalities;
to investigate the relationship between blood levels of tamoxifen and endometrial
abnormalities;
to investigate the relationship between body mass index and plasma tamoxifen levels
to assess whether all patients require the same dose;
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to evaluate the following screening tools - transvaginal ultrasound and out-patient
hysteroscopy in terms ofpicking up abnormalities and patient tolerability;
to investigate histology and markers of cell turnover in thickened endometrium;
to assess the incidence ofother side effects on tamoxifen;




All patients were recruited from the long term follow-up clinic in the Breast Unit at the
Western General Hospital. Patients attend 6 monthly for the first 2 years following
diagnosis and treatment of breast cancer, then yearly thereafter. Patients on tamoxifen
were identified from the clinic list prior to their attendance and were approached
immediately following their visit. All patients in the study group were disease free and on
tamoxifen as adjuvant treatment for breast cancer and had been on tamoxifen at the time of
recruitment for between 5 months and 16 years duration. 357 women on tamoxifen, both
pre (42) and postmenopausal (315) were recruited over the study period. All women had
an intact uterus at the time of recruitment.
Pilot Study
The first 120 women recruited were asked to take part in the pilot study which involved
having a transvaginal ultrasound scan, a pipelle biopsy and out-patient hysteroscopy
performed. 150 women were asked and 120 agreed to these investigations. Consent was
obtained for all procedures.
The aim of the pilot study was to identify the best method of screening in terms of picking
up abnormalities and tolerability of the procedure.
An ultrasound scan was performed on all women and pipelle biopsy was performed
immediately following the scan.
Patients returned within the next 10 days to have out-patient hysteroscopy performed. It
was not possible to perform all three investigations at one visit because pipelle biopsy may
cause bleeding, rendering it impossible to view the cavity with the hysteroscope.
Hysteroscopy is not ideally done prior to the pipelle because it uses insufflation with C02
gas in order to view the cavity. Pipelle works by suction and prior uterine insufflation with
C02 renders this difficult. The scan was performed in the Mammography Department and
the hysteroscopy in the Day Bed Area at the Western General Hospital, logistically making
it difficult to have all investigations performed at the same visit. Therefore, it was
necessary for patients to attend on two separate occasions.
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Study Group
Following the pilot study, the remaining 237 women recruited (from 260 approached)
underwent ultrasound scanning and patients with an abnormal scan went on to out-patient
hysteroscopy. Out-patient hysteroscopy was again performed at a separate visit and
consent was obtained for all procedures performed.
Controls
200 women with a diagnosis of breast cancer never having received tamoxifen were
approached and asked to act as controls. They were identified from the database of the
Edinburgh Breast Unit and from long term follow-up clinics. Where women were
identified from the database, a letter was sent to them explaining the study and asking if
they would agree to take part. Where they were identified from the long term clinic, they
were approached directly after their clinic appointment. 130 agreed to take part and all
women were asymptomatic at the time of investigation. They consented to ultrasound
scanning only as it was not anticipated that many of this group would require further
investigation for abnormalities.
All GPs were notified of patients entering the trial and were sent a copy of the patient
information sheet. GPs were thereafter notified of abnormal results and the subsequent
action taken.
Patients requiring investigation beyond hysteroscopy were referred to the Eastern General
Hospital under the care ofDr J B Scrimgeour. Further investigation consisted ofD & C
in 35 women and oophorectomy in 2 women.
Statistical Analysis
Statistical analyses were conducted using the Instat software package (Graphpad Software
Inc, San Diego, CA).
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Transvaginal Ultrasound Scanning
Experience in transvaginal ultrasound scanning was gained over a 4 month period from Dr
B B Muir, Consultant Radiologist. All scans were performed using an ATL Apogee 800
ultrasound machine (Advance Technology Laboratories UK Ltd, Letchworth, UK) with a
transvaginal probe specially purchased for this project.
All women recruited into the study had transabdominal pelvic ultrasound performed using
a 2-5MHz curved array probe immediately prior to transvaginal ultrasound to screen for
major pelvic abnormalities as the transvaginal probe has a narrow field of vision. Patients
were asked to attend with a full bladder which was necessary for the transabdominal
approach. Following the transabdominal scan, patients were asked to empty their bladder
prior to the transvaginal scan which was performed using a 5-8 MHZ endocavity
(transvaginal) probe.
All scanning was performed in a specific ultrasound room with the patient lying on a couch.
A gynaecologic examining table was not available so patients were asked to sit on a pillow
in order to tilt their pelvis forward making the scan easier. This allowed scanning of the
anterior pelvis which requires the transducer handle to be passed down toward the floor so
that the transducer tip is projected upward, directing the ultrasound beam into the anterior
pelvis. The vaginal probe was covered with a condom (ultra strong condom as
recommended for protection against infection, in particular HIV infection). A sonic
coupler was placed in the condom and KY jelly applied to the outside of the condom. The
probe was then passed into the vagina and advanced to the level of the vaginal fornix to
begin the scan.
A sonic coupler is needed to decrease the acoustic impedance as sound leaves the
transducer and enters the body. Even a small layer of air between the transducer and the
body results in marked sound attenuation and artefacts. To acoustically couple the
transducer to the vaginal mucosa, jelly was placed in the condom. Additional lubricant is
placed on the surface of the condom to serve as an acoustic coupler between the condom
and the patient [Dodson 1995],
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In each case the uterus was identified initially and its length, width and thickness measured
in millimetres by first directing the sound beam anteriorly and posteriorly in the pelvis,
giving an anterior posterior pelvic (AP-pelvic) plane image and then rotating the transducer
through 90 degrees to direct the sound beam across the pelvis from side to side giving a
trans-pelvic (T-pelvic) plane image. All measurements were made using the machine's
electronic callipers. The endometrium was then measured, double thickness, in millimetres
in both the T-pelvic and AP-pelvic position. The endometrium is visualised within the
uterus as a central echo and the whole endometrium was evaluated and measured at its
thickest part. Premenopausal endometrium can measure up to 10mm in the secretory phase
but the upper limit for postmenopausal endometrium is 5mm. Both ovaries, where present,
were visualised and checked for the presence of cysts by moving the transducer lateral to
the uterus in the T-pelvic plane. Premenopausal ovaries are generally easy to identify
because of their size and the presence of anechoic follicles within them. Postmenopausal
ovaries can be more difficult to identify but this study was interested in the detection of
ovarian cysts, which, like ovarian follicles, are easily identifiable if present. Any other
abnormalities were also noted, eg free fluid in the Pouch of Douglas, intracavity fluid or
fibroids [Dodson 1995],
Ultrasound images of the uterus and endometrium in the AP-plane and T-plane were frozen
and a hard copy was exposed onto single sided emulsion x-ray film using a multiformat
camera. All films were retained for future validation purposes.
The probe was decontaminated as recommended by the manufacturer between patients by
washing with Travisept (Chlorhexidine Acetate BP 0.015% and Cetamide Ph.Eur.0.15%)
and once weekly the transducer was disinfected by soaking in Travisept for 20 mins.
Of the 120 women in the pilot study, the first 10 in whom thickened endometrium was
detected were re-scanned by Dr B B Muir to confirm the investigator's findings. In all 10
cases, thickened endometrium was confirmed. Thereafter, Dr B B Muir re-scanned cases
only where the investigator was unsure of the findings and requested confirmation.
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Hysteroscopy
Out-patient hysteroscopy was performed in the Day Bed Unit at the Western General
Hospital. A trained nurse assisted with the procedure. A 3,6mm diameter Olympus HYF-P
flexible hysteroscope (KeyMed (Medical & Industrial Equipment) Ltd, Livingston,
Scotland) was used which did not require a local anaesthetic cervical block. Uterine
insufflation using an Olympus uteroflator was with C02 gas or, on occasion, saline.
Training required to perform hysteroscopy was obtained under Dr J B Scrimgeour and Dr
J A Milne, both Consultant Gynaecologists working at the Eastern General Hospital,
Edinburgh. Initially, hysteroscopy was performed with consent on women attending the
Eastern General Hospital as day cases for general anaesthetic hysteroscopy and D & C,
usually for investigation of abnormal bleeding/postmenopausal bleeding. Once competent
at the technique, further experience was gained by attending out-patient hysteroscopy
sessions run by Dr J A Milne at Leith Hospital, Edinburgh. Initial study hystcroscopics
were supervised and validated by Dr J B Scrimgeour. Subsequently hysteroscopies were
recorded on video and reviewed at the end of each session by Dr J B Scrimgeour. Where
abnormalities were detected or where hysteroscopy could not be performed, patients went
on to day case D & C and hysteroscopy for further assessment under general anaesthetic at
the Eastern General Hospital, Edinburgh.
Out-patient hysteroscopy took approximately 30 minutes to perform and all patients were
fully aware of potential side effects. The most common side effect is crampy lower
abdominal pain which is similar in nature to 'period pain', whilst a few patients experience
shoulder tip pain caused by the C02 gas permeating out of the fallopian tubes into the
abdominal cavity and tracking up the paracolic gutters, irritating the underside of the
diaphragm. The only potentially serious side effect is cervical shock which may result
from passing the instrument through the cervix. This leads to bradycardia and hypotension
and can result in loss of consciousness. A facial oxygen mask and oxygen supply and
intravenous atropine was readily available at all times for the treatment of cervical shock.
All patients underwent hysteroscopy in the lithotomy position. Vaginal examination was
performed before each procedure to determine size and position of the uterus. This was a
clean rather than sterile procedure although the hysteroscope was sterilised between patients
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using Nu-cidex. A vaginal speculum was passed and the cervix and cervical os visualised.
A uterine sound was passed to determine cavity length and direction. The cervix was
grasped with a vulsellum, ifnecessary, and the hysteroscope passed through the cervical os
into the uterine cavity. Several elderly women required minor cervical dilatation using
cervical dilators before the hysteroscope could be passed. In 8 women cervical dilatation
was not possible because of cervical stenosis and the procedure was abandoned. All 8
women proceeded to D & C for further investigation.
Insufflation took approximately 30 seconds and once a good view was obtained the uterine
cavity was inspected thoroughly from uterine fundus to internal cervical os and cervical
canal as the hysteroscope was withdrawn. Both ostia were identified in all cases.
The procedure was visualised using an Olympus camera attached to the hysteroscope and
a 21" Sony colour monitor. All hysteroscopies were recorded and retained on video for
validation purposes.
Where appropriate, an attempt was made to obtain endometrial specimens using a Sharman
curette and fixed in 10% buffered formaldehyde solution prior to being sent to pathology.
Biopsy forceps were used in an attempt to obtain material where the investigator was unable
to obtain specimens by means of the Sharman curette. Unfortunately, few specimens were
obtained by either of these methods and in cases where specimens were essential to exclude
serious underlying pathology, women proceeded to D & C.
Once the procedure was finished, patients were asked to remain lying down for 5-10
minutes to recover and allow any discomfort to subside and thereafter they remained in the
out-patient department for at least 30 minutes before going home.
All patients were informed of the result of the hysteroscopy before leaving the department.
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Pipelle Biopsy
Pipelle biopsy was attempted in the 120 women who took part in the pilot study. This was
done following the ultrasound scan and involved passing a standard plastic disposable
speculum into the vagina and visualising the cervix. Once visualised the pipelle was
passed through the cervix and specimens obtained by applying suction. Specimens were
fixed in 10% buffered formaldehyde solution and sent to the Pathology Department,
Western General Hospital, for review.
It became apparent early in the study that pipelle biopsy was not successful in a large
number of women and that few satisfactory specimens were obtained. The specific
problems encountered were:
1. Many of the women were postmenopausal and elderly and therefore suffered from
vaginal atrophy. The disposable speculums used are a standard size and, as such,
were too big for these women. They found the procedure too uncomfortable to
permit pipelle biopsy. The speculum used for the hysteroscopy were Cusco bivalve
speculum which are metal and variable in size and were used because there was the
facility to sterilise them between cases. Had the investigator had the facility to
sterilise the smaller metal speculum in the scanning room, this method may have
been more successful. This was not possible because of the conditions attached to
the use ofNu-Cidex. The financial constraints of the study did not allow for the
purchase of large numbers ofCusco speculum which would require to be sent to, and
await return from, CSSD (Central Stores and Supplies Department) within the
Western General Hospital for standard steam sterilisation.
2. Visualisation of the cervix and cervical stenosis was a further problem. The women
were not in an ideal position (unlike for the hysteroscopy where they were in lithotomy
on a gynaecological table with their legs on leg rests) to allow easy visualisation of the
cervix and to attempt dilation of the cervix where necessary, so whilst all pipelle
biopsies were attempted, only 59% were successful. A successful pipelle was classed
as one where the cervix was adequately visualised and the pipelle passed through the




One of the aims of the study was to investigate markers of proliferation in endometrial
specimens from women on tamoxifen. The aim was to obtain these specimens by means
of Sharman endometrial biopsy curette (Dupae Health Care, Leeds, UK) taken during
hysteroscopy or pipelle biopsy. Unfortunately insufficient samples were obtained by these
methods to make this feasible.
Specimens were subsequently identified from ISD Scotland (Information & Statistics
Department), Trinity Park House, Edinburgh. A list of all breast unit patients with a
diagnosis of breast cancer in the preceding 10 years was obtained from the SMR (Scottish
Morbidity Records) 6 database (Cancer registration) and supplied to ISD and was linked to
their SMR 1 database (General acute in-patient and day case discharges) to determine those
women who had also had a hysterectomy performed after the diagnosis of breast cancer had
been made.
From hospital notes it was then possible to determine whether or not they had been taking
tamoxifen at the time of their hysterectomy and from most notes the pathology details of
the hysterectomy could be determined. For ease of retrieval of specimens, only women
who had their hysterectomy in the Edinburgh area (Royal Infirmary, Western General,
Eastern General); St John's Hospital/Bangour Hospital, Livingston; Borders General
Hospital, Melrose and Roodlands Hospital, Haddington, were included. No patients were
approached but all consultant gynaecologists at the above hospitals, where a gynaecology
unit is still present, were contacted to obtain permission to retrieve gynaecology notes
where required. Identifying women who had received their gynaecological surgery in the
Edinburgh area also implied that they were most likely to be followed up from their breast
cancer in the regional centre serving these areas - the Edinburgh Breast Unit, Western
General Hospital, Edinburgh, making retrieval of oncology case notes possible.
By combining SMR 1 and SMR 6 data, 195 women were identified in the Edinburgh and
surrounding area. 134 sets of case notes were retrievable and all were studied by the
investigator. 48 women were identified on tamoxifen at the time of their hysterectomy and
a further 19 women were identified to act as controls (with a diagnosis of breast cancer but
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not receiving tamoxifen at the time of hysterectomy).
The pathology specimens for 48 women (34 study women and 14 controls) were retrieved
with the help ofDr Alistair Williams, Consultant Pathologist, Royal Infirmary, Edinburgh
and Dr Alistair Lessels, Consultant Pathologist, Western General Hospital, Edinburgh.
Haematoxylin and Eosin (H & E) slides from each specimen were retained to investigate
the pathological tissue changes on tamoxifen. The slides were studied blindly by the same




From the original specimen blocks of 16 women on tamoxifen at the time of hysterectomy
and 5 control women (with a history of breast cancer not on tamoxifen) 4 x 3 pm tissue
sections were cut and mounted onto superfrost slides to stain for markers of cellular
proliferation, ER and MIB 1. Staining was performed by Miss L MacFarlane, Pathology
Department, Western General Hospital, Edinburgh.
Antibody to oestrogen receptor (ER)
Sections were mounted on Superfrost slides and de-waxed in Xylene for 5 minutes twice,
to dissolve all paraffin wax, followed by immersion in pure alcohol twice for 30 seconds
each, followed by immersion in industrial methylated spirits for 30 seconds and then rinsed
in running water. Sections were incubated in 3% hydrogen peroxide for 10 minutes to
block endogenous peroxide activity (3mls Hydrogen peroxide in 1 OOmls distilled water)
and again rinsed in running water. Slides were then immersed in citrate buffer (pH 6.0) and
underwent 10 minutes pressure cooker pre-treatment in a microwave for optimal antigen
retrieval and were loaded onto a Shandon sequenza and placed in PBS (phosphate buffered
saline) for 5 minutes.
Slides were then incubated in lOOpl ofAvidin/Biotin blocking kit (Vector Laboratories Ltd,
Peterborough UK) for 30 minutes to block non-specific binding. 1 OOpl per slide ofprimary
antibody was applied (Dako ER (Dako Ltd, Ely, Cambridgeshire UK) antibody diluted in
Dako background reducing diluent and Biotin form the blocking kit) and incubated at room
temperature for 60 minutes. Sections were rinsed in PBS for 5 minutes.
Secondary antiserum, (Biotinylated anti-mouse IgG from Vector Laboratories) was applied
to slides and incubated at room temperature for 30 minutes and then washed in PBS for 5
minutes. Sections were then incubated in StrepABComplex/horseradish peroxidase as
instructed in the Duet kit for 30 minutes and rinsed in PBS.
Slides were then incubated in Dako Strept Avidin/Biotin complex reagent kit for 30 minutes
at room temperature, washed in PBS and then washed in deionised water to clean the
sections.
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Slides were removed from the Shandon Sequenza and DAB (Diaminobenzidine) applied
to each section and allowed to incubate for 5 minutes. They were washed in water and
enhanced in copper solution (copper sulphate and NaCI) for a further 5 minutes staining ER
positive cells brown and then counterstained in Mayers Haematoxylin for 1-2 minutes,
showing non staining nuclei blue. Acid alcohol was applied to remove excess haematoxylin
and weak ammonia solution (0.5% aqueous NH3) to turn the haematoxylin from purple to
blue. Slides were washed in tap water before being dehydrated by immersing in industrial
methylated spirits, followed by pure alcohol x 2 for 5 minutes each, then two changes of
Xylene for 5 minutes each and finally mounted in DPX (mounting medium).
MIB - 1 antibody to proliferating cells
A similar method was used for staining with MIB-1 antibody, directed against proliferating
cells. The primary antibody used was MIB-1 (Biogcncx, USA - British distributor,
A. Menarini, Wokingham, Berkshire, UK) and slides were incubated in primary antibody
for 30 minutes at room temperature. All other steps in the staining protocol were as for ER
as described above.
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Tamoxifen Metabolite Plasma Levels
All women had blood taken following their ultrasound scan to measure endometrial
thickness for measurement of plasma tamoxifen and its metabolites 4-hydroxytamoxifen
and desmethyltamoxifen. Although metabolite E is thought to be the most oestrogenic of
tamoxifen's metabolites, it is present in very small amounts and was not possible to
measure. 20 patients had a second blood sample taken at the time of hysteroscopy to
ensure blood levels were stable and to validate the technique. Blood was placed into
Heparin-Lithium vials and spun down at 3000rpm for 15 minutes to separate the plasma
fraction, which was then extracted into containers, wrapped in foil (because tamoxifen is
light sensitive) and frozen at (-40°C). Levels of tamoxifen and its metabolites were
measured by solid phase extraction and reversed phase high performance liquid
chromatography (HPLC) which was a new rapid technique developed in Edinburgh.
Materials
Standard solutions were prepared in methanol (MeOH) and stored at 4°C. MeOH and
acetonitrile (ACN) were ofHPLC reagent grade and triethylene (TEA) and sodium chloride
(NaCI) were obtained from Sigma (Poole, UK). Water was deionised (dH20) and bi-
distilled in an Analyst HP Select still.
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Plasma Preparation
Prior to extraction the samples were thawed and precipitated protein removed by
centrifugation at 469g for 5 mins.
The solid phase extraction technique is shown below.
1. Activation (2ml MeOH)
2. Wash (2ml dH20)
3. Load sample (lml plasma)
4. Wash (lml dH20)
5. Wash (lml dH20:MeOH, 50:50)
6. Wash (lml ACN)
7. Elution (2ml MeOH:NaCl,95:5)
8. Dry under vacuum
9. Re-suspend (200pl MeOH)
10. Inject 20pl onto column
Solid phase extraction was carried out on Bond-elut C2 3cm3 columns. An optimum sample
size of 1ml was applied to each column. Activation and pre-sample washing were carried
out using 2ml volumes, after which, sample loading and post-sample washes were carried
out using lml volumes. Final elution was with 2ml of 1M NaCl in MeOH (5:95, v/v).
Eluents were dried down in a Uniscience Univap centrifuge then re-suspended in 200pl of
MeOH and finally placed into 0.3ml, 8mm glass inert vials for analysis.
A second lml sample was extracted from each patient and to each duplicate sample lOpl
Cis-tamoxifen (CIS, 0.1 pg/ml) was added as an external standard to monitor extraction
efficiency. At the same time lOpl ofCIS was added to 190pl MeOH as a control.
lml x 2 of plasma from an untreated patient was also applied to columns, the second lml
sample having 1 Opl ofmixed metabolites (0.1 pg/ml) added. A second standard contained
lOpl ofmixed metabolites in 190pl MeOH.
56
High Performance Liquid Chromatography (HPLC)
The chromatography system consisted of a Merck Hitachi L-6000 solvent delivery system;
a Spark-Holland Basic Marathon autosampler (set to inject 20pl); an ICT Beam Boost
photochemical reaction unit; a Waters Associate Model 440 absorbance detector (set to
detect 265nm) and a Hewlett-Packard HP 3394 A integrator. The stationary phase was
pBondpack Cl8 packed in a 30cm x 3.9mm ID stainless steel column with a 1-cm Q8 guard
column and the mobile phase consisted of 1% TEA in MeOH. Mobile phase components
were passed through a 0.22pm filter and degassed prior to use. Elution was isocratic at a
flow rate of 1.2ml/min at ambient room temperature.
Method development established pH 8 as the optimal pH for resolution of tamoxifen and
its metabolites. A pBondpack CIg column was found to give the best peak separation,
symmetry and area to height ratios. The lowest signal-to-noise ratio was achieved for




From the literature there appears to be a 2-3 fold increase in the incidence of endometrial
cancer in women taking adjuvant tamoxifen. In view of this, should women taking
tamoxifen either as adjuvant therapy or as part of ongoing breast cancer prevention trials
be screened for endometrial abnormalities. Further, if screening is advocated what is the
optimum screening protocol?
The aim was to establish the incidence of endometrial abnormalities in asymptomatic
women on adjuvant tamoxifen and to evaluate the various screening methods available.
Symptomatic women, ie those who present with abnormal bleeding/discharge are
thoroughly investigated primarily to exclude malignancy and there have been various
studies assessing endometrial problems in symptomatic women on tamoxifen. Establishing
the incidence of abnormalities in asymptomatic women would enable conclusions to be
drawn regarding screening programme requirement and which screening tool was
appropriate. A further aim was to investigate the relationship between the length of time
on tamoxifen and the incidence and nature of any endometrial abnormalities.
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Patients and Methods
The pilot study was performed on the first 120 patients on tamoxifen recruited into the
study. They all consented to have transvaginal ultrasound scan (TV USS), out-patient
hysteroscopy and pipelle biopsy performed. This was to assess which was the best
screening method in terms of detection of abnormalities and tolerability of the procedure.
For each patient a proforma was completed to collect data on menopausal status, age, time
on tamoxifen/cumulative dose of tamoxifen, endometrial thickness on ultrasound scan,
details ofpipelle biopsy and hysteroscopy findings. With this information the relationship
between time on tamoxifen and endometrial abnormalities could be established.
All patients were asked to complete a procedure score evaluating the pain and discomfort
experienced during each procedure. This was done by means of a 10 point scale where
l=not uncomfortable and 10=very uncomfortable. This was completed after all three
procedures had been performed/attempted so patients were able to compare each procedure.
This was felt to be important because when evaluating a possible screening tool the
tolerability of each procedure needs to be established.
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Results
Table 1 gives patient details and results from endometrial screening for the first 120 women
on tamoxifen.
Of the 120 patients (age range 40-76) in the pilot study (18 premenopausal and 102
postmenopausal) 66 had an endometrium measuring <5mm or were within the accepted
cycle limits for premenopausal women (anything up to 10mm in the late secretory phase is
normal) and 54 had thickened endometrium as measured by transvaginal ultrasound scan.
The first 10 women with thickened endometrium on ultrasound scan had the scan repeated
by a single consultant radiologist to confirm endometrial thickness and in all cases
measurements were comparable.
107 women went on to have out-patient hysteroscopy. At hysteroscopy, all women with
normal thickness endometrium on scan had normal or atrophic endometrium. There were
2 women whose endometrium measured 4mm on scan who, although had a normal
endometrium at hysteroscopy, were found to have other abnormalities, one being a tiny
polyp at the internal cervical os and the other a small submucous fibroid.
13 women could not be hysteroscoped. This was because of cervical stenosis in 7 women,
a large cervical polyp in 1 woman, being unable to pass and open the speculum sufficiently
to view the cervix in 3 women and 1 refusal to have hysteroscopy; this latter woman agreed
initially to have all three procedures performed as part of the pilot study but, following a
normal scan, she declined any further investigation. One woman was not deemed fit enough
to have hysteroscopy performed as she became very breathless when placed flat at the outset
of the procedure.
Only 4 women who had a failed hysteroscopy had thickened endometrium on TV USS. All
4 went on to have a D & C to investigate this further; 3 were found to have atrophic
endometrium and the other had a benign polyp at D & C.
The remaining 9 women who had a failed hysteroscopy did not have thickened
endometrium on scan and had no further investigation performed. Each individual woman
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was discussed with a consultant gynaecologist who agreed that subjecting these
asymptomatic women to D & C was not justified.
Of the 50 women who were identified on TV USS to have thickened endometrium and went
on to have hysteroscopy performed, 19 actually had atrophic/normal endometrium at
hysteroscopy and 31 had benign endometrial changes.





This gives a 38% false positive scan rate (19/50) and a 26% (31/120) incidence of benign
changes although only 45% (14/31) of these benign changes are due to polyps and fibroids,
the remainder being cystic or oedematous endometrium.
Pipelle was attempted in all 120 women but was successful in only 49 (41%). Of those 49,
tissue was obtained in only 5, all of which were benign.
Of the 18 premenopausal women, pipelle was unsuccessful in 8 (44%), was successful but
no tissue was obtained in 8/18 (44%) and was successful and benign tissue obtained in 2/18
(11%). Similarly, in the 89 postmenopausal women (the 13 women where hysteroscopy
was also unsuccessful have been excluded from this calculation) pipelle was not successful
in 40/89 (45%), was successful but no tissue was obtained in 36/89 (40%) and was
successful and benign tissue obtained in 3/89 (<5%).
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Table 2 gives all patient details of time on tamoxifen and cumulative dose and endometrial
thickness on ultrasound scan.
Time on tamoxifen was calculated in months.
Cumulative dose was calculated by:
Dose per month = 365 x20mg/12 = 610mg
Cumulative does = dose per month (61 Omg) x time on tamoxifen in months
In one patient this calculation was not used because she did not take tamoxifen regularly.
Her cumulative dose was adjusted accordingly.
There was a highly significant positive correlation between length of time on tamoxifen
(and cumulative dose of tamoxifen) and endometrial thickness as measured using
transvaginal ultrasound scan, p=0.0003 on Spearman correlation.
The relationship between endometrial thickness and duration of tamoxifen use is
demonstrated graphically in Figures 1 and 2 and the relationship between endometrial
thickness and cumulative dose of tamoxifen in Figures 3 and 4.
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1. EF 74 post 17 N/atrophic No
2. HM 56 post 6 oedematous No
3. SP 67 post 7 N/atrophic Yes-NT
4. OK 61 post 20 N/atrophic No
5. CC 49 pre 3 N/atrophic Yes-NT
6. AC 53 post 4 N/atrophic Yes-NT
7. EB 52 pre 2 N/atrophic Yes-B
8. MC 67 post 4 N/atrophic No
9. BU 45 pre 5 N/atrophic No
10. EH 61 post 3 N/atrophic No
11. JB 65 post 7 cystic Yes-NT
12. AS 61 post 3 N/atrophic No
13. MS 67 post 3 N/atrophic Yes-NT
14. EB 69 post 38 oedematous No
15. JA 64 post 23 polyp Yes-NT
16. MM 52 pre 15 cystic No
17. MW 61 post 12 oedematous No
18. MMc 66 post 5 N/atrophic No
19. EM 45 post 2 N/atrophic No
20. MC 67 post 5 N/atrophic Yes-NT
21. MS 70 post 22 oedematous+polyp No
22. CM 64 post 2 not done
cervical stenosis
No
23. GK 50 post 6 N/atrophic No







25. MG 42 pre 5 N/atrophic No
26. HD 66 post 4 N/atrophic Yes-NT
27. MM 62 post 4 N/atrophic No
28. WK 45 post 3 N/atrophic Yes-NT
29. MK 70 post 3 N/atrophic No
30. MH 65 post 7 N/atrophic No
31. KR 58 post 11 N/atrophic Yes-NT
32. LR 67 post 8 N/atrophic No
33. ER 55 post 5 N/atrophic Yes-NT
34. JR 68 post 2 N/atrophic No
35. CS 53 post 7 submucous fibroid Yes-NT
36. SR 45 pre 3 N/atrophic Yes-NT
37. MR 64 post 4 N/atrophic No
38. JU 54 post 14 cystic
submucous fibroid
No
39. ED 60 post 7 N/atrophic No
40. AD 72 post 3 N/atrophic No
41. MM 67 post 3 N/atrophic Yes-NT
42. AS 75 post 2 N/atrophic No
43. AMc 68 post 6 N/atrophic No
44. CH 65 post 3 N/atrophic No
45. SD 72 post 6 polyp Yes-NT
46. JA 74 post 4 N/atrophic (polyp) Yes-NT
47. GT 69 post 3 N/atrophic No
48. LL 66 post 5 not done; unable to
pass speculum
No
49. KD 73 post 6 N/atrophic No
50. SM 61 post 4 N/atrophic No







52. NB 66 post 6 oedematous No
53. MM 74 post 7 N/atrophic Yes-NT
54. DS 52 pre 5 N/atrophic Yes-NT
55. JR 54 post 20 oedematous Yes-NT
56. ES 64 post 13 not done
cervical stenosis
No
57. MG 66 post 27 oedematous+polyp No
58. MD 59 post 3 N/atrophic No
59. MP 42 pre 7 N/atrophic Yes-NT
60. FB 71 post 13 cystic No
61. MR 54 pre 25 oedematous+cystic Yes-NT
62. ES 67 post 16 oedematous+polyp No
63. CA 65 post 19 oedematous+polyp No
64. PC 48 pre 4 N/atrophic Yes-NT
65. IH 74 post 3 N/atrophic No
66. FN 75 post 15 N/atrophic Yes-NT
67. EF 67 post 3 N/atrophic No
68. AL 76 post 5 N/atrophic Yes-NT
69. JC 52 pre 12 polyp No
70. DM 58 post 15 polyp No
71. FR 49 post 3 N/atrophic Yes-NT
72. JD 57 post 7 N/atrophic Yes-B
73. JF 64 post 9 not done
cervical stenosis
No
74. IR 54 post 4 N/atrophic Yes-NT
75. ED 62 post 6 N/atrophic Yes-B
76. JC 65 post 10 oedematous Yes-NT
77. MD 65 post 8 oedematous Yes-NT







79. MT 62 post 6 N/atrophic No
80. DS 64 post 3 N/atrophic No
81. MH 55 post 15 N/atrophic Yes-NT
82. EH 64 post 5 N/atrophic Yes-NT
83. DR 80 post 6 oedematous No
84. ER 67 post 4 not done - not fit
for procedure
No
85. KM 54 pre 6 N/atrophic
submucous fibroid
No
86. JB 50 pre 4 N/atrophic No
87. DK 76 post 11 polyp No
88. EG 68 post 4 N/atrophic No
89. EC 67 post 6 polyp No
90. AS 59 post 7 N/atrophic Yes-NT
91. BR 56 pre 4 N/atrophic Yes-NT
92. GC 59 post 20 N/atrophic Yes-NT
93. CR 60 post 2 N/atrophic Yes-NT
94. AM 65 post 3 not done
cervical stenosis
No
95. MM 71 post 3 not done - unable
to pass speculum
No
96. JD 40 pre 4 N/atrophic No
97. AB 48 post 3 N/atrophic Yes-B
98. JD 47 post 5 not done
declined procedure
Declined
99. AC 63 post 4 N/atrophic
submucous fibroid
Yes-NT
100. JB 52 pre 11 polyp Yes-B
101. JH 63 post 19 polyp Yes-NT







103. AG 50 post 2 N/atrophic Yes-NT
104. AF 79 post 9 not done No
105. IM 73 post 3 N/atrophic Yes-NT
106. IM 47 pre 14 polyp Yes-NT
107. RM 61 post 5 not done
cervical stenosis
No
108. AD 57 post 1 N/atrophic Yes-NT
109. HN 74 post 4 not done - unable
to pass speculum
No
110. CS 59 post 20 not done
cervical polyp
No
111. AS 52 post 3 N/atrophic Yes-NT
112. AS 42 pre 4 N/atrophic No
113. CT 56 post 4 not done
cervical stenosis
No
114. EW 70 post 12 polyp+cystic No
115. WW 58 post 3 N/atrophic No
116. IT 50 post 6 polyp No
117. SC 66 post 3 N/atrophic No
118. EC 65 post 3 N/atrophic No
119. ML 58 post 11 polyp Yes-NT
120. JM 59 post 5 N/atrophic Yes-NT
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Pipelle biopsy:
A 'No' response indicates that the procedure was attempted. Reasons for failure were:
1. cervix not visualised.
2. unable to pass the pipelle through the cervical os






Patient details regarding length of time on tamoxifen, cumulative dose of tamoxifen











1. EF 185 112850 12
2. HM 77 46970 6
3. SP 61 37210 7
4. OK 57 34770 20
5. CC 30 18300 3
6. AC 14 8540 4
7. EB 15 9150 2
8. MC 70 42700 4
9. BU 108 65880 5
10. EH 69 42090 3
11. JB 62 37820 7
12. AS 48 29280 3
13. MS 74 45140 3
14. EB 75 45750 38
15. JA 80 48800 23
16. MM 120 73200 15
17. MW 86 52460 12
18. MM 95 57950 5
19. EM 65 39650 2
20. MC 36 21960 5
21. MS 97 59170 22
22. CM 72 43920 2
23. GK 36 21960 6












25. MG 24 14640 5
26. HD 17 10370 4
27. MM 36 21960 4
28. WK 32 19520 3
29. MK 111 67710 3
30. MH 83 50630 7
31. KR 96 58560 11
32. LR 31 18910 8
33. ER 66 40260 5
34. JR 26 15860 2
35. CS 26 15860 7
36. SR 25 15250 3
37. MR 51 31110 4
38. JU 38 23180 14
39. ED 24 14640 7
40. AD 134 81740 3
41. MM 36 21960 3
42. AS 104 63440 2
43. AM 34 20740 6
44. CH 48 29280 3
45. SD 79 48190 6
46. JA 98 59780 4
47. GT 49 29890 3
48. LL 23 14030 5
49. KD 22 13420 6
50. SM 61 37210 4












52. NB 62 37820 6
53. MM 66 40260 7
54. DS 96 58560 5
55. JR 190 115900 20
56. ES 37 22570 13
57. MG 153 93330 27
58. MD 74 45140 3
59. MP 14 8540 7
60. FB 62 37820 13
61. MR 86 52460 25
62. ES 86 52460 16
63. CA 124 75640 19
64. PC 12 7300 4
65. IH 24 14640 3
66. FN 84 51240 15
67. EF 37 22570 3
68. AL 159 96990 5
69. JC 84 51240 12
70. DM 81 49410 15
71. FR 60 36600 3
72. JD 10 6100 7
73. JL 16 9760 9
74. IR 20 12200 4
75. ED 67 40870 6
76. JC 61 37210 10
77. MD 62 37820 8












79. MT 180 109800 6
80. DS 97 59170 3
81. MH 49 29890 15
82. EH 60 36600 5
83. DR 73 44530 6
84. ER 30 18300 4
85. KM 5 3050 6
86. JB 38 23180 4
87. DK 120 73200 11
88. EG 72 43920 4
89. EC 49 29890 6
90. AS 133 81130 7
91. BR 60 36600 4
92. GC 73 44530 20
93. CR 61 37210 2
94. AM 89 54290 3
95. MM 51 31110 3
96. JD 26 15860 4
97. AB 15 9150 3
98. JD 30 18300 5
99. AC 71 43310 4
100. JB 76 46360 11
101. JH 37 22570 19
102. MH 84 51240 30
103. AG 24 14640 2
104. AF 65 39650 9












106. IM 36 21960 14
107. RM 43 26230 6
108. AD 49 29890 1
109. HN 72 43920 4
110. CS 61 37210 20
111. AS 11 6700 * 3
112. AS 82 50020 4
113. CT 133 81130 4
114. EW 70 42700 12
115. WW 25 15250 3
116.IT 84 51240 6
117. SC 16 9760 3
118. EC 51 31110 3
119. ML 57 34770 11
120. JM 47 28670 5
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Table 3 shows the results from the procedure scores completed by each patient following
all three procedures.
13 patients did not complete all three procedure scores. This was because in 10 of the
women hysteroscopy was not possible and they were not asked to complete the three
procedure scores. One woman forgot to complete the scores and the remaining 2 were the
women who either declined to have hysteroscopy or were deemed not fit enough to have
the procedure performed. A further 5 patients did not score the pipelle biopsy because they
were in the group where pipelle was unsuccessful and therefore felt unable to score the
procedure. One woman did not score the hysteroscopy as it was not performed because of
cervical stenosis but she completed the other two scores.
All scores are summarised below.
Score TV USS Hysteroscopy Pipelle
1 59 27 30
2 30 21 28
3 14 21 20
4 4 11 14
5 - 14 6
6 - 4 2
7 - 2 -
8 - 6 -
9 - - 1
10 - - 1
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This summary table is demonstrated graphically in Figure 5
All patients scored the pain/discomfort associated with TV USS 4/10 or less (Fig 6) 75%
of patients scored the pain/discomfort during hysteroscopy 4/10 or less (Fig 7) and 90%
scored pipelle 4/10 or less (Fig 8).
From this analysis, TV USS was statistically better tolerated than out-patient hysteroscopy
or pipelle biopsy (PO.OOOl, Mann Whitney U test). There was no statistical difference
between hysteroscopy and pipelle biopsy (p = 0.0607, Mann Whitney U test).
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1. 2 4 4
2. 1 1 1
3. 1 1 1
4. 1 4 2
5. 2 2
6. 1 2 2
7. 1 3 5
8. 1 1 1
9. 1 6 1
10. 1 1 1
11. 4 4 4
12. 2 4 2
13. 2 5 4
14. 1 1 1
15. 2 1 6
16. 1 2 2
17. 2 2 2
18. 2 1 2
19. 1 3 3
20. 1 2 1
21. 1 1 1
22. 1 - 1
23. 1 2 3






24. 1 3 1
25. 3 4 -
26. 1 1 5
27. 3 6 4
28. 2 3 2
29. 1 5 3
30. 1 2 1
31. 1 1 3
32. 3 3 4
33. 2 5 2
34. 1 1 -
35. 3 4 3
36. 1 6 4
37. 2 1 2
38. 1 3 1
39. 1 1 -
40. 1 2 1
41. 3 3 3
42. 2 3 2
43. 1 1 1
44. 3 6 4
45. 1 1 1
46. 1 3 2








49. 2 8 3
50. 1 2 2
51. 1 1 1
52. 2 2 2
53. 2 2 2
54. 3 2 3
55. 1 4 1
56.
57. 3 4 2
58. 1 3 1
59. 4 8 4
60. 2 1 2
61. 2 2 2
62. 2 5 3
63. 1 5 1
64. 3 1 3
65. 3 3 3
66. 2 5 2
67. 1 3 6
68. 2 4 3
69. 2 2 2
70. 3 8 5
71. 2 5 4
72. 1 2 3
73.
101. 1 1 1






75. 1 3 2
76. 3 3 5
77. 2 2 2
78. 2 1 3
79. 1 5 5
80. 2 5 3
81. 1 3 1
82. 1 2 1
83. 1 3 2
84.
85. 4 5 4
86. 2 4 4
87. 1 1 2
88. 4 5 4
89. 1 1 1
90. 2 2 2
91. 3 5 3
92. 2 3 9
93. 3 7 3
94.
95.
96. 1 3 5
97. 1 1 1
98.
99. 1 8 1
100. 1 8 3
111. 1 3 2











103. 1 2 1 113.
104. 114.
105. 1 1 1 115. 1 7 10
106. 1 2 4 116. 1 5 3
107. 117. 1 2 1
108. 1 3 4 118. 2 8 -
109. 119. 1 3 1
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Discussion
One of the main aims of the pilot study was to establish the best algorithm for screening
asymptomatic women on tamoxifen with respect to detection of abnormalities. Once this
was established, the remaining women recruited into the study would be offered the best
screening test.
When implementing a screening programme, the WHO recommends that the test performed
should be:
1. Acceptable to patients.
2. Valid
[Wilson 1968]
Validity of a test involves repeatability and accuracy (high sensitivity and specificity, a high
positive predictive value and a low negative value).
This can be represented in the following table:
Screening Test Reference Test
+ve -ve
+ve true +ve false +ve total +ve by screening
(a) (b) (a + b)
-ve false -ve true -ve total -ve by screening
(c) (d) (c+d)
total true +ve total true -ve grand total
(a+c) (b+d) (a+b+c+d)
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Transvaginal ultrasound scan met the majority of these criteria. The procedure scores
completed by each patient confirmed that ultrasound scanning was significantly better
tolerated than hysteroscopy or pipelle biopsy (p<0.0001). This was not surprising because
of the less invasive nature of the technique making it more tolerable. There were no
significant side effects reported from having transvaginal ultrasound scanning performed.
Ultrasound also proved to be repeatable and accurate, ie valid. The first 10 women with
thickened endometrium on USS had the scan repeated by a consultant radiologist to confirm
endometrial thickness. In all cases the measurements were comparable. Thereafter only
in cases where the scan was unclear was it repeated by another operator (a consultant
radiologist with specific expertise).
Ultrasound scanning also proved to be highly sensitive as all endometrial abnormalities seen
at hysteroscopy were detected on ultrasound scan as thickened endometrium. There were
2 false negative results - both in patients who had endometrium measuring 4mm on
ultrasound scan with one having a tiny polyp at the internal os and the other a small
submucous fibroid. This is in keeping with other studies reporting an ultrasound sensitivity
of 54-97% [Alcazar 1996, Cacciatore 1994, Dijkhuizen 1996, Haller 1996, Towbin 1996,
Langer 1997],
However, TV USS did not have a high specificity because there was a high incidence of
false positive scan findings, ie 45% (54/120) ofwomen who had thickened endometrium
on ultrasound had no significant abnormalities at hysteroscopy. 38% of these women had
no abnormality at hysteroscopy (atrophic/normal endometrium) and 31% (17/54) had only
oedematous or cystic endometrium. The pathology detected was all benign, not requiring
any further treatment. The specificity achieved in the pilot study was 66% (70/106) and
is comparable with other studies where it has been reported as ranging from 48-90%,
although these studies were not investigating women on tamoxifen [Alcazar 1996,
Cacciatore 1994, Dijkhuizen 1996, Haller 1996, Towbin 1996, Cohen 1993(b), Langer
1997]. The presence of thickened endometrium on USS and normal endometrium at
hysteroscopy has been reported although the pathology accounting for this remains unclear
[Marconi 1997, Anteby 1992, Bornstein 1994, Touraine 1995],
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It became increasingly clear when performing the study that the longer women had been on
tamoxifen the more likely it was to find thickened endometrium on TV USS. In the pilot
study this relationship was highly significant (pO.OOOl). This has implications for
screening because the longer women are on tamoxifen the less specific the screening tool
becomes. The reason for this apparent endometrial thickening on USS is a matter of
debate. It has been postulated that the thickening is due to endometrial serosal or
superficial myometrial oedema and presumably the longer women are under the stimulus
of tamoxifen the more likely this is to occur. Although this relationship is highly
significant it is not uniform, ie patient No 29 was on tamoxifen for 111 months and had an
endometrium measuring 3mm yet patient No 56 took tamoxifen for 37 months and had an
endometrium measuring 13mm. From the pilot study there does not appear to be any
accurate way ofpredicting precisely who will have thickened endometrium on TV USS and
time on tamoxifen alone is not 100% predictive.
Similarly, where there was thickened endometrium on ultrasound, it was not possible to
predict those women who had atrophic/normal endometrium and those with benign changes
on hysteroscopy.
It would be desirable for TV USS to be more specific if it is to be used as a screening tool.
One way to do this would be to increase the abnormal cut off in postmenopausal women to
8mm from 5mm. This would reduce the number of false positive scans but attempts to
make tests more specific usually make them less sensitive. There is no scientific basis for
selecting an 8mm cut off and, as the mechanism behind this apparent thickening is unknown
and there is marked inter-patient variability, thus it was considered most sensible to persist
with the 5mm cut offwhich is currently used to assess postmenopausal endometrium in the
general population as it has been shown to accurately identify those with endometrial
abnormalities.
Transvaginal ultrasound has a number of advantages in that it is simple, quick, safe and
relatively cheap. Although it requires dedicated equipment and training, once a machine
is purchased and staff are trained, the cost per scan is minimal. It also has the advantage
that the ovaries can be screened at the same time to exclude ovarian pathology. Although
there is no evidence that tamoxifen exerts any effect on the ovaries, ovarian cancer is more
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common in older women. However, the high false positive rate of this test leads to
undesirable effects in terms of increasing patient anxiety because they require a second
investigation to exclude a serious underlying abnormality.
Hysteroscopy therefore could be considered as a more appropriate screening tool. It allows
direct vision of the endometrial cavity and directed biopsy and is regarded by many as the
'gold standard' investigation [Gimpelson 1995, Finikiotis 1989, Gupta 1996, Parasnis 1992,
Towbin 1996]. Studies have reported a high sensitivity (79-100%) and a high specificity
(93-100%) [Alcazar 1996, Cacciatore 1994, Haller 1996, Towbin 1996, Torrejon 1997],
However, a screening test should be cheap, simple, quick and acceptable to patients and
hysteroscopy does not fulfil these criteria [Indman 1995, Karlsson 1994], It is more
invasive than TV USS and significantly more uncomfortable for the patient (p<0.0001) as
assessed in the current study. Most studies, when attempting to reduce the discomfort
experienced, have used paracervical block [Cooper 1995, Towbin 1996] but on questioning
women in the present study, the discomfort experienced appeared to be related to
insufflation of the uterine cavity with CO, rather than from passing the instrument through
the cervical os (even in women where a small degree of cervical dilation was required). Of
interest, the pain experienced was similar in nature to that experienced when performing
the pipelle biopsy and an analysis of procedure scores demonstrated no significant
difference in discomfort experienced between hysteroscopy and pipelle biopsy. Other
studies have also shown out-patient hysteroscopy to be well tolerated [Nagele 1996, Cooper
1995, Bradley 1995], This would surprise most gynaecologists who believe pipelle to be
a relatively painless procedure.
Hysteroscopy is more expensive to perform than ultrasound scan. It requires more
specialised equipment and the cost per procedure is greater because equipment needs to be
sterilised between patients and nursing assistance is necessary. Consequently it takes
longer to perform (approximately 30 minutes per patient for hysteroscopy versus
approximately 20 minutes for TV USS). Whilst one assistant is essential to help with the
equipment, two are desirable, the second present mainly to distract and monitor the patient
during the procedure. Once established it is relatively quick and simple to perform and was
more acceptable to patients than anticipated which may be because the procedure was not
only explained fully to patients beforehand but they received an information leaflet to read
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at home prior to the procedure. Hysteroscopy does require specialised training to become
proficient in the technique and expertise in dealing with any side effects experienced, eg
cervical shock is also required.
As hysteroscopy allows direct vision of the whole endometrial cavity abnormalities,
particularly polyps can be clearly visualised and any biopsies which are performed can be
targeted. This gives an advantage over both ultrasound scanning and pipelle as any
abnormality detected on ultrasound scanning cannot usually be identified as anything other
than thickened endometrium. Pipelle biopsy is a blind procedure and as such may miss
focal lesions and abnormalities such as polyps.
The cystic endometrium seen in 4 women in the pilot study has been previously described
with tamoxifen therapy [Hulka 1993, Goldstein 1994, Cohen 1996(a), Ciatto 1994, Anteby
1992] but oedematous endometrium has not. This interesting finding would be in keeping
with the theory of tamoxifen causes serosal or superficial myometrial oedema explaining
why attempts at biopsying this were unsuccessful, suggesting that the pathology does not
lie in the endometrium, otherwise biopsy should have been possible. Marconi [1997] and
others have also suggested that at hysteroscopy biopsy of thickened endometrium seen on
ultrasound scanning is frequently unsuccessful at obtaining material but does not offer an
explanation for this [Touraine 1995],
There were a number of women who did not have hysteroscopy performed. This was
mainly because of cervical stenosis making it impossible to pass the hysteroscope through
the cervical os. Cervical stenosis is more common in nulliparous women and
postmenopausal women. In the presence of thickened endometrium in these women,
further invasive investigation in the form ofD & C is required. Of the 4 women in the pilot
study who went on to D & C, 3 had atrophic endometrium and 1 had a polyp. All of these
women had endometrium measuring >8mm so even if the ultrasound upper limit ofnonnal
was increased from 5mm to 8mm, these women would still have been subjected to invasive
procedures. It could be that paracervical block in these women may have allowed
sufficient dilatation of the cervical os to allow the procedure to have been performed as an
out-patient. Therefore, although hysteroscopy is an excellent investigative tool, it does
have limitations when being considered as a screening test.
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The third test investigated in the pilot group was pipelle biopsy. The pipelle du Cornier is
a device which has been in use since 1984 [Cornier 1984] and has become standard practise
for the out-patient investigation of abnormal uterine bleeding/discharge. It is relatively
easy to perform in the out-patient setting, is quick and cheap and acceptable to patients and
therefore appears to be a potential screening tool [Eddowes 1990], However, the results
obtained from the pilot study do not support its use as a screening tool. Although pipelle
was attempted in all women, it was only successful in 49 (41%) and of those 49 sufficient
tissue was obtained for pathological assessment in only 5, all of which were benign. This
is a very poor success rate, ie ability to pass the pipelle into the endometrial cavity, and is
not supported by most current literature which reports a 5-10% failure rate, although this
is higher in postmenopausal women (15-25%) [Batool 1994, Reid 1993]. The literature
reports failure to obtain an adequate sample in 20-30% of women [Gupta 1996, Guisa-
Chiferi 1996, Weber 1997] with higher rates in postmenopausal women. Batool [1994] in
his study of 70 postmenopausal women with bleeding reported that in only 13/70 was there
an adequate sample for diagnostic purposes and Fothergill [1992] reports that in two- thirds
of patients investigated for postmenopausal bleeding, no tissue was obtained.
Sensitivity of pipelle biopsy has been reported at between 70 and 84% [Antoni 1997, Gupta
1996] although Gimpleson and Goldchmit [1995] have reported that pipelle failed to make
a correct diagnosis in 9.7-33% of cases and Archer [1991] that insufficient tissue for
diagnosis was obtained in 24.5% of peri and postmenopausal women studied.
One possible reason for the low success rate of pipelle in the pilot group was because the
majority of women were postmenopausal but when the figures are split into pre and
postmenopausal, the failure rate is comparable as is the percentage where tissue was
obtained. It is interesting that in the majority ofwomen where pipelle was not possible,
hysteroscopy could be performed. There are a number of potential explanations for this.
Hysteroscopy was performed with women in lithotomy position which is the most ideal
position for performing any gynaecological examination, although in the clinic setting this
is not usually possible and in the pilot study women were not placed in this position for
pipelle biopsy. Also, because there were no facilities to sterilise equipment for the pipelle
biopsy (it was performed immediately following the ultrasound scan), a disposable
speculum was used with no vulsellum. A vulsellum was available for use during the
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hysteroscopy and is used to grasp the anterior lip of the cervix allowing the cervical canal
to be straightened making it easier to enter the endometrial cavity. Presumably the use of
a vulsellum at hysteroscopy accounted for some of the greater success with hysteroscopy.
As sterilising was possible at the time of hysteroscopy, Cusco speculums were also used.
Disposable speculums were of a standard size and one possible reason for the poor success
rate was that if a smaller Cusco speculum could have been used, particularly in
postmenopausal women who are more likely to have a degree of vaginal stenosis, then
perhaps pipelle would have been easier. This explanation is not supported by the poor
success rate in the premenopausal group as the majority of these women should be able to
tolerate the bigger disposable speculum.
The ideal situation therefore would have been to perform the pipelle at the same visit as the
hysteroscopy to standardise equipment and position but this was not ideal because ifpipelle
is performed first then it is likely to cause some uterine bleeding thus obscuring the view
at hysteroscopy. When hysteroscopy is performed first the uterine cavity is filled with C02
gas. As pipelle works by suction, performing hysteroscopy first would make it difficult to
obtain a sample using the pipelle as the suction device would be hampered by the presence
ofC02 in the cavity.
Whatever the possible explanations for the poor pipelle success rate, it remains that 18
women with thickened endometrium on ultrasound scan had no tissue obtained at pipelle.
A negative pipelle is insufficient to exclude endometrial disease and these women would
therefore have required further invasive investigation either by hysteroscopy or D & C.
What is also concerning is that pipelle has been reported to sample on average only 4.2%
(range 0-12.3%) of the endometrial surface even after the cannula is reintroduced three
times [Habiba 1994, Rodrigues 1993]. If pipelle is likely to miss focal lesions because it
samples only a small area of the cavity or associated polyps, then this questions the whole
rationale behind its use in a group ofwomen who are being screened primarily to exclude
focal endometrial cancer. Pipelle is also no better tolerated than out-patient hysteroscopy
which reinforces the conclusion that pipelle is not a good screening tool.
From these results it was concluded that pipelle biopsy should be abandoned in subsequent
assessment of these women. There is no single technique which is 'all encompassing and
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100% accurate' [al-Azzawi 1996] but transvaginal ultrasound appeared to be a good initial
diagnostic method, so the remaining women recruited into the study had TV USS performed
and only went on to out-patient hysteroscopy as a second line investigation if the scan was
abnormal. Although it was anticipated from the results of the pilot study this would subject
a number ofwomen to out-patient hysteroscopy, a normal scan was reassuring and could
be quickly, easily and relatively painlessly performed.
The low incidence of significant findings was surprising in view of other studies which had
led us to expect a much higher incidence of abnormalities, including hyperplasia (simple
and atypical) [Gal 1991, Uziely 1993, Lahti 1993, Cohen 1993(a), Cohen 1994(c)], Some
studies suggest up to 30% ofwomen having abnormal endometrium. What is not clear
from those studies however is what they classed as abnormal. This pilot study found no
significant pathological findings. If, however, all the benign changes are classed as
abnormal, then 31/120 = 25% ofwomen fell into this category. Larger numbers ofwomen




Having established a screening protocol where all women had a transvaginal ultrasound
scan perfonned and only went on to out-patient hysteroscopy if the scan was abnormal, the
aim was to recruit more women into the study and obtain a control population. Because
it is well accepted that women who have breast cancer are at a slightly higher risk of
endometrial cancer than the general population, controls were women who had had breast
cancer but had never been on tamoxifen.
The aim was to explore the relationship between tamoxifen and endometrial thickness on
ultrasound scan in greater numbers ofwomen to validate the results of the pilot study, and
to compare endometrial thickness in women on tamoxifen with a series of control women.
The true incidence of abnormal findings also needed to be further assessed as the pilot study
suggested a low frequency of significant pathology, which is contrary to what has been
reported in other studies. Larger numbers would confirm whether the incidence of
significant pathology was low by chance because of small numbers in the pilot study or
whether the low incidence was a true finding.




A further 237 women and 130 controls were recruited into the study. The initial aim was
to recruit a total of 500 women on tamoxifen and from patient enthusiasm this would have
been possible, but time constraints made this impossible.
As a result of the pilot study these women all had transvaginal ultrasound scanning
performed and only went on to out-patient hysteroscopy if the scan was abnormal. Pipelle
biopsy was not performed.
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Results
A total of 357 women on tamoxifen were studied. This included 120 women in the pilot
study and 237 women in the extended study. Table 1 gives patient details and results for
the remaining 237 women on tamoxifen (details ofthefirst 120 women can be found in
Pilot Study: Results) and Table 2 gives details of the control population.
The following results pertain to all 357 study women and 130 controls.
In the study group, 42 were premenopausal and 315 postmenopausal. Endometrial
thickness ranged from 1mm to 38mm, with a mean of 7.3mm and a median of 5mm, (95%
C.I. 0.63). 212 women had an endometrium measuring <5mm or within accepted cycle
limits in premenopausal women and 145 had thickened endometrium on scan.
Figures 1 and 2 show a normal uterus and endometrial thickness on tamoxifen and Figures
3, 4 and 5 show thickened endometrium on tamoxifen.
The control group of 130 women had endometrial thickness ranging from 1-10mm with a
mean of2.5mm and median of2mm, (95% C.I. 0.34). 23 women were premenopausal and
107 postmenopausal. None of the postmenopausal control patients had endometrium
>5mm in diameter or endometrium greater than accepted cycle limits in premenopausal
women requiring hysteroscopy.
The endometrium ofwomen on tamoxifen was significantly thicker than that of controls,
7.3mm compared with 2.5mm, p<0.0001, and is demonstrated graphically in Figure 6.
In control patients, length of time since diagnosis was used as a comparitor for time on
tamoxifen. In this respect the groups are not statistically similar because women who were
not taking tamoxifen were usually those whose diagnosis and treatment was many years ago
before tamoxifen was widely used.
97
As with the pilot study there was a highly significant positive correlation between the length
of time on tamoxifen and endometrial thickness, p<0.0001, demonstrated graphically in
Figures 7 and 8 and the cumulative dose of tamoxifen and endometrial thickness, p<0.0001
which is demonstrated in Figure 9.
A summary of correlation between time on tamoxifen and endometrial thickness for the
whole group is shown in Table 3. The group was split into 4 based on time on tamoxifen




Summary of correlation between time on tamoxifen and endometrial thickness.





Whole group 357 7.3 (0.32) 145 (41%)
0-2 yrs 44 4.5 (0.45) 10(23%)
2-5 yrs 118 5.8 (0.45) 32 (27%)
5-10 yrs 158 8.4 (0.53) 79 (50%)
10+yrs 37 10.8(1.18) 24 (65%)
Controls 130 2.5(0.17) 0
Of the women with thickened endometrium on scan 134 went on to have out-patient
hysteroscopy. There were 11 failed hysteroscopies. Reasons for failure included cervical
stenosis in 8 women, a cervical polyp in 2 women and a previous pelvic floor repair in 1
woman such that opening the speculum to view the cervix was impossible. All 11 women
went on to have D & C to investigate this further.
Of 134 successful hysteroscopies, 61 women had normal or atrophic endometrium at
hysteroscopy, giving a 46% false positive scan rate. This is a higher false positive rate than
was found in the pilot study (38%).
The remaining 73 women, all had benign changes to account for thickened endometrium
on TV USS.
99









Numerous attempts were made to sample oedematous endometrium in the out-patient
setting using pipelle, Sharman curette and other biopsy instruments; all were unsuccessful.
The first 10 women with oedematous endometrium proceeded to D & C; no tissue was
obtained in 7 and 3 had cystically dilated glands only. Subsequently this appearance was
not investigated further.
No cancers were detected in the study group of 357 asymptomatic women and there were
no women with thickened endometrium in the control group During the study period, 1
simple hyperplasia and 1 carcinoma was found in 2 women taking tamoxifen as adjuvant
treatment for breast cancer who were referred for hysteroscopy as part of investigation of
irregular vaginal bleeding.
An incidental finding was 20 (5.6%) ovarian cysts in the study group compared with 3
(2.3%) in the control group. This difference was not statistically significant (p=0.1528).
All but one of the cysts detected were simple cysts (Figure 10), the other in the study group
was multiloculated and suspicious ofmalignancy (Figure 11). This was removed and was
a simple serous cystadenoma. All other women with ovarian cysts had repeat ultrasound
scans at 3 monthly intervals and all cysts subsequently resolved spontaneously.
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121.EA 55 post 5 60 36660
122.IA 75 post 5 106 64660
123.EA 49 post 1 27 16470
124.DA 73 post 5 34 20740
125.SA 37 pre 3 37 22570
126.FA 74 post 5 48 29280
127.CA 37 post 3 26 15860
128.GA 59 post 5 51 31110
129.SB 63 post 10 cystic 38 23180
130.BB 61 post 8 cystic 183 111630
131.MB 65 post 15 N/atrophic 135 82350
132.AB 63 post 7 N/atrophic 157 95770
133.PB 57 post 4 134 81740
134.EB 59 post 12 N/atrophic 51 31110
135.EB 75 post 1 25 15250
136.EB 44 pre 4 38 23180
137.KB 46 pre 4 75 45750
138.AB 63 post 5 60 36600
139.MB 69 post 9 N/atrophic 89 54290
140.AB 50 post 1 37 22570
141.DB 62 post 3 27 16470
142.MB 49 pre 5 99 60390
143.EB 74 post 3 97 59170














145.HB 70 post 14 oedematous 50 30500
146.CB 67 post 18 oedematous 61 37210
147.MB 48 pre 1 50 30500
148.AC 72 post 20 cystic 122 74420
149.EC 66 post 3 75 45750
150.SC 59 post 4 117 71370
151 .JC 54 pre 1 38 23180
152.SC 60 post 4 86 52460
153.IC 72 post 14 cystic 74 45140
154.PC 57 post 2 27 16470
155.LC 58 post 4 74 45140
156.BC 53 post 3 14 8540
157.HC 60 post 5 73 44530
158.JC 73 post 7 cystic 75 45750
159.IC 52 post 4 23 14030
160.LC 71 post 2 73 44530
161.NC 68 post 4 71 43310
162.IC 75 post 4 57 34770
163.MC 63 post 18 oedematous 75 45750
164.AC 75 post 5 64 39040
165.EC 52 post 4 55 33550
166.MD 76 post 26 N/atrophic 113 68930
167.VD 57 post 4 62 37820
168.PD 41 pre 4 50 30500
169.MD 66 post 7 unable to do
Cx stenosis
58 35380














171.CD 62 post 13 N/atrophic 83 50630
172.ED 61 post 14 N/atrophic 18 10980
173.GD 61 post 5 37 22570
174.CD 67 post 5 91 55510
175.MD 59 post 4 182 111020
176.PD 65 post 3 138 84180
177.RE 71 post 14 oedematous 109 66490
178.EE 52 post 7 N/atrophic 62 37820
179.FF 40 post 3 27 16470
180.IF 62 post 1 25 15250
181 .JF 53 post 9 submucous
fibroid
93 56730
182.MF 41 post 4 25 15250
183.EF 65 post 5 28 17080
184.MF 67 post 11 N/atrophic 26 15860
185.SF 56 post 3 52 31720
186.TF 52 post 5 48 29280
187.SF 75 post 2 62 37820
188.MF 51 post 3 98 59780
189.MF 73 post 4 75 45750
190.JF 44 post 3 51 31110
191.HF 70 post 4 98 59780
192.NG 50 post 4 22 13420
193.MG 59 post 7 N/atrophic 48 29280
194.DG 66 post 15 polyp 64 39040
195.SG 75 post 4 61 37210














197.EG 60 post 3 74 45140
198.SG 39 pre 3 24 14640
199.EH 66 post 36 polyp 61 37210
200.MH 66 post 14 cystic 115 70150
201.PH 48 pre 14 polyp 49 29890
202.MH 73 post 10 N/atrophic 113 68930
203 .AH 57 post 5 65 39650
204.CH 37 pre 3 48 29280
205.MH 54 pre 30 cystic 44 26840
206.MH 48 pre 4 35 21350
207.EH 62 post 5 74 45140
208.CH 70 post 3 36 21960
209.CH 68 post 4 63 38430
210.DH 54 post 2 12 7300
211.AI 46 post 4 28 17080
212.SI 59 post 15 N/atrophic 12 7300
213.JJ 43 pre 3 18 10980
214.MJ 61 post 3 60 36600
215.MJ 56 post 4 63 38430
216.SJ 51 post 17 N/atrophic 91 55510
217.MJ 65 post 4 52 31720
218.NJ 68 post 3 68 41480
219.AJ 68 post 2 14 8540
220.MJ 64 post 3 49 29890
221.MK 48 pre 5 84 51240
222.JK 62 post 3 26 15860














224.AK 63 post 4 33 20130
225.GK 52 post 3 126 76860
226.TK 63 post 2 75 45750
227.WL 51 pre 5 136 82960
228.EL 50 post 4 62 37820
229.AL 59 post 5 97 59170
230.DL 72 post 5 22 13420
231.ML 64 post 8 N/atrophic 35 21350
232.PL 51 post 11 N/atrophic 49 29890
233.AL 50 post 6 N/atrophic 61 37210
234.GL 51 post 4 72 43920
235.JL 67 post 2 77 46970
236.RM 53 post 14 cystic 134 81740
237.MM 73 post 7 N/atrophic 51 31110
238.EM 70 post 12 N/atrophic 122 74420
239.SM 67 post 4 71 43310
240.MM 56 post 5 85 51850
24 l.EM 65 post 5 28 17080
242. IM 73 post 31 unable to do
Cx stenosis
85 51850
243.AM 58 post 10 cystic 74 45140
244.CM 71 post 5 97 59170
245.IM 68 post 9 polyp 80 48800
246.GM 36 pre 3 16 9760
247.AM 66 post 3 66 40260
248.NM 64 post 5 26 15860














250.IM 51 pre 2 62 37820
251.SM 43 post 3 26 15860
252.JM 62 post 26 N/atrophic 122 74420
253.JM 57 post 4 98 59780
254.SM 69 post 5 61 37210
255.JM 67 post 5 82 50020
256.JM 57 post 7 N/atrophic 72 43920
257.MM 47 pre 8 submucous
fibroid
73 44530
258.IM 61 post 10 oedematous 131 79910
259.HM 57 post 3 15 9150
260.OM 48 pre 12 N/atrophic 62 37820
261.MM 57 post 5 20 12200
262.AM 61 post 5 50 30500
263.BN 48 post 12 oedematous 31 18910
264.MN 59 post 4 63 38430
265.EN 60 post 5 25 15250
266.AN 60 post 2 37 22570
267.FO 65 post 5 64 39040
268.EO 53 post 4 51 31110
269.JP 44 pre 10 oedematous 46 28060
270.CP 59 post 4 60 36600
271.KP 48 post 5 61 37210
272.EP 68 post 16 oedematous 54 32940
273.MP 59 post 4 61 37210
274.MP 62 post 3 12 7300














276.MR 63 post 11 oedematous 86 52460
277.GR 73 post 19 oedematous 134 81740
278.LR 59 post 2 53 32330
279.JR 64 post 9 N/atrophic 32 19520
280.AR 42 post 5 153 93330
281.MR 61 post 11 N/atrophic 109 66490
282.JR 65 post 6 unable to do
Cx stenosis
104 63440
283.IR 58 post 18 polyp 124 75640
284.MR 74 post 4 9 5490
285.HR 52 post 5 17 10370
286.JR 61 post 4 37 22570
287.ER 60 post 2 32 19520
288.CR 57 post 2 33 20130
289.RS 62 post 3 41 25010
290.MS 42 pre 8 N/atrophic 100 61000
291.AS 47 post 2 27 16470
292.TS 51 pre 2 62 37820
293.ES 50 pre 4 39 23790
294.SS 73 post 19 cystic 49 29890
295.TS 60 post 2 21 12810
296.KS 38 pre 5 61 37210
297.MS 63 post 8 N/atrophic 26 15860
298.RS 69 post 15 N/atrophic 86 52460
299.GS 61 post 8 oedematous 38 23180
300.CS 76 post 5 128 78080














302.AS 45 post 4 52 31720
303.RS 49 post 11 N/atrophic 120 73200
304.AS 68 post 5 37 22570
305.JS 69 post 4 128 78080
306.KS 45 pre 5 32 19520
307.CS 54 post 9 cystic 69 42090
308.SS 70 post 7 cystic 23 14030
309.RS 52 post 2 18 10980
310.MS 69 post 3 120 73000
31 l.AS 47 pre 5 38 23180
312.AS 61 post 4 182 111020
313.IS 69 post 13 N/atrophic 157 95770
314.ES 75 post 11 cystic 20 12200
315.NS 54 post 3 38 23180
316.CS 54 post 3 136 82960
317.AT 49 post 7 N/atrophic 110 67100
318.MT 52 post 4 73 44530
319.RT 70 post 13 N/atrophic 60 36600
320.CT 75 post 4 121 73810
321.CT 54 post 2 13 7930
322.HW 62 post 3 26 15860
323.MW 67 post 17 N/atrophic 111 67710
324.LW 64 post 4 86 52460
325.MW 53 post 5 52 31720
326.YW 53 post 4 12 7300
327.WW 67 post 2 25 15250














329.JW 63 post 5 28 17080
330.VW 63 post 2 83 50630
331.GY 68 post 4 71 43310
332.AD 71 post 9 unable to do
Cx polyp
160 97600
333.MG 74 post 8 declined
hysteroscopy
61 37210
334.CS 68 post 7 unable to do
Cx stenosis
73 44530
335.AS 76 post 2 96 58560
336.IW 85 post 6 unable to do
Cx stenosis
70 42700
337.JT 50 pre 12 oedematous 54 32940
338.EH 68 post 15 N/atrophic 99 60390
339.MR 53 post 16 N/atrophic 148 90280
340.EC 74 post 11 cystic 121 73810
341.MD 59 post 7 cystic 67 40870
342.AM 66 post 6 N/atrophic 108 65880
343.MM 68 post 7 N/atrophic 109 66490
344.CM 62 post 19 N/atrophic 98 59780
345.MD 70 post 16 N/atrophic 99 60390
346.YH 57 post 9 N/atrophic 61 37210
347.HS 61 post 8 N/atrophic 76 46360
348.JP 68 post 10 N/atrophic 62 37820
349.ED 65 post 23 N/atrophic 74 45140
350.JF 67 post 15 oedematous 65 39650
351.IW 71 post 11 N/atrophic 81 49410














353.NT 65 post 11 oedematous 109 66490
354.ES 64 post 8 N/atrophic 63 38430
355.JK 74 post 12 cystic 62 37820
356.RB 71 post 7 N/atrophic 123 75030
357.MM 56 post 18 N/atrophic 144 87840
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Table 2
Control patient details and results.




1. RCH 54 post 1 85
2. WP 52 post 2 112
3. IW 68 post 1 198
4. AH 59 post 1 127
5. FS 42 pre 3 113
6. SM 61 post 2 13
7. PM 67 post 2 162
8. AJ 59 post 1 198
9. MM 57 post 1 148
10. IW 57 post 1 114
11. MG 63 post 1 185
12. MM 62 post 2 125
13. JR 67 post 2 241
14. ES 55 post 2 185
15. ME 70 post 3 159
16. SJ 45 pre 2 137
17. IG 59 post 1 199
18. CL 59 post 3 14
19. EM 54 post 2 117
20. EH 48 post 2 108
21. RB 50 post 1 80
22. CH 37 pre 2 77
23. CR 73 post 2 195
24. KT 57 post 2 24
Ill




25. EM 47 pre 6 160
26. AB 69 post 2 44
27. MA 61 post 1 195
28. EA 61 post 2 195
29. MM 31 pre 7 14
30. AN 69 post 1 197
31. BA 57 post 4 62
32. RW 75 post 1 176
33. ER 68 post 2 213
34. MM 49 pre 7 178
35. BL 64 post 2 138
36. ER 54 post 1 272
37. JW 60 post 1 96
38. MM 67 post 1 146
39. AC 70 post 1 72
40. BM 61 post 1 70
41. CP 66 post 1 37
42. MC 52 post 2 9
43. MM 42 pre 9 25
44. MD 55 post 3 62
45. MB 49 post 2 95
46. EM 60 post 3 136
47. IR 60 post 3 133
48. LG 41 pre 3 101
49. RK 38 pre 3 25
50. AB 57 post 1 179
51. DB 55 post 1 106
52. AG 57 post 1 80
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53. MB 65 post 1 263
54. AB 51 post 2 122
55. LA 43 pre 3 25
56. IC 47 post 1 76
57. AB 58 post 3 169
58. MP 53 post 1 90
59. MC 53 post 1 85
60. JS 44 pre 6 112
61. ES 65 post 1 87
62. HM 54 post 2 34
63. MP 68 post 2 90
64. MM 58 post 4 123
65. SP 53 pre 7 24
66. MB 59 post 2 78
67. MM 57 post 1 237
68. MA 67 post 1 248
69. SB 70 post 3 286
70. CM 66 post 4 27
71. AH 41 pre 2 73
72. IW 75 post 4 176
73. MW 57 post 2 114
74. IG 59 post 5 210
75. AW 69 post 1 169
76. AS 50 post 3 71
77. JM 53 post 1 114
78. JD 66 post 2 25
79. BW 45 pre 5 157
80. AS 63 post 2 154
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81. MA 62 post 1 72
82. EG 74 post 3 164
83. SM 62 post 1 173
84. MM 66 post 3 116
85. MM 62 post 2 35
86. MF 71 post 2 81
87. MA 58 post 1 62
88. AH 66 post 2 168
89. MG 72 post 2 38
90. PT 67 post 2 201
91. DM 41 pre 6 93
92. AS 57 post 2 70
93. AS 53 post 1 99
94. JC 54 post 1 28
95. IV 47 post 1 106
96. K1 63 post 3 47
97. DR 57 post 2 71
98. MG 54 post 3 143
99. MP 63 post 1 30
100. PM 47 pre 4 90
101. MM 48 post 2 97
102. EM 50 post 2 74
103.NL 59 post 2 150
104. PL 69 post 1 133
105. EB 52 post 3 27
106. BM 48 post 2 82
107. MB 66 post 2 111
108. MM 59 post 1 69
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109. BW 52 pre 3 98
110. AM 41 pre 3 102
lll.ES 60 post 2 58
112. JR 46 pre 9 187
113. CR 61 post 1 113
114.10 52 post 3 14
115. EM 56 post 2 86
116. PC 50 post 1 221
117. HA 61 post 1 52
118. MW 68 post 3 192
119. WB 59 post 3 172
120. SM 51 post 2 219
121. MS 66 post 2 114
122. MR 48 pre 4 102
123. EC 55 post 1 106
124. MD 54 post 2 119
125. DW 51 post 3 94
126. JL 46 post 1 58
127. SN 54 post 2 162
128. MS 44 pre 5 75
129. NM 42 pre 8 99
130. JK 57 post 1 113
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2 examples of thickened cystic endometrium on TV USS.
Figure 3
Figure 5
Thickened cystic endometrium on TV USS.
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Figure 6
Mean endometrial thickness of study versus control group.
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Figure 7
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Figure 10
Simple ovarian cyst on tamoxifen.
Figure 11
Multiloculated ovarian cyst on tamoxifen.
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Discussion
The main aim of this part of the research project was to assess the incidence of endometrial
abnormalities in asymptomatic women on tamoxifen and address whether screening was
valuable and, if so, what the optimal screening protocol was. There is clear evidence of an
increased risk ofendomentrial cancer in women taking tamoxifen (from 1:1000 women/year
to 2:1000 women/year) [Assikis 1996, Fisher 1994, Fornander 1989, Cohen 1995(a), Cohen
1994(a), Friedl 1994, Jaiyesimi 1995, Rutqvist 1987, Sismondil994] but it is accepted that
the benefits from tamoxifen in reducing recurrence both locally and metastatic and reducing
the number of contralateral breast cancers is greater than the number of extra women who
develop endometrial cancer. Recent studies have also demonstrated a reduction in breast
cancer incidence with prophylactic use of tamoxifen and it has a produce licence in the
USA for prevention of breast cancer in high risk women. As the risks of endometrial
cancer do not warrant cessation of the drug, the role of endometrial screening needs to be
assessed.
Up to 30% of women taking tamoxifen have been reported to develop endometrial
abnormalities ranging from benign polyps and simple hyperplasia to atypical hyperplasia
and cancer [Cohen 1993, Gal 1991, Sismondi 1994, Cohen 1993, De Muylder 1991,Neven
1991, Rullo 1993, Fotiou 1998, Cohen 1999], This is an alarmingly high incidence of
abnormalities and was one of the main reasons for undertaking the present study.
However, from published reports it is unclear whether the abnormalities which develop on
tamoxifen are related to cumulative dose and are therefore time dependent, or whether the
abnormalities have been identified in mainly symptomatic women as opposed to the present
study which investigates asymptomatic women. Cohen [1999] has reported recently that
endometrial pathology is more likely to be diagnosed in symptomatic women on tamoxifen.
If the current study had confirmed a similarly high incidence of significant abnormalities
in asymptomatic women on tamoxifen then it may have proved necessary to implement a
screening programme for all women on tamoxifen - whether they were taking tamoxifen as
treatment for their breast cancer or as part of the ongoing tamoxifen prevention studies.
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This would have significant economic implications and thus the results of the present study
were important.
The pilot study detected an incidence of benign changes in 25% of women and this is in
keeping with the high incidence of abnormalities reported in the literature but none of these
abnormalities were significant, consisting only of polyps and submucous fibroids in 11%
and cystic or oedematous endometrium in 14%. The significance of these latter findings
is unclear and whether they can be regarded as truly 'abnormal' is doubtful.
This study aimed to confirm (or refute) the findings of the pilot study by enrolling larger
numbers. The pilot study investigated the validity and acceptability to patients of
transvaginal ultrasound scanning, out-patient hysteroscopy and pipelle biopsy and
concluded that patients enrolled into the study thereafter would have transvaginal
ultrasound scanning performed and only go on to out-patient hysteroscopy if the scan was
abnormal. The study group of 357 women on tamoxifen included the 120 women from the
pilot study. Because of common risk factors between breast cancer and endometrial
cancer, a control population of 130 women, all of whom had breast cancer but had never
taken tamoxifen, were chosen. Because it has been routine practice for the last 10 years
to give all postmenopausal women tamoxifen, control patients tended to have been treated
earlier in time than study patients giving 2 non comparable groups with reference to time
since diagnosis.
In the 357 women with breast cancer on adjuvant tamoxifen, 145 (41%) had apparent
endometrial thickening on transvaginal ultrasound scan and therefore as part of the protocol
went on to have out-patient hysteroscopy performed. At hysteroscopy 61 of these women
(46%) were found to have atrophic/normal endometrium, 21 had polyps, 6 submucous
fibroids, 23 cystic endometrium and 23 oedematous endometrium. There were no cases
of hyperplasia or cancer detected in the study group although 1 patient with simple
hyperplasia and 1 patient with cancer was detected in 2 symptomatic women on tamoxifen
referred for out-patient hysteroscopy. The risk of endometrial cancer in women on
tamoxifen is of the order of 2:1000 women/year and therefore it could be argued that the
study population of 357 women was not large enough to detect cases of endometrial cancer
but from the literature other significant abnormalities, eg hyperplasia, would have been
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expected in a population of this size. TV USS has a reported sensitivity of 54-97% and
specificity of 48-90% [Alcazar 1996, Cacciatore 1994, Dijkhuizen 1996, Haller 1996,
Towbin 1996, Langer 1997] and hysteroscopy a sensitivity of 79-100% and specificity of
93-100% [Alcazar 1996, Cacciatore 1994, Towbin 1996, Haller 1996], In combination,
it is highly unlikely that any significant lesions were missed to account for the lack of
abnormalities detected in this study population. 212 women (59%) had normal
endometrium on TV USS and therefore could be reassured and no further investigation was
required. The endometrium ofwomen on tamoxifen was significantly thicker on TV USS
than that of controls (mean 7.3mm on tamoxifen versus 2.5mm control; p<0.0001) and this
is a finding supported by others [Rayter 1994, Kedar 1994, Lahti 1993], None of the
control patients had thickened endometrium as measured by TV USS requiring further
investigation.
61 of the 145 women on tamoxifen with thickened endometrium on TV USS had
atrophic/normal endometrium at hysteroscopy. Although it had been established from the
pilot study that TV USS was sensitive, it was not highly specific (66%) with a 38% false
positive scan rate in the pilot study. TV USS was chosen as an initial screening tool
because it was simple, cheap, quick to perform and highly acceptable to patients.
However, the main study confirmed an overall 46% false positive scan rate thus subjecting
large numbers ofwomen to unnecessary further invasive investigation and accompanying
anxiety without significant benefit. This is particularly important in a group ofwomen who
have already been through the trauma of a diagnosis and treatment of breast cancer. The
high false positive rate questions the use of TV USS in a mass screening programme and
indicates it would cause unnecessary anxiety to a large number of women without
significant disease.
Benign abnormalities (polyps and submucuous fibroids) were detected in 27/145 women
who had thickened endometrium on USS. The incidence of polyps in asymptomatic
women in the general population is unknown so the significance of these asymptomatic
polyps is unclear. In general gynaecological practise, symptomatic polyps would be
removed - in premenopausal women because they cause dysfunctional uterine bleeding and
in postmenopausal women, because of the concern they may have malignant change as a
cause for postmenopausal bleeding. We know from postmortem studies that the incidence
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of occult endometrial cancer is significant [Horwitz 1981] and it would be logical to assume
therefore that not all polyps are symptomatic. Following discussion with the consultant
gynaecologist involved in the present study, women with polyps were offered either D&C
to remove the polyp or repeat hysteroscopy 6 months later to review the polyp. Recent
studies have suggested that there is a higher incidence of malignant foci developing in
polyps of women on tamoxifen than in the general population [Ismail 1994(a),(b),
Ramondetta 1999, Nouvo 1989] therefore ifpatients decided not to have their asymptomatic
polyp removed, repeat hysteroscopy was deemed necessary. 12 women opted for removal
and all polyps were benign and 9 opted for repeat hysteroscopy. At repeat hysteroscopy
all women remained asymptomatic and none of the polyps had changed in size or character.
All hysteroscopies were recorded on videotape so initial and repeat hysteroscopy could be
compared.
It was concluded that none of these benign abnormalities could be considered as significant
abnormalities.
Cystic/oedematous endometrium was found in 46 women. Again, it is questionable
whether this is significant or even whether this should be classed as abnormal in women on
tamoxifen. Cystic appearances of the endometrium on TV USS have been previously
reported in women taking tamoxifen [Cohen 1996, Anteby 1992, Aleem 1995, Ciatto 1994,
Goldstein 1994, Hulka 1993], At hysteroscopy most of the endometrium appeared benign
and consisted of several thin-walled cysts filled with clear fluid which tended to rupture
whilst attempting to biopsy them. The 'oedematous' appearance has not been previously
described although some have described an unusual appearance at hysteroscopy with the
absence ofpathology from women on tamoxifen [Touraine 1995, Goldstein 1994], These
women had thickened endometrium at USS and at hysteroscopy the endometrium appeared
thickened and 'boggy'. The appearance at hysteroscopy suggested that biopsy of the
endometrium would be straightforward but despite trying various biopsy techniques and a
variety of instruments, no tissue could be obtained. In view of this, the first 10 women with
this appearance proceeded to D&C as there was concern both about the underlying
pathology and the failure to obtain a tissue diagnosis. Surprisingly, even at D&C no tissue
was obtained in 7 out of 10 of these women (indicating atrophic endometrium) and the
histology of the remaining 3 patients showed cystically dilated glands but no other
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endometrial abnormality. In view of these findings it was felt inappropriate to subject the
other 13 asymptomatic women with the same hysteroscopic appearance to further
investigation.
It has been suggested that a thickened cystic appearance on TV USS may be caused by
endometrial serosal or superficial myometrial oedema. The appearance at hysteroscopy
and lack of tissue obtained is consistent with oedema causing the superficial endometrium
to appear thickened when in fact it is atrophic. It could be hypothesised that discrete cysts
seen in some women is one end of a spectrum caused by tamoxifen, and perhaps the initial
event, which subsequently develops into the more generalised oedematous appearance seen
at hysteroscopy, which in the 3 women where tissue was obtained corresponds
histologically to cystically dilated glands as the only 'abnormality'. However, in the
patients studied, there was no difference in the mean length of time on tamoxifen between
those with cystic or oedematous endometrium to support this hypothesis. There is as yet
no sound scientific explanation for these appearances but they do appear to be specific to
tamoxifen use.
Unfortunately, there were no specific features on TV USS which predicted whether the
apparently thickened endometrium was atrophic/normal, oedematous, cystic or whether
other benign changes eg polyps would be found at hysteroscopy. These results from TV
USS show that it does not consistently identify true endometrial thickness in women on
tamoxifen and casts further doubt about its role as a screening tool. Others have also
concluded that USS from women on tamoxifen did not distinguish atrophy from other
benign processes [McGonicle 1998, Mourits 1998],
The pilot study found a highly significant (pO.OOOl) positive correlation between
endometrial thickness as measured by TV USS and length of time on tamoxifen. This
correlation was confirmed in the main study and the association remained highly significant
(p<0.0001). However, apparently thickened endometrium on TV USS does not necessarily
indicate either that the endometrium is actually thickened or that there is a higher incidence
of benign lesions in asymptomatic women who take tamoxifen for long periods. Some
have suggested that the risk of carcinoma is time and dose dependent [Anderson 1991,
Fornander 1989, Nayfield 1991] but others have disagreed with this [Cohen 1994(b), Neven
1994(a), Plourde 1995] and the NSABP findings suggest that the incidence remains constant
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over time on the drug. Caution is therefore required when interpreting TV USS in women
on tamoxifen and when TV USS in such a patient suggests endometrial thickening it would
seem appropriate to proceed to out-patient hysteroscopy as the next investigation rather
than in-patient general anaesthetic procedures such as D&C to sample the endometrium as
a large number of these women will have no significant endometrial pathology.
A direct correlation of apparent endometrial thickening with increasing duration of
tamoxifen was a subject which required further study. As sampling the endometrium was
a problem, it was considered the only way to investigate this further was to study the
endometrium of women who had undergone hysterectomy whilst on tamoxifen for the
treatment of breast cancer. This work is described in detail in a subsequent chapter
{Endometrial Pathology).
Although there was a highly significant correlation between length of time on tamoxifen
and endometrial thickness on TVUSS, there remained wide individual variation between
women for which no explanation could be found, eg patient 144 was on tamoxifen for 120
months and she had an endometrium measuring 4mm while patient 148 who had been
taking tamoxifen for 122 months and had an endometrium measuring 22mm. Nonetheless,
the longer a woman is on tamoxifen, the more likely she is to have apparent endometrial
thickening on TV USS and to require further investigation if regular screening were to be
introduced.
Wilson and Jungner in the 1960's assessed the criteria which need to be addressed before
embarking on a screening programme, including information about the disease itself, the
test to be employed and the economics involved and their criteria have been adopted by the
World Health Organisation. The disease should be reasonably common and serious and
its natural history should be known. It should have a latent/symptomatic period during
which time it would be appropriate to screen, treatment is available and treatment at the
time of diagnosis should improve prognosis. Facilities for diagnosis should be in place
prior to establishing the screening programme. There should be agreement on who to treat
as a case and established treatments should exist for patients found to have the disease. The
test should be valid and acceptable to patients and the cost of screening should be
economically balanced in relation to expenditure on medical care as a whole.
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This study so far has concentrated on the tests available and their ability to pick up
endometrial abnormalities to validate the screening tools. It has been established that there
is no ideal screening modality. A screening tool is not necessarily the best investigation
available, which many would regard to be hysteroscopy, because hysteroscopy has
limitations when considering its use in mass screening in both economic terms (equipment,
operator time) and acceptability to patients. TV USS in contrast is well tolerated and
fulfills a number of the other criteria as a screening tool but it has been shown in this and
other studies to have a high false positive rate thus subjecting large numbers of
asymptomatic women to more invasive procedures [Bertelli 1998, Neven 1994(a), (b),
Langer 1997, Cecceni 1995, Lahti 1993, Cohen 1993(b)],
This study failed to find any significant abnormalities in a large group of asymptomatic
women raising doubt about the appropriateness of introducing a screening
programme/regular gynaecological review for women on long term tamoxifen which others
have suggested [Ross 1995, Litta 1995, Bisset 1994, Barakat 1995, 1996, Dew 1995, Daniel
1996, Cuenca 1998].
Concentrating on the disease itself and what screening would achieve, it is known that
endometrial cancer is slow growing and unlike ovarian cancer, tends to present early with
vaginal bleeding. Because it presents early it is usually superficial and well differentiated,
of low grade and early stage at diagnosis and therefore is associated with a good prognosis
with an overall 80% 5 year survival (compared to 75-79% for breast cancer and 25% for
ovarian cancer). It has been suggested in isolated reports that women who develop
endometrial cancer on tamoxifen are more likely to develop high grade, poorly
differentiated tumours [Assikis 1996, Altaras 1993, Hardell 1988, Seoud 1993], supporting
the case for screening, but whole world literature does not confirm this.
What one aims to achieve from screening by picking disease up earlier than it would present
clinically is to reduce the number of deaths from the disease. Breast cancer and cervical
cancer screening achieve this because they pick up the disease during its
latent/asymptomatic period. It is debatable whether endometrial screening can do this
because it usually presents clinically early in its evolution with vaginal bleeding. It also
does not seem economical to screen all women on tamoxifen using TV USS or any other
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available tool to detect 1 extra endometrial cancer/1,000 women/year. This does not
compare well with the 6/1000 pick up of breast screening.
Taking all these factors into consideration it can be concluded from this part of the study
that screening asymptomatic women on tamoxifen is not indicated. Women on tamoxifen
should be educated about the risks of this drug and be advised to report any symptoms in
the form of abnormal bleeding/discharge for prompt investigation.
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Ovarian Pathology
There is limited evidence that like the association between breast and endometrial cancer
there is a positive association between breast and subsequent ovarian cancer again reflecting
common risk factors [Ewertz 1990], The additional effect of tamoxifen on the ovary is
unclear. This study reported no difference in the incidence of ovarian cysts with tamoxifen
use, however, others have found a significantly high incidence of functional cysts associated
with tamoxifen use in premenopausal women compared with controls, most of which
resolved spontaneously [Shushan 1996, Cohen 1999(a)].
Most agree that small unilocular cysts are best managed conservatively as they have a low
incidence of malignant potential and only large complex cysts be surgically removed to
exclude malignancy. Cohen et al [1996(b)] in a small study, suggested that
postmenopausal women may be more susceptible to ovarian malignancy with tamoxifen
use, however, numbers were small and other reports sporadic therefore this has yet to be
confirmed [Hochner Celnikier 1995, Carter 1991], The current study, nor that of Cook et
all [1995] or Lindahl et al [1997] would confirm this finding.
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Other Investigative Tools
This study concentrated on the relative merits and pitfalls of ultrasound scanning,
hysteroscopy and pipelle biopsy as investigative tools for assessing the endometrium of
women on tamoxifen. However, these are not the only tools which have been suggested
to assess these women.
Saline infusion sonography (SIS) has been suggested as a technique which is less invasive
than hysteroscopy but gives more information regarding the endometrial cavity than
ultrasound scanning along. It involves inserting a narrow catheter into the uterine cavity
and injecting a small amount of fluid into the cavity prior to performing the ultrasound scan.
The catheter remains in situ during the scan in order for further fluid to be instilled into the
cavity during the procedure if required to enhance the view [Goldstein 1996]. Some have
advocated that the changes seen in the endometrium of women on tamoxifen on normal
ultrasound scanning can be enhanced using SIS negating the need for further more invasive
investigations. Goldstein [1996] reported five patients with bizarre heterogenous uterine
changes on scan who underwent hysteroscopy and revealed smooth, atrophic endometrium.
These patients were then viewed with SIS and the changes thought to be endometrium were
shown to be located in the proximal myometrium, giving an explanation for the lack of
tissue obtained at hysteroscopy. He does not extrapolate from this whether, if SIS had been
performed prior to hysteroscopy, no further invasive investigation would have been
performed. Others have suggested that SIS is useful for identifying polyps and submucous
fibroids and therefore gives a more accurate measurement than of endometrium alone
[Fleischer 1997, Karlsson 1994, Cohen 1995(b)] however this would not negate the need
for further investigation in most women on tamoxifen as thickened endometrium still
requires biopsy and polyps may still require removal. Some authors suggest the need for
further assessment of SIS in tamoxifen users but accept its limitations at present [Cohen
1999, Barakat 1995, Karlsson 1994],
Magnetic Resonance Imaging (MRI) has also been studied as an investigative tool for
women on tamoxifen. Ascher et al [1996] studied 35 postmenopausal women and found
2 distinct endometrial patterns, the first of which was homogenous and in keeping with
atrophic or proliferative endometrium on histology. Ascher suggests that MRI may be
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helpful in determining which patients require endometrial sampling but in view of the cost




Having established that tamoxifen causes apparent endometrial thickening on ultrasound
scan and that this is related directly to the length of time a woman takes tamoxifen, it is
important to establish whether this thickening is reversible following cessation of
tamoxifen.
Although it is unknown why tamoxifen causes this scan appearance, it is likely to be due
to endometrial serosal or superficial myometrial oedema and therefore it may be reversible
after stopping tamoxifen.
The policy in Edinburgh until recently was to continue tamoxifen until the time of first
recurrence, but following studies questioning the benefits of adjuvant tamoxifen for periods
longer than 5 years, the majority ofwomen who had been on tamoxifen for over 5 years
stopped the drug following assessment of their endometrium. This presented an
opportunity to study the effect of cessation of tamoxifen on the endometrium.
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Patients and Methods
20 postmenopausal women (age range 53-74 years) who had thickened endometrium on
ultrasound scan but atrophic, oedematous or cystic endometrium at hysteroscopy were
asked if they would be willing to return after a time interval off tamoxifen to have the
transvaginal ultrasound scan repeated. Women approached to return for scan off tamoxifen
were those who reported that they would not object to returning for a third time. They were
asked immediately following their normal hysteroscopy and no women approached declined
to attend for a repeat scan.
All women stopped their tamoxifen following hysteroscopy and were off tamoxifen for
between 6 and 11 months (mean 8.75 months) prior to repeat ultrasound scanning.
Duration of tamoxifen use ranged from 61-148 months (mean 98 months) and ultrasound
thickness on tamoxifen ranged from 6-23mm (mean 12.4mm).
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Results
The results for these 20 women are summarised in Table 1.
At the second look ultrasound scan 16/20 (80%) had a reduction >2mm in endometrial
thickness. This was a significant reduction at p=0.0013. Endometrial thickness prior to
cessation of tamoxifen ranged from 6-23mm (mean 12.4mm, median 11mm, 95%C.l. 2.16)
and following cessation of tamoxifen ranged from 4-15mm (mean 7.8mm, median 7, 95%
C.I. 1.38)
This is demonstrated graphically in Figure 1.
Figures 2, 3 and 4 show changes in endometrial thickness following cessation of tamoxifen.
6/16 (38%) women whose endometrium reduced in thickness had an endometrium of
normal thickness (<5mm) at second look ultrasound scan.
Of the 4 women whose endometrium remained unchanged or the reduction was <2mm
(considered unchanged to allow for intra-observer error) 2 had only marginally thickened
endometrium at the outset (7mm and 6mm) and the other 2 had endometrium measuring
10mm and 16mm. Both these women had normal or atrophic endometrium at
hysteroscopy. There was nothing to distinguish these 4 women in terms of time on
tamoxifen or length of time since cessation of tamoxifen, from the women whose
endometrium decreased in thickness on ultrasound scan off tamoxifen.
137
Table 1














338.EH 15 N/atrophic 5 99 6
339.MR 16 N/atrophic 6 148 9
340.EC 11 cystic 9 121 8
341.MD 7 cystic 7 67 7
342.AM 6 N/atrophic 6 108 7
343.MM 7 N/atrophic 5 109 10
344.CM 19 N/atrophic 15 98 9
345.MD 16 N/atrophic 15 99 8
346.YH 9 N/atrophic 5 61 8
347.HS 8 N/atrophic 5 76 8
348.JP 10 N/atrophic 10 62 8
349.ED 23 N/atrophic 11 74 9
350.JF 15 oedematous 7 65 9
351.IW 11 N/atrophic 9 81 9
352.JH 19 N/atrophic 9 191 11
353.NT 11 oedematous 6 109 10
354.ES 8 N/atrophic 5 63 10
355.JK 12 cystic 9 62 11
356.RB 7 N/atrophic 4 123 9
357.MM 18 N/atrophic 8 144 9
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Figure 1
Mean endometrial thickness on and off tamoxifen.
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Figure 2
Reduction in endometrial thickness following tamoxifen cessation.
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Figure 3
Reduction in endometrial thickness off tamoxifen.
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Figure 4
Reduction in endometrial thickness following tamoxifen cessation.
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Discussion
The ultrasonographic endometrial appearances from women on tamoxifen are well
documented. Anteby [1992(a)] described 4 women who had been on tamoxifen for 1-4
years and had an endometrial thickness of 12-34mm. All were sympton free but he
described ultrasonographically a thick irregular endometrium containing cystic areas which
were compatible with endometrial hyperplasia/neoplasia. However, at hysteroscopy, all
had atrophic endometrium. He suggested that rather than this being purely endometrium
on USS, tamoxifen was affecting the myometrium in some way to produce this false
sonographic effect. Achiron [1995(a)] described the ultrasound findings as 'a peculiar
endometrial honeycombe appearance' - abnormal endometrial thickening with multiple
small cystic structures and heterogenous hyperechogenicity and more recently Neven
[1998(a)] referred to the effect as 'Gruyere-cheese appearance'. Other workers have
described similar cases where thickened endometrium is present on ultrasound scan but at
biopsy atrophic rather than the expected hypertrophic endometrium the scan predicted was
found [Aleem 1995, Ciatto 1994, Neven 1995, Goldstein 1994, Bornstein 1994, Cecchini
1996],
There have been a number of hypotheses regarding this.
Aleem [1995] suggested that the transvaginal ultrasound picture may represent small
subendometrial sonolucencies in the proximal myometrium. Cohen [1993(b)] in a study
of 72 asymptomatic women where there was no obvious correlation between the
endometrial pathological findings and endometrial thickness assumed the discrepancy was
due to echogenic cystic changes in the distal myometrium.
Ismail [1998(a)] regards this as a form of endometrial hyperplasia because the
endometrium, although not technically abnormal, shows a low level ofproliferative activity
in epithelial and stromal cells, focal glandular crowding, endometrial stromal fibrosis and
cystic dilatation of endometrial glands. Neven [1998(a)] argues that what is seen does not
show clear endometrial proliferation or atypia and a similar picture has been classified as
senile cystic atrophy in women not on tamoxifen. He believes that tamoxifen merely
enhances the appearance of stromal fibrosis leading to cystically dilated endometrial glands.
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While some refer to this as glandulocystic atrophy, he reclassifies this as pseudopolypoid
glandulocystic endometrium or extensive senile cystic atrophy. It is clear from the
literature that the pathology causing this apparent endometrial thickening remains under
debate.
More recently, apparent endometrial thickening caused by tamoxifen has been related to the
length of time on tamoxifen. The earlier findings in this thesis of 357 women on tamoxifen
found this correlation to be highly significant and confirmed that thickening on ultrasound
scan does not necessarily indicate endometrial pathology in that the study showed a 46%
false positive scan rate. This finding has been confirmed in 3 other studies. Bertelli
[1998] showed that 54% of patients on TV USS had endometrium >5mm which often
appeared as multiple irregular sonolucencies suggesting the presence of cysts. However,
ultrasound findings did not correlate with biopsy results, where no abnormalities were
found. Hann [1997] investigated endometrial thickness on USS and also found a direct
correlation between endometrial thickness on USS and duration of tamoxifen treatment.
48% of scans revealed an endometrial thickness of 8mm or more (which was used as the
normal cut off) and concluded that endometrial thickness showed no correlation with
symptoms. Bese [1996] in a similar study, used 10mm as the abnormal endometrial cut-off
and found that women on tamoxifen had significantly thicker endometrium on ultrasound
than controls but that there was a discrepancy between the sonographic findings and
histology.
Although initially workers suggested that ultrasound scanning was the best tool for
investigating women on tamoxifen and that all cases of thickened endometrium required
further investigation, more recently some have questioned the role of ultrasound scanning
in women on tamoxifen because of the high false positive results and the effect of tamoxifen
duration on endometrial thickness as assessed by ultrasound [Hulka 1993, Love 1999,
Bertelli 1998, Bornstein 1994], Most now agree that USS thickness does not correlate with
pathological findings and that this effect appears to be unique to tamoxifen use.
Tamoxifen is known to stimulate endometrial growth in some women and it is accepted that
tamoxifen use is associated with an increased incidence of endometrial abnormalities,
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including cancer. However, from knowledge about tamoxifen to date, it is impossible to
predict from thickened USS appearances who is going to have significant pathology, benign
or otherwise, from those who have atrophic/normal endometrium. This requires further
research because the use of ultrasound would subject 46-58% of women, who we know
from hysteroscopy and biopsy do not have significant pathology, to have unnecessary
invasive procedures.
Whilst some workers have screened women with ultrasound prior to commencing tamoxifen
[Berliere 1998, Tomas 1995, Willen 1998] and have monitored increasing endometrial
thickness over time, no one has investigated women following cessation of tamoxifen to
establish whether this phenomenon resolves.
The 20 women studied all had thickened endometrium on USS on tamoxifen with a range
of 6-23mm (mean 12.4mm) and had a mean duration of tamoxifen use of 98 months.
Following cessation of tamoxifen over a time period of 6-11 months there was a significant
reduction in endometrial thickness from a mean of 12.4mm on tamoxifen to a mean of
7.8mm off tamoxifen (p=0.0013).
16/20 of the women studied had a reduction in endometrial thickness of>2mm suggesting
that in these women, the tamoxifen effect is reversible and it could be postulated that if
followed over a longer time period the endometrial thickness would revert to normal. In
this group of 16 women over the period studied, although all had a reduction, only 6 fell to
within normal limits (<5mm).
The remaining 4/20 women did not have a significant decrease in endometrial thickness.
In 2 of these women the endometrium was only minimally thickened at the outset but the
other 2 had endometrium measuring 10mm and 16mm. There was no obvious explanation
why in these patients endometrial thickness did not decrease. It may be possible that
follow-up was not long enough to identify a significant reduction.
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A further hypothesis is that tamoxifen may have been stopped prior to pathology developing
in these women with thickened endometrium on ultrasound scan. This would support a
progressive effect theory where in some women the endometrium is never affected by
tamoxifen (and there are some women who are on tamoxifen long tenn whose endometrium
is normal both ultrasonically and hysteroscopically), some develop apparent thickening on
ultrasound scan but are hysteroscopically and histologically normal but potentially, if left
unchecked, develop into pathology - benign or otherwise. Supporting this theory is the fact
that polyps which develop on tamoxifen often have glandulocystic elements [Corley 1992,
Nuovo 1989]. Ismail [1994] has also suggested that polypogenesis may form an important
intermediate stage between simple hyperplasia and malignancy and that there may be a dose
threshold of tamoxifen for this to occur.
Normal < > Thickening >Thickening > Pathology
(reversible) (non reversible) Benign > Malignant
The reduction in thickness in some women with cessation of tamoxifen suggests that
whatever is responsible for the apparent endometrial thickening is in most women
reversible. Anecdotally, Rutqvist (1997) reported recently an update from the Stockholm
trial which showed that the risk of developing endometrial abnormalities did not appear to
reduce following cessation of tamoxifen. Potentially, Rutqvist may be studying women
with irreversible changes which may have been present in 4 of our 20 women.
The other interesting group ofwomen who have been ignored by investigators to date is the
group whose endometrium is never affected by tamoxifen regardless of length of time on
the drug. Clearly there is some as yet undiscovered trigger which does not affect these
women. These women may be at a lower risk of endometrial cancer and an understanding
of why these women's endometrium is unaffected by tamoxifen would be a significant




Tamoxifen has been shown to cause increased endometrial thickening on ultrasound scan
in 41% of asymptomatic women studied. On further investigation, (out-patient
hysteroscopy), 46% of these women had normal or atrophic endometrium and the remainder
all had benign features in the form of polyps or submucuous fibroids to account for the scan
appearances. There have been several hypotheses to account for this apparent endometrial
thickening but the histology remains unclear.
One of the aims of this thesis was to investigate this false positive scan appearance
histologically to establish a cause for this finding. As endometrial biopsies were to be
taken from all thickened endometria at hysteroscopy for histology, a second aim was to
study markers of cell proliferation, ER and MIB 1, to assess the effect of tamoxifen on
endometrial cell turnover.
Unfortunately, despite numerous attempts to biopsy the endometrium of women at
hysteroscopy using various biopsy forceps and Sharman Endometrial Biopsy Curette,
(Dupae Health Care, Leeds, UK) insufficient samples were obtained. Several other
workers have reported the fact that tamoxifen treated endometrium is difficult to biopsy
even in the presence of ultrasonographic abnormalities but the reason for this is yet to be
established.
Therefore in order to obtain sufficient samples from tamoxifen treated women and controls,
pathological specimens from hysterectomised women were retrieved and studied.
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Patients and Methods
195 women were identified as previously described Methods : Tissue Specimens. In 134
cases, medical records were retrievable and were investigated and from these 48 women
were identified as being on tamoxifen at the time of their hysterectomy and 19 women
identified to act as controls. Only women who had hysterectomy performed for benign
pathology were included.
Pathology specimens from 34 women on tamoxifen and 14 controls were traced and suitable
for investigation. 47 of the specimens were hysterectomy specimens and one was an
endometrial polyp (the hysterectomy specimen in this patient was not traceable). In several
patients there were D & C specimens (endometrial curettings) available in addition to the
hysterectomy specimen but these were not investigated. Reasons for hysterectomy
included menorrhagia/dysfunctional uterine bleeding, fibroid uterus, uterine prolapse,
ovarian cyst and postmenopausal bleeding (no malignant cause identified).
The age range of women on tamoxifen was 44 - 73 years (mean 58 years) and that of
controls 34-79 years (mean 53 years).




Representative haematoxylin and eosin (H&E) endometrial slides from each patient were
identified for investigation. Following receival of surgical specimens by the pathology
department, tissue blocks from these specimens are cut and from these, 4pm sections are
cut, mounted and stained (H&E) for histological investigation. Therefore for each
specimen received there are several tissue blocks and H&E slides. One slide showing a
representative section of endometrium and myometrium was chosen from each patient for
the purposes of this study.
Each slide was then assessed blindly by one investigator (Dr Alistair Williams, Consultant
Pathologist, Edinburgh Royal Infirmary) studying various aspects of the endometrial glands
and stroma and the interface between endometrium and myometrium. All information was
recorded onto a histology proforma for further assessment.
149
Immunohistochemistry
A sub-group of the study population, 16 women on tamoxifen and 5 controls, had further
tissue sections cut and stained to investigate markers of cellular proliferation, ER and
MIB 1. The methodology was described in Methods : Immunohistochemistry.
These sections were thereafter blindly assessed simultaneously by two investigators, the
author and Dr Margaret Mclntyre, Consultant Pathologist, Western General Hospital,
Edinburgh. Each slide was scored semiquantitatively on the proportion of cells staining
positive for ER and MIB 1 and the intensity of the staining.























For each slide the endometrial glands and stroma were scored separately for ER and MIB1
as the glands and stroma appeared to stain to differing degrees making a single score
inaccurate.
A Total Score = PS + IS was calculated for each modality.









From the histological evaluation of the endometrial glands and stroma the results from the
34 tamoxifen treated patients and 14 controls are summarised in Tables 1 and 2.
The factors which were significantly different between tamoxifen users and controls were;
Tamoxifen users were significantly more likely to show glandular cystic dilatation, low
stromal cellularity and the presence or prominence of collagen within the endometrial
stroma. None of the other factors investigated reached statistical significance.
Figure 2 shows an H&E slide from a tamoxifen user with the typical cystic dilatation and
Figure 3 an H&E slide showing collagenous endometrial stroma.
The mean age of tamoxifen users was 58 years and that of controls 53 years which was not
significantly different. This is of importance because menopausal state may have been an
important factor in tamoxifen's histological effect on the endometrium.
1. cystic dilatation of endometrial glands
2. pattern of stromal cellularity






















Widely spaced 19 4

































Thin walled 24 10






H & E slide showing endometrial cystic dilatation secondary to tamoxifen use.
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Figure 3
H&E slide showing collagenous endometrial stroma in a tamoxifen user.
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Immunohistochemistry
The tissue block from which the H&E slide assessed was taken was identified and further
sections cut, mounted and stained as previously described to assess markers of cell
proliferation ER (oestrogen receptor) and MIB 1.
The results for ER and MIB 1 staining for tamoxifen users and controls are in Tables 3, 4,
5 and 6 respectively.
In the tamoxifen group there were 16 patients - 4 premenopausal and 12 postmenopausal,
and in the control group 5 patients - 2 premenopausal and 3 postmenopausal. There was
no significant difference in ER or MIB 1 expression between pre and postmenopausal
patients in either the tamoxifen or control group.
The glandular cells of the endometrium stained positive for ER in all tamoxifen users and
all controls and the stromal cells positive for ER in 12/16 (75%) of tamoxifen users and 3/5
(60%) of controls. Glandular cells were positive forMIB 1 in all tamoxifen users and 60%
(3/5) of controls and stromal cells for MIB 1 in 50% (8/16) of tamoxifen users and 80%
(4/5) controls.
There was no significant difference in expression ofER orMIB 1 between study and control
patients for endometrial glands or stroma. The MIB 1 staining in endometrial stroma
almost reached statistical significance (p=0.073) indicating that tamoxifen users were less
likely to stain positive for MIB 1 than controls. Table 7 shows mean and median scores
for ER and MIB 1 in tamoxifen users and controls.
Figures 4 and 5 show staining for ER and MIB 1 in tamoxifen users and Figures 6 and 7
staining for ER and MIB 1 in controls.
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Table 3
Immunohistochemistry ER results from tamoxifen users.
Pathology No Glands Stroma
PS IS Total PS IS Total
26456/91 4 3 7 4 3 7
25138/91 5 1 6 - - -
11151/91 4 1 5 4 1 5
7080/92 5 3 8 - - -
6946/92 5 1 6 3 1 4
1515/93 4 2 6 4 2 6
8686/93 5 3 8 4 3 7
19132/93 5 2 7 - - -
22436/93 5 2 7 4 2 6
14851/95 4 1 5 4 1 5
14002/95 4 1 5 4 2 6
5020/95 3 1 4 4 1 5
12995/95 5 2 7 4 2 6
23681/94 5 2 7 3 2 5
17418/94 5 2 7 - - -
13779/94 5 2 7 1 1 2
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Table 4
Immunohistochemistry ER results from control patients.
Pathology No Glands Stroma
PS IS Total PS IS Total
10065/92 5 3 8 - - -
17864/92 3 1 4 1 1 2
22957/92 5 3 8 3 2 5
26014/94 3 1 4 - - -
5554/95 5 3 8 3 2 5
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Table 5
Immunohistochemistry MIB 1 results from tamoxifen users.
Pathology No Glands Stroma
PS IS Total PS IS Total
26465/91 3 2 5 - - -
25138/91 1 2 3 - - -
11151/91 1 2 3 1 2 3
7080/92 3 3 6 1 2 3
6946/92 1 3 4 1 3 4
1515/93 2 3 5 1 3 4
8686/93 3 3 6 1 3 4
19132/93 1 2 3 - - -
22436/93 1 3 4 1 1 2
14851/95 1 3 4 - - -
14002/95 1 3 4 - - -
5020/95 1 3 4 - - -
12995/95 1 3 4 1 3 4
23681/94 1 3 4 1 3 4
17418/94 3 3 6 - - -
13779/94 1 5 6 - - -
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Table 6
Immunohistochemistry MIB 1 results from control patients.
Pathology No Glands Stroma
PS IS Total PS IS Total
10065/92 1 3 4 - - -
17864/92 - - - 3 3 6
22957/92 2 3 5 1 3 4
26014/94 - - - 2 3 5
5554/95 1 3 4 1 3 4
161
Table 7

























ER staining from tamoxifen user.
Score : Glands (5+2) 7 Stroma (3+2) 5
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Figure 5
MIB 1 staining from tamoxifen user.
Figure 6
ER staining from control patient.
Score : Glands (3+1) 4 Stroma 0
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Figure 7
MIB 1 staining from control patient.




The histology responsible for apparent endometrial thickening on ultrasound scan seen in
women on tamoxifen from current literature is uncertain. This effect has been noted as far
back as 1992 when Anteby et al described 4 women who had endometrial thickening on
ultrasound scan but atrophic endometrium at hysteroscopy in the presence of this ultrasound
finding and has been confirmed by several other groups since then [Anteby 1992],
It is now accepted that tamoxifen treated endometrium can be very difficult to biopsy even
in the presence of ultrasonographic abnormalities and this has been described as
'endometrial honeycomb appearance' [Achiron 1995 (a)] and 'Gruyere-cheese appearance'
[Neven 1998(a)], In addition, it is usually not possible to predict what the histology will
be from the ultrasonographic appearances.
Hulka [1993] described multiple sonographic appearances including hyperechoic,
homogenous tissue, hyperechoic tissue with multiple small cystic spaces, heterogenous
tissue with small cystic spaces and solid heterogenous tissue in a group of 11 patients
undergoing sonography. She concluded that, because several pathologic findings could
coexist in tamoxifen patients, making it difficult to assign a single ultrasound feature to a
single pathologic diagnosis, ultrasound was of limited value.
Bornstein [1994] studied 22 tamoxifen patients, 7 symptomatic and 15 asymptomatic, all
with ultrasound abnormalities - irregular thickening of the endometrium, some with cystic
formations. He found no pathology or inadequate material for assessment from all 15
asymptomatic patients and polyps in 2/7 symptomatic women. He suggested that the
discrepancy between ultrasound and histology may be due to stromal oedema which was
insignificant and not a true abnormality. In view of these findings he also questioned the
role and need for screening.
Touraine [1995] described 40 women on tamoxifen who underwent hysteroscopy. 22 had
previously had ultrasonography performed and in 20 women 'hyperplasia' had been
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diagnosed. At hysteroscopy all 40 women had 'a smooth, white and brilliant endometrium
associated in most cases with multiple scattered protuberences.' In 16 of these women
biopsy was not possible because of the 'intensity of atrophy' and the remaining 24 all had
atrophic endometrium on histology. He described dilated cystic glands on histology, with
a flattened epithelium but a dense stroma with an abundance of collagen and large
oedematous areas. Mitoses were uncommon and he described the whole picture as cystic
glandular atrophy.
Achiron et al [1995 (a), (b), 1996] described thickened, irregular cystic endometrium on
ultrasound scanning in 20 postmenopausal women on tamoxifen, 8 ofwhom had polyps and
the remaining 12 no significant pathologic findings - scanty, senile, cystic atrophic
endometrium. Both Achiron and later McGonigle [1998] suggested that this appearance
may be better investigated by sonohysterography as this may distinguish between polyps
and 'cystic atrophy', the polyps requiring removal as the overall incidence of endometrial
polyposis in the tamoxifen population ranges from 39-50% and some have suggested may
be a precursor to hyperplasia or carcinoma. Achiron concluded that tamoxifen stimulates
the endometrial epithelium and stroma and together with the myometrium may cause the
thick echogenic honeycomb appearance without necessarily causing epithelial disease.
Willen [1998] prospectively followed 29 patients on tamoxifen. All had ultrasound prior
to commencing tamoxifen and at regular intervals thereafter. Where endometrial thickness
was >5mm at any point in the screening programme they underwent histological evaluation.
His group reported proliferation of stromal cells with slight hyperchromasia and definite
increased cell density. In general the epithelium was described as atrophic with polyp
formation but sometimes showed features of proliferation with mitoses, or cytoplasmic
'snouts' bulging into the lumen. The glands also demonstrated cystic dilatation.
McGonigle et al [1998] studied 35 tamoxifen treated women with endometrial thickness
>5mm on ultrasound scan. 23/35 patients were found to have polyps accounting for their
thickened endometrium but 10/35 (29%) had endometrial cystic atrophy to explain the USS
findings. This was defined as multiple cystic spaces lined by atrophic epithelium present
within a dense fibrous stroma. Changes were often seen extending to the endomyometrial
junction. However, ultrasonographic findings did not distinguish between the presence of
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endometrial polyps or cystic atrophy and concluded that cystic atrophy was probably a
benign process unlikely to cause an increased risk of endometrial cancer.
Bertelli et al [1998] studied 110 asymptomatic patients on tamoxifen and found that 54%
had an endometrial thickness of >5mm, often with multiple irregular sonolucencies
suggestive of cysts, but that ultrasound findings did not correlate with abnormalities at
biopsy and therefore questioned the use of sonography in asymptomatic women. He
suggested that the tamoxifen induced hyperproliferation may be mediated through the
endometrial stroma in that hypertrophy of the sub endometrial stroma was seen
histologically in some of the biopsy specimens.
Mourits et al [1999] conclude that the histologic changes can be summarised as hyperplastic
endometrial stroma and atrophic epithelium and this would explain the fact that several
endometrial pathologies, atrophy, hyperplasia or polyps present with similar
ultrasonographic findings.
Neven et al [1998(a)] report that in postmenopausal women not on tamoxifen
histopathological evidence of flattened or cuboidal epithelium overlying fibrous endometrial
stroma containing cystic dilated endometrial glands is not rare and is usually referred to as
senile cystic atrophy but he believes that tamoxifen greatly enhances this appearance of
stromal fibrosis leading to cystic dilated endometrial glands. He suggests that referring to
the appearance as hyperplastic is misleading and reclassifies it as pseudopolypoid
glandulocystic endometrium or extensive senile cystic atrophy.
Ismail [1994(a), 1995, 1998(a)(b), 1999] has published widely on this topic reporting
macroscopic 'Swiss cheese like cut surface' with generalised thickening of the
endometrium within which are numerous cysts of varying size. Microscopically she finds
cystic dilatation of the endometrial glands with some glands showing glandular budding,
fibrotic endometrial stroma and collagen bundles separating stromal cells, the stroma being
relatively 'paucicellular'. Tamoxifen induced polyps show patchy periglandular stromal
condensation and a proliferation of epithelial and stromal cells. There appears to be no
cytological atypia and minimal mitotic activity. Thus there is a spectrum of proliferative
abnormalities and she suggests that this may form an important intermediate stage between
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simple hyperplasia and malignancy. She attributes the problem of inadequate tissue
sampling to endometrial stromal fibrosis and does not accept the term 'glandulocystic
atrophy' as this implies normal atrophic endometrium. Ismail maintains that tamoxifen
stimulated endometrium shows a degree of low proliferative activity in epithelial and
stromal cells, focal glandular crowding, endometrial stromal fibrosis and florid cystic
dilatation which is best regarded as a form of hyperplasia.
This lack of ability to satisfactorily biopsy the endometrium in these women led to the
hypothesis that it may be myometrial in origin and represent superficial myometrial
oedema.
Goldstein [1994] described a heterogenous bizarre ultrasonographic appearance in five
women which he felt initially to be endometrial in origin but following saline infusion
(sonohysterography) was thought to represent small subendometrial sonolucencies in the
proximal myometrium and was reinforced by the fact that hysteroscopy revealed a smooth
endometrium and histology, inactive endometrium. He concluded that this appearance
may represent abnormal adenomatous-like changes in the proximal myometrium. Cecchini
[1996] and Cohen [1993(a), 1994(a)(b)] also detected endometrial thickening without
abnormality and suggested that the changes may be myometrial because of the inability to
obtain adequate biopsy specimens.
Summarising all the evidence to date, the appearance on ultrasound scan would suggest the
thickening to be endometrial in origin, with a typically normal appearance at hysteroscopy
which is difficult to biopsy. Transvaginal ultrasound does not differentiate between this
and other endometrial pathologies making it of limited use. This effect appears to be
unique to tamoxifen use, but its histological classification remains under debate.
It would have been ideal to have obtained adequate tissue specimens at hysteroscopy from
the population of asymptomatic women studied to investigate the histology causing the
apparent endometrial thickening but despite numerous attempts to do so in the out-patient
setting this was found to be difficult, as previously described. Therefore it was necessary
to use the second study population described.
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This study, the first to use a control population to investigate histology, found that
tamoxifen users had significantly more cystic dilatation of endometrial glands, low stromal
cellularity but the presence or prominence of collagen within the endometrial stroma.
These results confirm those of other workers apart from the degree of stromal cellularity
which we found to be low while others have suggested stromal proliferation and dense
stromal cellularity. These results would agree with suggestions that the quantity of
collagen within the stroma could account for the difficulty in biopsying tamoxifen induced
endometrium.
The significance of these endometrial findings is yet to be established.
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Immunohistochemistry
Tamoxifen, effective in the treatment of breast cancer, is thought to down regulate
oestrogen receptors (ER) in the breast by acting as an oestrogen receptor antagonist.
However, tamoxifen acts as a partial agonist on the endometrium, and through mechanisms
unknown is responsible in users for an increased incidence of endometrial abnormalities
including cancer.
The aim was to investigate possible mechanisms of action further by assessing the
expression ofER in the endometrium of tamoxifen users and controls to test the hypothesis
that tamoxifens mode of action is to upregulate ER expression in the endometrium, giving
some explanation for its agonist effects. In addition, MIB 1 was assessed in the same
groups as a marker of epithelial proliferation to examine whether cellular proliferation was
an important factor in the carcinogenic potential of tamoxifen.
In the normal population all endometrium has been shown to contain oestrogen receptors,
with the highest values seen in the proliferative phase of the menstrual cycle and the lowest
values in the secretory phase. Ehrlich et al [1981] showed that 93% of endometrial
hyperplasia and 79% of endometrial cancer was positive for ER and suggested that the
proportion of ER staining fell with increasing tumour anaplasia [Bayard 1979, Mortel
1981],
Kommoss et al [1998] in a retrospective study, evaluated the presence of ER in the
endometrium of40 tamoxifen users. They found positive ER staining in the glandular cells
of all 40 women and weak to moderate ER staining was also observed in endometrial
stromal cells. They detected ER positive cells in the endometrium of 16/20 control patients
(80%) but concluded that the persistent finding ofER positive glandular cells in tamoxifen
users supported its suspected oestrogen agonist effect. Gorodeski [1992] gave tamoxifen
in a single dose and monitored ER for 4-96 hours post administration. He found that ER
increased following tamoxifen, confirming agonistic properties and that the highest relative
increase in ER levels were seen in menopausal women indicating that postmenopausal
endometrium is sensitive to tamoxifen.
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However, there have been varying reports regarding tamoxifen's effect on endometrial ER.
Carlson et al [1984] investigated tamoxifen's use in the treatment of endometrial cancer
when it was thought that tamoxifen was a pure antioestrogen and found that in 17 patients
with endometrial cancer tamoxifen decreased ER expression in 9 but increased ER
expression in the remaining 6 women possibly due to tumour heterogeneity and concluded
that the trend was towards tamoxifen decreasing ER. Neumannova et al [ 1985] showed a
depletion in cytosol ER and an increase in nuclear ER but a tendency towards a decrease
in total cellular ER while Kokko et al [1981] suggested that tamoxifen administration did
not alter ER concentration. Perez-Lopez [1993] showed that tamoxifen significantly
reduced endometrial receptor levels compared to controls.
In the small population investigated in this study there was no significant difference in ER
or MIB 1 expression in tamoxifen users or controls regardless of menopausal state.
All glandular cells in tamoxifen users did stain positive for ER and MIB 1 and this may
reflect the histology seen with tamoxifen use, namely large cystically dilated glands which
has been shown to be unique to tamoxifen use and indicates a degree of activity in the
glandular elements of the endometrium. Histology investigated as part of this study
revealed low stromal cellularity in tamoxifen users and this may be reflected in the fact that
only 75% of stromal cells stained positive for ER and 50% for MIB 1 indicating a lower
degree of stromal activity. The degree of stromal staining for MIB 1 was almost
significantly less in tamoxifen users compared to controls (p=0.073).
Kuwashama [1996] found low positivity for ER in women on tamoxifen with endometrial
cancer (1/7) and suggested that tamoxifen may not in fact operate through oestrogenic
pathways. Other mechanisms of action of tamoxifen have included the formation ofDNA
adducts. In rat liver, tamoxifen is metabolised to alpha-hydroxytamoxifen, the proximate
carcinogen, which is activated by further metabolism to a sulphate ester which gives rise
to high levels of DNA adducts. Barakat et al [1998] found that in vivo DNA adduct
formation in tamoxifen treated women did not differ from that in untreated patients and that
there was no good evidence for in vivo DNA adduct formation [Powles 1995]. This has
been supported by other workers in vivo and in vitro regardless of dose or length of
treatment [Vergote 1998, Carmichael 1996, 1999].
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Proto-oncogene expression in endometrium has also been suggested as a possible
mechanism of action. In rat endometrium the persistent over expression of c-fos and jun-B
has been demonstrated and the products of these cellular oncogenes (AP-1 transcription
factor) are thought to play important roles in regulating cellular function in many tissues
including uterus [Nephew 1996, Zhao 1998, Neven 1993 (a)]. Robertson [1998] found a
similar up regulation of c-fos in ewes.
Tamoxifen can also induce chromosomal changes in rat hepatocytes and mutations of the
tumour suppressor gene p53 in rat livers leading to hepatocellular carcinoma in rats. p53
is the most commonly mutated gene in human cancers and has been correlated with higher
grade advanced stage, recurrence risk, metastases and more aggressive tumours.
Ramondetta [1998] examined hysterectomy specimens from endometrial cancer in breast
cancer patients on and off tamoxifen and found that tamoxifen associated tumours
expressed p53 mutations more frequently than non users and that p53 mutations may play
a role in the development of tamoxifen associated tumours [Carmichael 1999].
There have also been reports of an increased incidence of cancer foci developing in polyps
associated with tamoxifen use. Dal Cin et al [1998] investigated genomic changes in
endometrial polyps but found no evidence for tamoxifen induced chromosome changes or
gene rearrangement to support this carcinogenic theory.
Other growth factors have also been postulated to play a role in tamoxifen associated
endometrial tumours including IGF-1 and IGFBP (upregulation of), adrenomedullin (a
growth factor for endothelial cells which is angiogenic) and TGF-B, although none
convincingly [Fornander 1991, Zhao 1998, Laatikainen 1992, Nephew 1996, Kuo 1995,





Tamoxifen is the most commonly prescribed adjuvant therapy for women with breast cancer
and since its introduction in 1971 has been used by millions ofwomen worldwide. As a
chemotherapeutic agent it is extremely well tolerated with few serious toxic side effects
apart from its effect on the endometrium.
However, women taking tamoxifen do report a number of less serious side effects, which,
although not life threatening, can be troublesome and affect quality of life, eg hot flushes,
night sweats and weight gain. Few studies have assessed the incidence of these side effects
in women on long term tamoxifen and have compared them to a control population of
similar age with breast cancer.
The aim was to assess the incidence of non-toxic side effects in the study group of 357
women on long term tamoxifen and 130 control women who had been treated for breast
cancer but had not received tamoxifen to assess which side effects were significant.
175
Patients and Methods
All patients were asked to complete a side-effect questionnaire asking whether they were
experiencing various symptoms including hot flushes, sweats, weight gain, fluid retention
etc. Only current symptoms were included for analysis.
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Results
Tables 1 and 2 give questionnaire results for women on tamoxifen and controls respectively.
All 357 women on tamoxifen and 130 controls completed the questionnaire. The results
can be summarised as follows:
Study Group Control Group
357 130
Hot flushes/sweats 210 (59%) 59 (45%) p=0.0099
Weight gain 155 (43%) 47 (36%) NS
Low energy 87 (24%) 36 (28%) NS
Fluid retention 85 (24%) 15 (12%) p=0.0033
Low libido 76 (21%) 28 (22%) NS
Vaginal dryness 81 (23%) 32 (25%) NS
Vaginal discharge 149 (42%) 16 (12%) pO.OOOl
This is demonstrated graphically in Figure 1.
The only side effects which were significant were hot flushes/sweats, 'fluid retention' and
vaginal discharge.
Fluid retention is generally a subjective phenomenon and its significance should be
interpreted with caution.
Although there appeared to be an increase in the percentage of women reporting weight
gain on tamoxifen, this was not statistically significant.
Other side effects which women were questioned about (example questionnaire over)
included nausea, irritability, skin rash, breathlessness and hair loss but these only occurred
in very small numbers ofwomen and none were significantly different so were not included
in the analysis.
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Check list for Patients on Endocrine Therapy (C-PET)





Hormone treatment for breast cancer sometimes causes side-effects.
Please go through this list, and tick (/) boxes that apply to you,
leaving other boxes blank. This information will help in your discussions
with your nurse or doctor.
Dose:




1would like to talk



































1. EF Y Y N Y N N N
2. HM N Y N Y N N N
3. SP N Y N N N N Y
4. OK Y N N Y Y Y N
5. CC N N N N N N N
6. AC Y N N Y N N N
7. EB Y N Y Y N N N
8. MC N Y N Y Y N Y
9. BU Y Y N Y Y N N
10. EH Y Y Y N N Y N
11. JB Y Y N N Y Y Y
12. AS Y Y N N Y N Y
13. MS N N N N N N N
14. EB Y Y Y N N N N
15. JA Y Y Y Y Y N Y
16.MM N N N N N N N
17.MW Y Y Y N Y Y Y
18.MM N N N N N N N
19. EM Y Y N Y N Y N
20. MC N N N N N N Y
21. MS N N N N N N N
22. CM N N N Y N N N
23. GK Y Y N N N N N
















25. MG Y Y Y Y N N Y
26. HD Y N Y N N Y N
27.MM Y N Y N Y Y N
28.WK Y Y N Y Y Y N
29.MK N N Y N N N N
30.MH N Y N Y N N Y
31.KR Y Y N N N N N
32. LR Y Y N N N N Y
33. ER N Y N N N N N
34. JR N N Y N Y Y Y
35. CS Y N N N N Y Y
36. SR N Y N N N N Y
37. MT Y Y N N Y Y Y
38. JU Y Y Y Y N Y N
39. ED Y Y Y N N N Y
40. AD Y Y Y Y N Y N
41.MM N N N N N Y Y
42. AS N N N N N N N
43. AM Y N N N N N N
44. CH Y N N N N N N
45. SD N N N Y N N N
46. JA N N N N N N N
47. GT N N N N N N N
48. LL Y Y N N N N N
49. KD Y N Y N N N Y
50. SM N N Y N N N Y
51. IN N N N N N N N
















53.MM N N N N N N N
54. DS Y Y N N N Y N
55. JR N N N N N N N
56. ES Y Y N Y N N Y
57. MG Y N N N N N Y
58. MD N Y N N N N Y
59. MP Y N Y Y N N N
60. FB N N N N N Y Y
61. MR Y N N N N N Y
62. ES N Y Y N N N Y
63. CA Y Y N N N N N
64. PC Y N N N N N N
65. IH N N N N N N N
66. FN N N N N N N N
67. EF N Y Y N Y N N
68. AL N Y N Y N N N
69. JC N Y N Y N N N
70. DM N Y N Y N N Y
71. FR N N N N N Y Y
72. JD Y Y N N N N N
73. JL N N Y N N Y N
74. IR Y N N N N N N
75. ED Y N N N Y N N
76.MD N N N N N N Y
77. MD N N N N N N N
78. WP Y Y N N N N N
79. MT N N Y N Y Y N
















81. MH Y N N N N N N
82. EH N N N N N N N
83. DR Y N N Y N N Y
84. ER N N N N N N Y
85. KM Y Y Y N Y Y Y
86. JB Y Y Y N Y N Y
87. DK Y N N N N N N
88. EG N N N Y N Y N
89. EC Y N N N N N N
90. AS Y N Y N Y Y N
91. BR Y Y Y N Y N Y
92. GC N N N N N N Y
93. CR Y Y Y N Y N N
94. AM N Y N Y Y N N
95.MM Y Y Y N N N N
96. JD Y Y Y Y Y N N
97. AB Y Y N Y Y N N
98. JD Y N N N N Y N
99. AC N N N N N Y Y
100.JB Y Y Y N N N N
101.JH Y Y Y N N N N
102.MM Y Y N N N Y N
103.AG Y N N N N N N
104.AF Y Y N N Y N Y
105.IM Y Y Y Y N N N
106.IM N N N N N N N
107.RM Y N N N N N N
















109.HN N Y Y N N N N
110.CS Y Y N Y N N Y
11 l.AS Y N Y Y Y N N
112.AS Y N N N N N N
113.CT N N N N N N N
114. EW N N N N N N N
115.WW Y Y Y Y Y N Y
116.IT Y N N N Y Y N
117.SC N N N N N N N
118.EC N N N N N N Y
119.ML Y Y Y Y N N Y
120.JM Y Y N Y N N N
121.EA Y N Y N Y N N
122.IA Y N Y Y N Y N
123.AE Y Y N N Y Y Y
124.DA Y N N N N N N
125.SA Y Y N N Y Y Y
126.FA N N N Y N N Y
127.CA Y Y N Y Y Y N
128.GA Y Y N Y N N Y
129.SB N N N N N N N
130.BB N Y N N N N N
131.MB N Y Y N Y Y Y
132.AB Y Y N N N N N
133.PB N N N N N N N
134.EB N N N N N Y N
135.EB N N N N Y N N
















137.KB N N N Y N N N
138.AB Y Y N N N N Y
139.MB N N N N N N Y
140.AB Y Y Y N N N N
141.DB Y N N N N N N
142.MB N N Y N N N Y
143.EB Y Y Y Y Y Y Y
144.SB N N N N N N Y
145.HB Y N N N N N N
146.CB Y Y Y Y Y N Y
147.MB Y Y N Y N Y Y
148.AC N N N N N N N
149.EC N Y N N N N N
150. SC Y N Y N Y N Y
151 .JC Y N N N N N N
152.SC N Y N N N N N
153.IC N N Y N N N Y
154. PC Y Y N N N N N
155. LC Y Y N N N N N
156. BC Y Y Y N N N N
157. HC Y N N N N N Y
158. JC N N N N N N N
159. IC Y N N N N N N
160. LC Y N N N N N N
161. NC N N N N N N Y
162.IC N N N N N Y Y
163.MC N N Y N N N N
















165. EC Y Y Y N Y N N
166.MD N N N Y N N N
167.VD N Y N N N N N
168. PD Y Y N N Y N N
169.MD Y Y N N N N N
170.ID Y Y N N N N Y
17 l.CD Y N Y N Y Y Y
172.ED Y Y Y N N N Y
173.GD Y N N Y N N N
174.CD N N N N Y Y N
175.MD Y Y N N N Y Y
176.PD N N N N N N N
177.RE N Y N N N N N
178.EE Y N N N Y Y Y
179.FF Y Y Y Y N N Y
180.IF N N Y N N N N
181 .JF N N N N Y Y Y
182.MF Y Y N N Y N Y
183.EF N N Y N N Y N
184.MF Y N N N N N N
185.SF Y N N N N N N
186.TF Y Y Y Y Y Y N
187.SF Y N Y N N N Y
188.MF N Y N Y N N N
189.MF N N N N N N N
190.JF Y Y Y N N N N
191.HF Y N Y N Y N Y
















193.MG Y Y N N Y Y N
194.DG N N N N N N N
195.SG N N N N N N Y
196.JG Y N N Y Y N N
197.EG N Y N Y N Y N
198.SG Y N N N N N N
199.EH Y N N N N N Y
200.MH Y N N N Y N Y
201.PH Y Y Y N Y Y N
202.MH N N N N N N Y
203.AH Y N Y N N N N
204.CH Y N N N N N Y
205 .MH Y N N N N N N
206.MH N N N N N N N
207.EH Y N N Y N N N
208.CH Y N Y N N N Y
209.CH N N N N N N N
210.DH Y Y N Y Y N Y
21 l.AI Y Y Y Y N Y N
212.SI Y N N Y N Y N
213.JJ Y Y Y Y N N N
214.MJ Y Y Y N Y N N
215.CJ Y Y Y Y Y Y Y
216.SJ N Y N N N N Y
217.MJ Y N N N N Y Y
218.NJ Y N N N N N Y
219.AJ Y N N N N N Y
















221.MK Y Y Y Y Y Y Y
222.JK Y N N N N Y Y
223.PK Y Y N N N Y N
224.AK N N N N N N N
225.GK N Y N Y N Y Y
226.TK N Y N N N Y N
227.WL Y N N N Y N N
228.EL Y N N N N N N
229.AL N N N N N N N
230.DL N N N N N N N
231.ML Y N N N N N N
232.PL Y Y N N N Y Y
233.AL Y N N N Y Y N
234.GL Y Y N N Y N N
235.JL N N N N N N Y
236.RM N N N Y N N Y
237.MM N N N Y N N N
238.EM N N N N N N Y
239.SM Y Y N Y Y N Y
240.MM N N N N N N N
241.EM N N Y N N N Y
242.IM Y N N N N N Y
243.AM N Y Y N N Y Y
244.CM Y N N N N N N
245.IM N Y Y Y N N Y
246.GM N Y N Y N Y Y
247.AM N N N N N N N
















249.AM N N N N N N N
250.IM Y N N N N N N
251.SM Y Y Y N Y N Y
252.JM N Y N N N N N
253.JM Y N N N N N N
254.SM Y N N N N N N
255.JM N N Y Y Y Y N
256.JM Y N N Y N N Y
257.MM N N N N N N Y
258.IM Y N N N N N Y
259.HM Y N N N Y Y N
260.OM Y N N N N N N
261.MM Y Y Y Y N Y Y
262.AM N N N N N N N
263 .BN Y Y N Y N N N
264.MN Y Y Y Y N N Y
265.EN N N N N N N Y
266.AN Y N N N N N N
267.FO Y Y N N Y N Y
268.EO Y Y N Y N N N
269.JP N N N N N N Y
270.CP N Y Y N N N Y
271.KP N Y N N N N N
272.EP Y Y N Y Y Y Y
273.MP Y N N N Y N N
274.MP N N Y Y N Y Y
275.JP N Y N N N N Y
















277.GR Y N N N N N N
278.LR Y Y Y N Y N Y
279.JR Y Y Y N Y Y Y
280.AR Y N N N N Y N
281.MR Y Y N Y N N Y
282.JR N N N N N N N
283.IR N N Y N N Y N
284.MR N Y N N N N Y
285.HR Y Y N Y Y N Y
286.JR Y Y N N N N Y
287.ER Y N N N N N Y
288.CR Y N N N Y N Y
289.RS N N Y N Y Y Y
290.MS N N N N N N N
29 l.AS Y Y N N N N Y
292.TS Y Y N Y N Y N
293.ES Y Y Y Y N N Y
294.SS N N N N N N Y
295.TS N Y Y N N N N
296.KS N N N N N N Y
297.MS Y N N N N N Y
298.RS Y N N N N N N
299.GS Y N Y Y Y Y Y
300.CS N Y N N N N N
301.MS Y Y N N N Y N
302.AS Y N N N Y N N
303 .RS Y Y N N N N N
















305.JS Y N N N N N N
306.KS Y Y N N Y Y Y
307.CS Y N N N N N N
308.SS N N N N N N Y
309.RS Y N Y N N N N
310.MS N N N N N N N
311.AS N N N N N N N
312.AS Y N N N N Y Y
313.IS N N N N N N N
314.ES Y Y N N Y N Y
315.NS Y N N N Y Y N
316.CS Y Y N N N N N
317.AT N Y N N N N N
318.MT N N N N N N N
319.RT Y N N N N N N
320.CT N N N N N N Y
321.CT Y N N N N Y N
322.HW Y N N N N N Y
323.MW N N Y N N N N
324.LW Y N N N N Y N
325.MW Y Y N Y Y N Y
326.YW Y Y Y Y N Y Y
327.WW Y Y N Y N N N
328.JW Y Y N N Y Y Y
329.JW N N N N N N N
330.VW N N N N N N N
331.GY N N N Y N N N
















333.MG Y Y N N N Y Y
334.CS Y Y Y Y N N Y
335.AS N N N N N N N
336.IW N Y N N N N N
337.JT N N N N N N Y
338.EH N N N N N N Y
339.MR Y N N N N N N
340.EC N Y N N N N Y
341.MD Y N N N N N N
342.AM N Y N N N N Y
343.MM Y N N N N N Y
344.MC Y N N N N N Y
345.MD Y Y N N N N Y
346.YH N N N N N N N
347.HS Y Y N Y N N Y
348.JP Y Y Y Y N N N
349.ED N N Y N N N N
350.JF N N N N N N Y
351.IW Y Y N Y N N N
352.JH N N N N N Y Y
353.NT Y N Y N Y Y Y
354.ES Y N N N N N N
355.JK N N N N N N Y
356.RB N Y Y Y Y Y Y
357.MM Y Y Y N Y N Y
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1. RC Y N N N N N N
2. WP N N N N N N N
3. IW Y Y N N Y Y N
4. AH N Y N N N N N
5. FS N N N N N Y N
6. SM N N Y N N N Y
7. PM N N Y N N N N
8. AJ Y Y Y N N Y N
9. MM N Y N Y N Y N
10. IW N N N N N N N
11. MG N Y Y Y N Y Y
12. MM Y N Y Y N N N
13. JR N N N N N Y N
14. ES Y Y N N N Y N
15. ME N Y N N N N N
16. SJ N N N N N N N
17. IG N N N N N N N
18. CL N Y Y N Y N N
19. EM Y N Y N N N Y
20. EH Y N Y N N N N
21. RB Y Y Y Y Y N N
22. CH Y N N N N N N
23. CR N N N N Y N N
















25. EM N N N N N N Y
26. AB N N Y N Y Y N
27. MA Y Y N N Y Y Y
28. EA N N N N N N N
29. MM N Y N N N N N
30. AN N Y N N N Y N
31. BA Y N N N N N N
32, RW N N N N N N N
33. ER Y N N N N N N
34. MM N N N N N N N
35. BL Y Y N N N N N
36. ER N Y N N N Y N
37. JW Y N N N Y N N
38. MM Y N Y N N N N
39. AC Y N N N Y Y N
40. BM N Y N N N N N
41. CP N Y Y N N N Y
42. MC Y N N N N N N
43. MM N N N N N Y N
44. MD Y Y N Y N N N
45. MB Y Y Y N Y Y N
46. EM Y N N N N N N
47. IR Y Y N Y N N N
48. LG N N N N N N N
49. RK N Y Y N N N N
50. AB Y N N N N N N
51. DB N N N N Y Y Y
















53. MB N Y N N N N N
54. AB Y N N Y Y Y N
55. LA N N N N N Y N
56. IC N N Y N N N N
57. AB Y Y Y N N N N
58. MP Y Y Y N N N N
59. MC Y N N N Y Y N
60. JS N Y N N N N N
61. ES N N N N N N N
62. HM Y Y Y N N N N
63. MP N N Y N Y N N
64. MM Y Y N N Y Y N
65. SP N N Y N N N N
66. MB Y N N Y Y Y N
67. MM N N N N N N N
68. MA N N N N N N N
69. SB N N N N N N N
70. CM N N N N N N N
71. AH N N N N N N N
72. IW Y Y N N N N N
73. MW N N N Y N N N
74. IG N N N N N N N
75. AW N N N N Y Y N
76. AS Y N Y N Y Y Y
77. JM N N N N N N N
78. JD N N N Y N Y N
79. BW N N N N N N N
















81. MA Y Y Y N N N N
82. EG Y N N N Y N Y
83. SM N Y N Y N N N
84. MM Y Y N N N N N
85. MM N N N N N N N
86. MF N N N N N N N
87. MA Y Y N N N N N
88. AH N Y N N N N N
89. MG N Y N N N Y N
90. PT N N N N N N N
91. DM N N N N N N N
92. AS N Y N N N N N
93. AS Y Y Y N Y N N
94. JC Y N N N N Y N
95. IV Y N N N N N N
96. KL N N N N N N N
97. N N N N N N N
98. MG Y Y N N N N N
99. MP N N N N N Y N
100. PM N N N N N N N
101.MM Y N N N N Y Y
102.EM Y N N N N N N
103.NL Y N N N N N N
104. PL N N Y N Y N Y
105.EB Y N N N N Y N
106.BM Y N N N N N N
107.MB N Y Y N N N N
















109.BW Y N N N N N N
11 O.AM N Y N N N N Y
111.ES N Y N N Y N N
112. JR N N Y N Y N N
113. CR Y Y N N N N N
114.10 Y Y Y Y Y N N
115.EM Y Y Y Y Y N N
116. PC N Y N Y N N N
117.HA Y N N N Y Y Y
118.MW N N N N N N N
119.WB N N N N N N N
120.SM Y N Y N Y Y N
121.MS Y N N N N N N
122.MR Y N N N N Y Y
123.EC Y N N N N N N
124.MD Y Y Y Y N Y N
125.DW Y Y N N N Y N
126.JL Y N Y N Y N N
127.SN Y N Y N Y N N
128.MS N N Y N N N N
129.NM N N N N N N N























































Tamoxifen is the most common chemotherapeutic agent in current use. Studies have
shown it to be of benefit in pre and postmenopausal patients with oestrogen receptor
positive breast cancer in terms of up to 40% decrease in local recurrence, distal metastases
and contralateral cancer. It has been used to treat over 3 million women worldwide.
However, no drug is without side effects and tamoxifen has a number of recognised toxic
and non-toxic effects.
Some of the toxic effects of tamoxifen reported include ocular toxicity, liver derangement,
haematological changes (leucopenia, thrombocytopaenia), hypercalcaemia, tamoxifen flare
and its effect on the endometrium.
Toxic effects requiring discontinuation of the drug are rare and withdrawal from treatment
occurs in less than 3% of patients overall [Heel 1978], The Christie trial reported that 2%
of women had to reduce the dose of tamoxifen to 1 Omg/day because of distressing side
effects and 4% stopped the drug in less than 1 year [Riveiro 1988]. In the Scottish trial, 28
of the 641 patients given adjuvant tamoxifen stopped the drug because of toxicity (4%),
mostly during the first year of therapy [Scottish 1987], Both trials refer to tamoxifen being
discontinued because of toxicity but neither specifies what side effects were experienced,
ie whether they were distressing but not life-threatening, eg hot flushes/sweats or more
serious, eg ocular, hepatic or haematological effects.
An association between tamoxifen and ocular disease was first recognised in 1978 and
various effects have been reported including retinopathy, optic neuritis, corneal changes,
macular oedema and keratopathy. Kaiser-Kupfer [1978] reported 4 cases of ocular toxicity
amongst a group ofwomen receiving high dose tamoxifen (120-320 mg/day) for metastatic
breast cancer. These patients who had taken tamoxifen for 17-27 months developed a loss
in visual acuity as a result of retinopathy affecting mainly the macula and accompanied by
macular oedema. 3 of the 4 patients also had unusual corneal changes [Vizel 1982].
Approximately 21 cases of tamoxifen related ocular toxicity have been reported as case
reports and the most common clinical abnormality is decreased central visual acuity which
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has been reported in 16 of the 21 cases. 10 of these 16 patients experienced improvement
in their vision following cessation of tamoxifen [Nayfield 1996], Both development of
ocular toxicity and potential improvement in visual acuity may be related to total
cumulative dose of tamoxifen. Most of the reports have been associated with high dose
tamoxifen or high cumulated doses although there have been a few reports at conventional
dosage [McKeown 1981, Kaiser-Kupfer 1978]. Longstaff et al [1990] found no ocular
toxicity in a blind study comparing standard dose tamoxifen to controls.
Overall, therefore, the incidence of any ocular complications from tamoxifen is low.
However, if caught early, any complications may prove reversible. Although there is little
evidence to support regular opthalmological screening of women on tamoxifen, anyone
presenting with visual disturbances or a worsening of visual acuity should be investigated
[Nayfield 1996],
Thromboembolic complications have also been reported with tamoxifen therapy [Hendrick
1980]. Lipton et al [1984] reported 7 patients who developed venous thrombosis or
pulmonary embolism within 6 months of starting tamoxifen treatment. This was in a group
of 220 patients, giving an incidence of 3.2%. Jungi, Wagenknecht and Lerner have also
reported pulmonary emboli in patients during tamoxifen administration [Heel 1978],
However, the mechanism for this is not clear and a causal relationship has not been
established. Some studies suggest this may be due to a decrease in functional activity of
antithrombin III [Enck 1984, Lipton 1984, Love 1989] but studies from Jordan, Auger and
Mackie do not support this theory. Evidence from the large tamoxifen trials suggest a
small increased incidence of thrombophlebitis only [Enck 1984, Lipton 1984, Love 1989],
Hypercalcaemia may be an early complication of tamoxifen therapy. In a study by Legha
et al [ 1981 ] 2.3% ofpatients with metastatic breast cancer developed hypercalcaemia within
a median of 7 days (range 4-11) of starting tamoxifen therapy. All patients had bone
metastases. Hypercalcaemia is a well known complication of hormonal therapy in breast
cancer using oestrogens and androgens. Hormone induced hypercalcaemia usually has a
rapid onset (within 5-10 days of starting hormonal therapy) and calcium levels return to
normal when the drug is stopped. It can occur spontaneously in 10-25% of breast cancer
patients especially when osteolytic bone metastases are present, but tends to occur gradually
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and therefore the symptoms develop slowly. Some have suggested that hypercalcaemia
along with 'tamoxifen flare' may signify tumour response [Villalon 1979, Arnold 1979].
Although tamoxifen is an antioestrogen, its apparent hypercalcaemic effects appear to be
similar to oestrogen induced hypercalcaemia therefore this may represent one of
tamoxifen's partial oestrogenic effects [O'Connell 1981]. Legha [1981] concluded that
although hypercalcaemia occurs infrequently, ifpatients have proven bone metastases then
calcium levels should be checked regularly during the first few weeks of tamoxifen therapy
and that tamoxifen should be continued or interrupted only until calcium levels fall again.
This side effect is potentially serious but is usually short lived and requires supportive
measures only. Although tamoxifen was developed as an antioestrogen it has been found
to have partial oestrogen actions, ofwhich hypercalcaemia may be one.
Hepatotoxicity is another partial oestrogenic side effect. However, the concern about
hepatocellular carcinoma is based on laboratory studies alone [Jordan 1995]. There have
been several studies of large doses of tamoxifen inducing liver tumours in rats but this has
never been reported in humans at a standard 20mg/day dose. There have been 2 reports of
women developing hepatocellular carcinoma who took 40mg/day of tamoxifen but in a
tumour that is very rare in the general population anyway, cause and effect is difficult to
prove.
Another important partial oestrogenic side effect of tamoxifen is its effect on the
endometrium and its use is associated with an increased incidence of both benign and
malignant endometrial lesions. The incidence of endometrial cancer is increased in breast
cancer patients on tamoxifen from 1:1000 women/year to 2:1000 women/year [Jaiyesimi
1995], The endometrial effect of tamoxifen is addressed in detail in the earlier Pilot Study
and Endometrial Screening sections.
However not all of tamoxifen's oestrogenic effects are detrimental. Tamoxifen is known
to act as a partial oestrogen on bone and the cardiovascular system which may prove of
some benefit [Love 1992, 1994, Jordan 1987, 1999, McDonald 1995]. Recent studies have
suggested a minimal increase in bone mineral density in women taking tamoxifen, which,
particularly in postmenopausal women confers a protective effect similar to that seen with
hormone replacement therapy. This may reduce the fracture rate in postmenopausal
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women, which causes considerable morbidity and mortality in this group. Love et al
[1992] found that tamoxifen use was associated with a significant preservation of the bone
mineral density of the lumbar spine in postmenopausal women but were unable to
determine whether this would correlate with a decrease in the risk of fractures. Turken et
al [1989] found similar but non-significant results. Jordan et al [1987] studied the effect in
rats and suggested that tamoxifen helped to maintain bone density such that tamoxifen may
be useful in retarding the development of osteoporosis and thus, logically, fractures as a
result of that.
Tamoxifen also causes oestrogenic changes in blood lipids by reducing low density
lipoproteins and total cholesterol and increasing high density lipoproteins. This may have
the effect of reducing cardiovascular disease which in postmenopausal women remains the
biggest cause of morbidity and mortality. Powles et al [1990] in their prevention study
reported that tamoxifen significantly reduced serm cholesterol, fasting low density
lipoproteins and apoprotein B levels in postmenopausal women. In premenopausal women
the effect on serum cholesterol and LDL was present but smaller and there was no
significant effect on other lipid and lipoprotein fractions. The Scottish trial reported a
reduction in the incidence of fatal myocardial infarction in postmenopausal women on
tamoxifen as compared to controls and the Stockholm trial showed a reduction in the
incidence of hospital admissions for cardiovascular illness in tamoxifen users as compared
to controls. The NATO trial also reported a reduction in non cancer deaths in tamoxifen
users [NATO 1988, Jaiyesimi 1995].
The vast majority ofwomen who receive tamoxifen will never experience any toxic side
effects. However, a number of other non life-threatening effects have been reported
commonly including hot flushes/sweats, weight gain, fluid retention, nausea and vomiting,
reduced libido, vaginal dryness, vaginal discharge, skin rash and non specific central
nervous system symptoms including depression, irritability, headache, sleep disturbance and
lethargy. Depression has been reported in 1-15% of women taking tamoxifen and been
specifically attributed to tamoxifen [Shariff 1995], Although non toxic, these side effects
can be extremely distressing as they affect daily living and quality of life long term. The
most distressing and frequent effect is hot flushes/sweats and in the population studied there
was a significant difference between the study population and controls (p=0.0099). Other
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studies have reported a similar significant difference [Love 1991, Ray 1996]. Some women
report a reduction in vasmotor symptoms over time and there are various treatments
available, eg clonidine, venlafaxine and megestrol acetate which have varying success, but
despite this it still remains a very distressing symptom [Love 1993, Loprinzi 1994],
A number ofwomen report weight gain in association with tamoxifen use. Although there
was a difference between the study group and controls with regard to weight gain it was not
statistically significant and may reflect a general decrease in self-esteem and negative body
image following breast surgery. Kumar et al [ 1997] looked at weight gain associated with
tamoxifen therapy and also found that although there was a mean weight gain of 1,2kg in
all patients, there was no significant difference for those receiving tamoxifen against those
not receiving tamoxifen and weight gain during treatment with tamoxifen was not correlated
with treatment duration.
Another highly significant side effect found in the population studied was vaginal discharge
(pO.OOOl). Ray et al [1996] also reported a significant difference in vaginal discharge and
Love et al [1993] reported an increase in gynaecological symptoms (unspecified). Only 5%
(a non significant difference) reported vaginal discharge in a study by Powles et al [1989]
to evaluate the acute toxicity and feasibility of tamoxifen for the prevention of breast
cancer. Sobel [1996] reported specifically on an increase in vulvovaginal candidiasis in
postmenopausal women secondary to tamoxifen. The present study did not assess whether
discharge was secondary to infection. This effect almost certainly reflects the partial
oestrogenic nature of tamoxifen on the genital tract. Boccardo [1981] and Ferrazzi [1997]
found an increase in the karyopicnotic index of vaginal tissue of women on tamoxifen
reflecting oestrogenisation of the vaginal tissue similar to that of premenopausal women.
Patients can be reassured that unless the discharge is blood stained/brown it is not
significant. Many postmenopausal women expressed concern about whether the discharge
experienced was normal or not but when reassured did not report that they found this effect
distressing.
Fluid retention was also reported significantly more often in women taking tamoxifen than
in the control population. This could also be a partial oestrogenic effect of tamoxifen in
that in premenopausal women fluid retention is experienced most commonly
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premenstrually. Oedema has been reported in 2-7% of patients in studies by Cole, Ferrazzi
and Lerner [Heel 1978] and in combination with a degree ofweight gain may prove a very
distressing symptom.
Thus, although these symptoms are not life threatening they occur in a significant number
of women taking tamoxifen who find them distressing and which affect quality of life.
They may in some instances cause women to decrease the dose of tamoxifen taken or even
stop tamoxifen altogether. Women should be warned about the possible side effects, toxic
and non-toxic, and be adequately supported whilst taking the drug.
Anecdotally women report differences in severity of some side effects, eg hot flushes and
nausea with tamoxifen produced by different phannaceutical companies and it may be
worth trying a different preparation of the drug if symptoms prove troublesome.
There are several options for the treatment of common side effects, in particular hot flushes.
Megestrol acetate (megace), a progestogen, can be effective as can other centraly acting
agents such as venlafaxine (a serotonin and noradrenaline reuptake inhibitor) or prozac
(fluoxetine). For vaginal dryness, replens, a non hormonal vaginal preparation which has
an acid pH, can be tried initially but ifproves inadequte, topical oestrogen preparations such




[trans- l-(4-[2-dimethylamino)ethoxy]phenyl-l ,2-diphenylbut-1 -ene] - Tamoxifen, is readily
absorbed following oral administration, has a long plasma half-life of 7 days and reaches
steady state levels by the end of the first month of treatment [Jordan 1990]. Serum levels
of tamoxifen at steady states are extremely variable (50-300ng/ml) and blood levels of
tamoxifen have been shown not to correlate with breast cancer response [Etienne 1989,
Jaiyesimi 1995, Lemer 1990]. There are, however, no data relating serum tamoxifen levels
to endometrial abnormalities.
The aim was to establish the relationship between serum tamoxifen levels and endometrial
abnormalities to determine whether increased plasma levels correlated with increased
incidence of endometrial abnormalities. All women are prescribed 20mg/day tamoxifen
irrespective of height and weight (body mass index [BMI]). Chemotherapeutic agents are
adjusted for the above factors but traditionally all hormonal agents have been prescribed
irrespective of BMI. One theory is that high plasma levels of tamoxifen might correlate
with the presence of endometrial abnormalities. However, the very low incidence of
abnormalities detected in this present study group was such that it was the aim to study the
relationship between plasma tamoxifen levels and endometrial thickness on ultrasound.
Tamoxifen is extensively metabolised in patients to primarily 4-hydroxytamoxifen and
desmethyltamoxifen. Desmethyltamoxifen accounts for about 50-75% ofmetabolites but
is actually a relatively weak antioestrogen. A further 25% remains as tamoxifen itself and
the remainder consists of 4-hydroxytamoxifen and other metabolites. Although 4-
hydroxytamoxifen is present at very low concentrations in serum it has an extremely high
binding affinity for the oestrogen receptor and therefore plays a significant role in the
antitumour activity of tamoxifen. There is, however, a large inter-patient variability in 4-
hydroxytamoxifen levels [Etienne 1989].
Metabolites Z, Y(from N-desmethyltamoxifen), E and bisphenol have also been discovered;
metabolite E and bisphenol are oestrogenic metabolites as they both lack the
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dimethylaminoxy side chain necessary for antioestrogenic properties [Osborne 1994],
Figure 1 shows tamoxifen and its main metabolites [Lerner 1990, Poon 1993],
A review of the literature indicated that not only were there no data comparing plasma
tamoxifen levels with endometrial abnormalities but that the 20mg/day dose of tamoxifen
that is most commonly prescribed appeared to have been arrived at empirically and indeed
doses of40mg or 60mg daily have been prescribed in some countries. All women receive
the same dose irrespective of BMI and although there is evidence that blood levels of
tamoxifen do not correlate with breast cancer response, there is a wide variation in steady
state plasma levels and there is no explanation for this. A secondary aim was to establish
whether BMI influenced plasma levels and could be an explanation for the wide variation
in steady state plasma levels.
The analysis of tamoxifen and its metabolites is difficult because of low plasma
concentrations and light instability of the target compounds [Fried 1994], High
performance liquid chromatography is used initially and then sensitivity enhanced by
photochemical activation which converts tamoxifen by UV radiation, from a phenylethylene
to a phenanthrene. Levels are estimated following UV fluorescence. Thin layer
chromatography has also been used as an alternative to HPLC but these methods are time
consuming and result in variable extraction efficiencies (60-90%). A new method was
established in Edinburgh which included a rapid and simple solid phase extraction making
it feasible to assess plasma levels for the whole study group [MacCallum 1996],
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Figure 1








Although samples were taken from all 357 women to measure plasma tamoxifen and its
metabolites 4-hydroxytamoxifen and desmthyltamoxifen results were obtained for only 160
women. Whilst all 357 samples were prepared for analysis, as described previously in
Methods: Tamoxifen Metabolite Plasma Levels there were problems with the HPLC which
led to reduced extraction rates. Extraction rates of <50% were not analysed. During the
method development extraction efficiencies of approximately 60% were achieved and
between day variation in extraction efficiencies was low (<10%). For the purposes of this
study extraction efficiencies were calculated for each sample run from cis spiked plasma
compared to cis/MeOH standard and if the efficiency of each run was less than 50% then
the sample result was discarded.
During the course of the study there were separate problems with the autosampler and the
beam boost which led to a time delay between sample extraction and HPLC. The
prolonged storage of samples may have affected the sample and thus the extraction rates.
However, the technique used had been previously validated by storing patients plasma
samples at -40°C and assaying these stored samples at regular intervals (1, 2, 4, 8 and 12
months). These showed no detectable degradation and therefore this was not thought to
be the main cause of difficulties. Time constraints did not allow rerun of the samples with
reduced extraction rates so the following results pertain to samples with extraction rates
>50%.
During the method development tamoxifen (TAM), 4-hydroxytamoxifen (40HT),
desmethyltamoxifen (DMT) and cis-tamoxifen were measured but cis-tamoxifen was
detectable in only 3/59 (5%) of plasma samples so was not measured as part of this study.
Standard curves were constructed for each metabolite (Figure 2) which were prepared using
7 replicate concentrations (over a range of 0.002 - 2pg/ml) ofmixed metabolites in MeOH
and plasma. Mean values were plotted as concentration versus area under the curve which
was the area taken from the plot produced by the integrator for each sample. Standard curve
equations for the line of best fit were then used for the calculation of metabolite
concentration in the study samples.













A figure is given for the 'area under the curve' on the plot produced from the
integrator from which the actual level of tamoxifen or metabolite is calculated.
Because extraction efficiencies for each metabolite were not 100% an efficiency
factor was required (to obtain 100% efficiency) and metabolite concentration was
then calculated. This was calculated from accuracy and precision data from the
standard curve. Accuracy was how near expected values were to observed values
and precision was day-to-day variance in observed values. These data give values for
the efficiency factors which were used in the final calculation along with the
equations for line of best fit.




Concentration (y) = mean area under the curve (a) x efficiency factor (e).
Calculate (x) which is the amount (concentration) of metabolite in 20pl of the
original plasma sample using the standard curve equations and multiply (x) by 50 to
obtain a value in ng/ml of plasma. A worked example is shown below.
Standard Curve Equations
4-OHT log x =
DMT log x =
TAM log x =
log v - 4.3632
1.114
log v - 4.644
0.96096




Result from patient MH
Results 40H DMT TAM
Standards (mixed) 120000 220000 220000
Standard (CIS) - - -
Effic factors (e) 1.59 1.64 1.69
Plasma 255390 246680 112320
Plasma + CIS 332550 324150 136840






* this value was used to check the efficiency of each run (190490/300000 x 100 = 62.8%.
If <50% then the sample result was discarded)
Measuring 40H for patient MH
y = a x e
y = 293970 x 1.59
y = 467412
Place this into the standard equation
log x = logy -4.3632/ 1.114
log x = log (467412) - 4.3632/1.114





Blood samples were taken from all 357 study patients, spun down and stored for analysis
as previously described. Extraction was carried out on 333 samples due to time constraints
and only results with recovery rates of over 50% were included for analysis. 160 results
were available for plasma tamoxifen and desmethyltamoxifen and 152 for 4-
hydroxytamoxifen. Total tamoxifen was therefore calculated from the 152 patients where
results were available for all 3 metabolites.









Mean 66.5 47.4 115.2 235.0
SD 44.5 32.5 88.0 155.9
Median 52.6 38.1 85.0 187.8
Range 12.2-277.5 4.1-160.8 10.4-492.1 34.7-892.2
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Endometrial Thickness
Plasma levels of tamoxifen (TAM), 4-hydroxytamoxifen (40HT), desmethyltamoxifen
(DMT) and total metabolites (the sum of all three) were compared with endometrial
thickness as assessed by transvaginal ultrasound scan and the results for patients where






Figures 4, 5, 6 and 7 demonstrate this graphically.
From the graphs it can be seen that there was a positive correlation between all the
metabolites and endometrial thickness although none reached statistical significance. The
relationship between endometrial thickness and both plasma tamoxifen and
desmethyltamoxifen was of borderline significance.
Despite the positive correlation there was a wide scatter of points around the line making
it difficult to extrapolate clinical management decisions from these results.
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Figure7 Relationshipb tweento alamoxiflevelandendometrialthick ss.
Body Mass Index
Each patient had height and weight recorded at the time of their first visit and body mass
index (BMI) recorded using the following standard calculation.
BMI = weight Ikgl
height (m2)
A BMI of <25 is normal whereas >30 indicates obesity.
Thereafter the relatonship between BMI and plasma tamoxifen and its metabolites was
investigated. The results are summarised below:




TAM 66.2(41.3) 70.0(49.9) 58.9(39.3) p=0.522
4-OHT 50.3(32.4) 46.6(32.1) 38.9(25.9) p=0.045
DMT 117.9(89.8) 120.6(95.0) 97.2(65.6) p=0.349
Total 245.7(156.1) 241.1(168.9) 194.9(121.7) IIp -J <1
These results are demonstrated graphically in Figures 8, 9, 10 and 11.
There was a significant negative correlation between body mass index and plasma
4-hydroxytamoxifen. Therefore, as BMI increases, levels of4-hydroxytamoxifen appear
to fall. The correlations between body mass index and tamoxifen, desmethyltamoxifen and
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Figure10 Relationshipb tweenBMIandplasmadesmethyl amoxifenl vels.
10.052345 BodyMassIndex
Figure11 Relationshipb tweenBMIandto alplasmaamoxiflevels.
Discussion
The wide variation in plasma levels of tamoxifen and its metabolites are well recognised.
Lien et al reported mean plasma tamoxifen levels of 163ng/ml (range 79-299),
desmethyltamoxifen levels of 199ng/ml (range 76-410) and 4-hydroxytamoxifen levels of
4.2ng/ml (range 0.7-7.1) in patients receiving 30mg/day tamoxifen. Although this group
received a greater dose of tamoxifen than this study population, studies in the literature
agree that the daily dose of tamoxifen is largely irrelevant with regard to plasma levels and
does not play a role in the wide patient variation observed [Robinson 1994, Osborne 1998,
Ross 1995], Robinson [1994], in a study of 20mg/day reported mean plasma levels of
108ng/ml for tamoxifen, 238ng/ml for desmethyltamoxifen and 2.8ng/ml for 4-
hydroxytamoxifen and MacCallum [1997] of 30ng/ml for tamoxifen, 190ng/ml DMT and
54ng/ml for 4-OHT. Concentrations of desmethyltamoxifen are generally higher and 4-
hydroxytamoxifen very low. The present study population also exhibited a wide range of
plasma levels in keeping with the literature although mean plasma 4-OHT levels of
47.4ng/ml (range 4.1-160.8) were higher than most other reports apart from MacCallum et
al which report similarly high levels and may have occurred because the same method was
used. This wide plasma variation did not appear to follow a normal distribution, however,
as one might have expected.
There is no satisfactory explanation for the wide variation in plasma levels seen.
Tamoxifen has a long half-life (7 days) and desmethyltamoxifen even longer (14 days).
Steady state is achieved after 30 days and serum levels have been shown to be stable long
term - for at least 10 years of therapy. There are no significant peak and trough differences
in plasma levels and variations observed between individuals are not usually seen in serial
samples from the same patients. Most studies report no metabolic tolerance developing
[Langan-Fahey 1990, Fabien 1980, Jordan 1990, Lerner 1990, MacCallum 1996, Osborne
1998]. Fabien suggested that large variations in individual patient sampling may be a result
of variation in drug absorption and metabolism as influenced by other medications and
hepatic and renal function but this has yet to be confirmed.
Langan-Fahey's [1990] study is the only one to assess whether the high individual variation
in plasma levels is related to obesity. Levels of tamoxifen and desmethyltamoxifen were
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found not to correlate with indices of obesity. The present study confirmed these findings
but did find a significant negative correlation between plasma 4-hydroxytamoxifen and
body mass index. So as BMI rises, levels of 4-OHT fall. In isolation, the clinical
significance of this finding is uncertain.
Significant differences in tamoxifen and metabolite levels have also been reported in tissue,
both breast tumour and other and do not correspond with responding and resistant tumours
either but may perhaps reflect tumour heterogeneity [Lerner 1990, MacCallum 1997],
Studies have been performed investigating tamoxifen and metabolite levels in the rat and
mouse uterus. Robinson [1991] found a greater accumulation of tamoxifen,
desmethyltamoxifen and 4-hydroxytamoxifen in liver and uterus following very large oral
doses and there was a higher concentration of both tamoxifen and DMT compared with
blood in the rat uterus, more than lOOx greater. One suggested explanation for this
observation was the presence of high affinity anti-oestrogen binding sites within the liver
and uterus but more recent literature would not support this theory [Robinson 1994].
Studies have yet to be reproduced investigating tamoxifen and metabolite levels in human
endometrium and whether these correlate with endometrial pathology. The present study
aimed to correlate plasma levels with endometrial abnormalities but when limited pathology
was found, the aim was altered to correlate plasma levels with endometrial thickness on
ultrasound scan. There was no significant correlation between plasma levels and
endometrial thickness although a correlation with plasma tamoxifen and
desmethyltamoxifen almost reached statistical significance. This information is of limited
use as endometrial thickness on ultrasound scan has been shown not to correlate well with
pathology (46% false positive scan rate in women on tamoxifen). In addition, there was
no relationship between plasma 4-hydroxytamoxifen (the most oestrogenic of the
metabolites measured) and endometrial thickness which one may have anticipated in view
of tamoxifen's oestrogenic action on human endometrium.
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AROMATASE INHIBITOR - LETROZOLE
Introduction
Letrozole or CGS 20 267, 4,41-(lH-l,2,4-Triazol-l-ylmethylene)bis-bezonitrite is one of
the third generation oral aromatase inhibitors. It is a potent and highly specific non¬
steroidal inhibitor in vivo and has been found to be 200 times more potent than
aminoglutethamide in-vitro and more selective [CGS 20 267 1988]. Because of the
concerns regarding the potentially serious side effects of tamoxifen newer, more specific,
endocrine agents including letrozole have been under investigation as alternative therapies.
In Phase 1 trials letrozole was found to significantly suppress oestrone and oestradiol levels
peripherally and showed antitumour activity in some patients resulting in an overall clinical
response rate of 33% [Iveson 1993].
Treatment with aromatase inhibitors is aimed at achieving maximal oestrogen suppression
with minimum toxicity. In Phase 1 trials, doses of 0.1mg, 0.5mg and 2.5mg letrozole all
produced significant oestrogen suppression (95%) but there was a tendency for increasing
doses to produce increasing suppression (although this was not statistically significant). In
addition, over a wide dose range, letrozole does not significantly change levels of
gonadotrophins, ACTH, Cortisol, aldosterone or TSH supporting its selectivity for the
inhibition of aromatase alone.
Studies ofpostmenopausal women with metastatic breast cancer who progress on tamoxifen
have shown an overall survival advantage for patients receiving letrozole over megestrol
acetate or aminoglutethamide [Santen 1999] and aromatase inhibitors are now being used
in adjuvant trials to determine the efficacy of aromatase inhibitors versus tamoxifen versus
combination of antioestrogen and aromatase inhibitor.
This study aimed to investigate the effectiveness of 2 doses of letrozole (2.5mg and lOmg)
as primary medical therapy (neo adjuvant) for patients with locally advanced and large
operable breast cancer. Neoadjuvant therapy has been used to treat large operable and
locally advanced breast cancers but studies to date have concentrated mainly on the use of
chemotherapy. A few centres have assessed endocrine agents in this setting, ofwhich the
225
most commonly used is tamoxifen, but this is the first study to assess the third generation
aromatase inhibitor, letrozole, as neoadjuvant treatment.
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Patients and Methods
24 postmenopausal patients (age range 53-87 years) were treated in sequence, the first 12
received 2.5mg of letrozole, the second 12 were treated with lOmg of letrozole. All
patients had oestrogen receptors assayed on tumour biopsy specimens using either an
enzyme immunoassay (ER-EIA) using the Abbott kit, according to the manufacturer's
instruction or an enzyme immunochemical assay on immunohistochemistry. Patients were
classed as oestrogen receptor positive if they had greater than 20fmol receptor/mg/cytosol
protein or a histoscore of>80 (histoscore calculated by multiplying the percentage of cells
staining by the intensity of the staining graded from 0-3) [McCarty 1985],






T4a Involvement of chest wall
b Involvement of skin
c a and b together
d Inflammatory cancer
N 0 No regional node metastasis
N 1 Mobile ipsilateral nodes
N 2 Fixed ipsilateral nodes
N3 Internal mammary node involvement
MO No evidence ofmetastasis
M 1 Distant metastasis
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Only patients with large operable or locally advanced breast cancers without evidence of
metastases were included in this study, T2>3cm, T3 T4b, NO-1, MO. Patients were MO on
the basis of normal biochemistry and no metastases on a chest x-ray or bone scan. All 24
patients gave written informed consent.
At the outset of the study all tumours were measured clinically using engineers' calipers in
four different directions 45 ° apart and the tumour volume calculated using the formula:
V = D3 x 71
6
(V: volume, D: mean diameter)
They also had mammograms and using the measurements on the oblique and craniocaudal
views the largest tumour diameter and the diameter at 90° to the axis was measured. The
mean mammographic diameter was calculated and tumour volume calculated using the
formula:
V = D3 x 71
6
(V: volume, D: mean diameter)
Patients also had a breast ultrasound and four scans performed at 45° apart using the
machine's electronic callipers and tumour volume was estimated according to the following
formula:
V = D2 x d x 71
6
(V: volume, D: mean diameter, d: mean thickness)
All methods ofmeasurement have been described by Forouhi et al [1994],
Patients receiving lOmg of letrozole also had a short synacthen test performed prior to
starting treatment and after completion of three months' treatment with this dose of
letrozole. This was to confirm that higher doses of letrozole had no effect on steroid levels.
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Patients were treated with letrozole for three months. During this time they were
monitored at monthly intervals and had clinical and ultrasound tumour volumes calculated
at each visit.
A second mammogram was performed at the end of the three months and mammographic
volumes calculated. Percentage change in tumour volume was used to assess tumour
response. Modified WHO criteria were used, a partial response (PR) being defined as a
50% or greater reduction in tumour volume and a complete response (CR) being no
measurable tumour. Progression of disease (PD) was defined as greater than 25% increase
in tumour volume with no change (NC) being defined as a volume decrease of less than
50% or a volume increase of no greater than 25%.
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Results
All 24 patients completed the three month course of neo-adjuvant therapy. The only
reported side effect was in one patient who was taking 2.5mg of letrozole and reported
transient pale stools. A second patient taking lOmg of letrozole had low platelet levels at
the end of treatment. Subsequent investigation demonstrated that this patient had bone
marrow involvement which had not been detected by any pre-operative investigations.
There were no abnormalities in any of the synacthen tests indicating that even at the 1 Omg
dose there was no effect on adrenal corticosteroid production. All bone scans performed
prior to and following treatment were normal.
Letrozole 2.5mg
Table 1 shows the clinical tumour volumes at 0 and 3 months and the % reduction in
tumour volumes and Table 2 the imaging response (% reduction in volume on ultrasound
and mammography).
Figure 1 shows the changes in tumour volumes at 3 months as assessed by clinical
examination, mammography and ultrasound.
On the basis of the modified WHO classification, of the 12 patients treated by 2.5mg of
letrozole there were five complete clinical responses and seven partial responses. Results
based on the best imaging response were 1 complete response, 10 partial responses and 1
no change.
Letrozole lOmg
Table 3 shows the clinical tumour volumes at 0 and 3 months and the % reduction in
tumour volumes and Table 4 the imaging response. Figure 2 shows the same data as above
for the 12 patients who took lOmg letrozole.
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There were 2 complete clinical responses, 8 partial responses with 2 patients being
classified as having stable disease. Best imaging responses were 11 partial responders and
1 no change.
When comparing the results of 2.5mg and lOmg letrozole, there were no apparent
differences between responses for these two doses. All but two patients had a greater than
50% reduction in clinical tumour volume.
Nine patients were suitable for breast conservation at the outset of treatment but by the end
of the three month course of letrozole all patients were eligible for treatment by breast
conservation. Histology demonstrated that all cancers were completely excised. There
was one complete pathological response in a patient treated by 2.5mg letrozole and three
patients had microscopic disease only, two in the 2.5mg and one in the lOmg group.
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Figure 3
Mammograms of breast malignancy pre and post letrozole treatment.
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Discussion
Neo-adjuvant therapy has to date consisted ofprimary chemotherapy or primary endocrine
therapy in the form of tamoxifen. Indirect comparisons in the World Overview indicate
that survival using adjuvant tamoxifen as primary endocrine therapy appears equivalent to
chemotherapy in young women and superior to chemotherapy in older women with
oestrogen receptor positive tumours. Since the benefits of chemotherapy are unknown in
women over 70 years, endocrine therapy is particularly important in this group which
represent about a third of all breast cancers.
There have been several small trials investigating neo-adjuvant treatment with tamoxifen
and Keen et al [1997] showed significant reductions in tumour volume over a 3 month
period with tamoxifen (75% response in a group ofpostmenopausal women with high levels
of oestrogen receptor). Response rates in this series with letrozole appear to be at least as
good and possibly better than with tamoxifen, however, with 7/24 patients having a
complete clinical response and 22/24 (92%) having a greater than 50% reduction in clinical
tumour volume.
One of the aims ofprimary endocrine therapy is to reduce tumour volume in order to make
breast conservation a feasible surgical option. Such have been the reductions in tumour
volume in this study that all women were suitable for the less extensive surgery of wide
excision following 3 months of letrozole therapy. From a cosmetic perspective this is
advantageous and because many of these patients are elderly as, in this elderly population,
mastectomy is associated with a 1% mortality [Hunt 1980]. Only 9/24 patients were
suitable for breast conservation at the outset of treatment but by the end of the 3 month
course of letrozole all women were eligible for breast conservation. Letrozole is at least
as effective as tamoxifen in the neo-adjuvant setting and as it appears to be associated with
less side effects than tamoxifen and no endometrial effects its role as neo-adjuvant
treatment of elderly women with ER positive breast cancer needs further investigation.
Third generation aromatase inhibitors are being used in the management of tumours
resistant to anti-oestrogens and should, in the long term, establish themselves as important
drugs in the endocrine management of patients with breast cancer. Before tamoxifen can
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be displaced as first line endocrine therapy, results from randomised clinical trials will need
to show that these newer agents have comparable efficacy in this setting and have less
toxicity. Even then it will be necessary to demonstrate that the benefits of using aromatase
inhibitors are superior to those of conventional anti-oestrogens which have been used for
over 25 years. Another option is to use aromatase inhibitors in combination with
antioestrogens to produce complete oestrogen blockade but the disadvantage with this
approach is that all methods of hormonal manipulation are used up front giving no further
option if endocrine resistance develops. We know from clinical trials to date that third
generation aromatase inhibitors block up to 90% of oestrogen production. Of concern, if
these drugs are to be used in the adjuvant setting, is the effect of long term oestrogen
suppression in a postmenopausal group with the potential morbidity from bone loss and
cardiovascular complications. At present aromatase inhibitors have not been used in
premenopausal women as there are very high levels of aromatase in the premenopausal
ovary which are too high for blockade to be achieved by current clinical doses of the drug.
Also, aromatase inhibitors do not influence other areas ofpotential oestrogenic activity, for
example a5 androgens, large quantities of which are produced in the adrenal cortex and
which are capable of eliciting oestrogenic responses including stimulation of hormone
dependent breast cancers. Nor will the aromatase inhibitors affect exogenously derived
oestrogens (synthetic, industrial pollutents, phyto-oestrogens).
The role that aromatase inhibitors could play in the treatment of oestrogen dependent
gynaecoloical disorders such as fibroids or endometriosis has not been fully investigated.
The dose could be titrated against symptoms and complete oestrogen suppression which is
produced using current treatments could be avoided. However, early data would suggest
that aromatase inhibitors alone are not the answer as they appear to cause ovarian
hyperstimulation in the premenopausal population.
There is no doubt that the third generation oral aromatase inhibitor, letrozole provides a
promising alternative to conventional 'antioestrogens' such as tamoxifen used as first line
treatment for breast cancer at least in the short term in terms of efficacy and lack of toxicity.
Long term studies are required to show whether this effect is sustained and there are no
problems with long term morbidity. Third generation aromatase inhibitors are being
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investigated in the adjuvant setting and there are currently protocols in place to assess the
gynaecological effects but results are several years away and perhaps a sound clinical model
is required to assess its effects rather than waiting for results from ongoing adjuvant studies.
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CONCLUSION
This study has focused on the endometrial changes secondary to tamoxifen use in breast
cancer patients. Prior to commencement of the study the increased incidence of
endometrial cancer and other endometrial pathology associated with tamoxifen use was
regularly being reported and was of growing concern, but the question ofwhether screening
women on tamoxifen was required had not been addressed. The main aim of this study was
to answer this question and establish the best screening method if this was to be employed.
It is one of the largest studies to prospectively assess both women on tamoxifen and controls
and has shown conclusively that screening women on tamoxifen is not of benefit in terms
of detecting abnormalities and therefore the cost to the patient and to the health service
cannot be justified. Previous studies have reported high incidences of endometrial
abnormalities in particular endometrial hyperplasia, which may be a precursor to
endometrial cancer but this study which investigated asymptomatic women failed to
confirm these findings and found no cases of hyperplasia or cancer in this population.
Benign abnormalities found were in the form of submucous fibroids and endometrial
polyps. All polyps removed were benign, but some have suggested that tamoxifen
associated carcinoma may develop from existing polyps in symptomatic women and should
therefore be removed when found. It was difficult to extrapolate current literature which
mainly pertains to symptomatic women to the asymptomatic population studied and each
case was therefore assessed individually to avoid exposing large numbers of asymptomatic
women who have already dealt with a diagnosis of breast cancer to unnecessary anxiety and
invasive procedures.
The author accepts that with current knowledge it may have been preferable to investigate
pre and postmenopausal women separately from the outset as tamoxifen may affect the two
groups differently.
There is no ideal screening method available as ultrasound scanning, both transabdominal
and transvaginal (the main method employed in this study) gave false positive results in
46% of cases, subjecting large numbers of women to the more invasive procedures of
hysteroscopy and D & C. It is also not possible from the scan appearance to predict those
women who will have atrophic endometrium on further assessment from those with benign
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changes. Out-patient hysteroscopy has been shown to be effective as second line
investigation, being relatively east to perform and with tolerable discomfort, but is time
consuming and relatively expensive. Attempts to perform pipelle biopsy, a simple out¬
patient procedure performed in many gynaecology out-patient clinics, was not as successful
as anticipated and may have been due in part to not having ideal equipment/facilities with
which to perform this. Outwith these limitations pipelle biopsy has been shown in studies
to miss focal abnormalities by only sampling part of the endometrium and was shown in this
study to be as uncomfortable to perform as out-patient hysteroscopy, which allows direct
visualisation of the whole endometrial cavity in the vast majority of cases. It was accepted
therefore not to persevere with pipelle biopsy.
It would have been ideal to have been able to sample all endometria at hysteroscopy and
although this was attempted in all cases with 'apparently oedematous endometrium' this
proved unsuccessful in the majority. This is an accepted limitation of the study but
histology was thereafter investigated by other means.
The ultrasound appearance confirmed by this study and the difficulty obtaining endometrial
specimens for histology has been previously reported. Although in the early 1990's no
explanation was given for this, the histology responsible for this appearance has gained
more interest in recent years, in particular from workers such as Ismail and Neven. No
definitive definition exists, some considering this to be a form of atrophy and others a form
of hyperplasia, but all agree the phenomenon is endometrial in origin and peculiar to
tamoxifen use. This study confirmed the findings of cystically dilated endometrial glands
and found low stromal cellularity with the presence or prominence of collagen within the
stroma. The significant presence of collagen may account for the difficulty biopsying the
endometrium and the large cystically dilated glands for the appearance of the endometrium
on ultrasound scan and at hysteroscopy.
Immunohistochemistry of hysterectomy specimens from women on tamoxifen looking at
ER and MIB 1 staining failed to show a significant difference in the expression of either
with tamoxifen use. Although not quite significant, tamoxifen users were less likely to
stain positive for stromal MIB 1 which may coincide with the low stromal cellularity found
on histology, indicating a lower degree of stromal activity in tamoxifen users. Several
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other modalities of action on the endometrium have been investigated including proto-
oncogene expression, chromosomal changes, growth factor expression, but the cellular
mechanism for tamoxifen's effect remains unknown.
Of interest, this ultrasound phenomenon would appear to be reversible in most women.
This is the first study to rescan women following tamoxifen cessation and show that
endometrial thickness reduces significantly off tamoxifen. A progressive effect of
tamoxifen on the endometrium has been postulated by this study, whereby the initial effects
of tamoxifen are reversible and can be seen as endometrial thickening on ultrasound scan
without pathology, but thereafter benign abnormalities occur, polyps or hyperplasia, which
may over time develop malignant foci. This clearly requires further investigation. The
other interesting group of women who require further investigation is those in whom
tamoxifen never affects the endometrium regardless of the time they are exposed to the
drug.
The side effects experienced by women on tamoxifen rarely lead to cessation of the drug
but are common and are troubesome for some women. This study reports no serious side
effects but an increased incidence of hot flushes and sweats, fluid retention and vaginal
discharge. Hot flushes and sweats are well documented and vaginal discharge is most
likely to reflect the oestrogenic action of tamoxifen on vaginal epithelium producing a
'physiological' discharge. Women should be warned of this as, although it is common with
tamoxifen use, any change in the discharge requires investigation.
Plasma levels of tamoxifen and its metabolites 4-hydroxytamoxifen, and
desmethyltamoxifen were measured to assess whether metabolite levels correlated with
endometrial thickness on ultrasound scan because all women receive 20mg/day of
tamoxifen regardless ofbody mass index and this may have provided some explanation for
the ultrasound findings. The initial aim had been to correlate plasma levels with
endometrial abnormalities but in view of the low incidence of abnormalities detected in the
study group, the aim was altered. There was a positive correlation between all metabolites
and endometrial thickness but none reached statistical significance and there is little clinical
significance to this finding. In addition, the relationship between tamoxifen and its
metabolites and body mass index was assessed. The only outcome which reached
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statistical significance was the negative correlation between 4-hydroxytamoxifen and BMI
which again is of little clinical significance.
As a direct result of this study, women in Edinburgh on tamoxifen do not undergo
endometrial screening but are informed of the small increased risk of endometrial cancer
associated with tamoxifen use and are asked to report any abnormal vaginal discharge or
bleeding which can be promptly investigated.
Tamoxifen is currently being assessed for chemoprevention in healthy women so for this
group of women the results of this study are important although this study concentrated
mainly on postmenopausal women. Two large trials, the Royal Marsden Trial and the
BCPT-NSABP trial have been ongoing in the last few years and the IBIS trial (International
Breast Intervention Study) which aimed to recruit 7000 women. The Royal Marsden Trial
is studying women with a strong family history of breast cancer but has failed to show any
effect of tamoxifen on breast cancer incidence in healthy women. This is unlike the BCPT-
NSABP trial which showed a reduction of 45% in breast cancer frequency in healthy
women such that all women are now being offered tamoxifen. The rationale for prevention
trials are the lifetime risk ofdeveloping breast cancer versus the fact that tamoxifen reduces
contralateral breast cancers in 30-40% of patients. The beneficial effects of tamoxifen on
blood lipids, bone density and the cardiovascular system must also be weighed against the
endometrial risk. There is such a large discrepancy in results from these two trials that
larger numbers of women need to be involved and longer follow-up is required [Powles
1998, Lasset 1998], The IBIS trial will be of importance to establish whether a similar
reduction in the incidence of breast cancer is found [Howell 1998]. In addition the Marsden
trial indicates that side effects are low and that the other oestrogenic benefits conferred by
tamoxifen are present [Powles 1990, 1992],
Alternatives to tamoxifen have also been developed. More specific SERM's (Selective
Oestrogen Receptor Modulators) eg raloxifene, toremifene and faslodex are currently under
trial and will hopefully show fewer detrimental endometrial effects than tamoxifen.
Aromatase Inhibitors, ofwhich letrozole is one, are also promising alternatives. Letrozole
has been shown to be at least as effective as tamoxifen in the treatment of breast cancer and
because of its different mode of action is likely to have no long term endometrial side
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effects. However, the morbidity associated with long term oestrogen suppression in pre
and postmenopausal women remains to be determined.
Tamoxifen remains the drug of choice for the adjuvant treatment ofbreast cancer and
despite its detrimental effects, the benefits from its use far outweigh its risks.
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